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Abstract 
The aim of this research was to explore the structure-activity relationship (SAR) of 
ferrocenyl-bioconjugates. A series of N-(ferrocenylmethylamino acid)-fluorinated-benzene 
carboxamide derivatives and a series of N-(ferrocenyl)-benzoyl-aminoalkane derivatives have 
been synthesised, structurally characterised and biologically evaluated for their anti-
proliferative activity on various cancer cell lines, principally, the (estrogen receptor positive) 
MCF-7 breast cancer cell line.  
The anti-cancer effect of ferrocene is due to the generation of a reactive oxygenated species. 
As part of the primary SAR study, a series of N-(ferrocenylmethylamino acid)-fluorinated-
benzene carboxamide derivatives have been synthesised, structurally characterised and 
biologically evaluated. This series involved the attachment of amino acids, such as glycine, 
L-alanine and β-alanine and also a fluorobenzoyl unit to a ferrocenylmethylamine moiety in 
order to enhance the bioavailability of the compounds thus increasing their anti-cancer effect. 
The synthesis of N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide 
derivatives was achieved by coupling the free N-terminus of the ferrocenylmethylamine with 
the carboxylic acid group of the N-(fluorobenzoyl)-amino acid using N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) and 1-
hydroxybenzotriazole (HOBt) coupling protocol. All compounds were characterised by a 
range of spectroscopic techniques including: 
1
H, 
13
C, 
19
F, DEPT-135, and HMQC NMR in 
addition to IR, UV, and MS 
The attachment of a benzoyl spacer lowers the redox potential of the ferrocene moiety thus 
making the iron atom between the cyclopentadienyl rings, easier and more accessible to 
oxidation. A series of N-{(ferrocenyl)-benzoyl}-aminoalkanes have also been synthesised 
and characterised and biologically evaluated on the MCF-7 breast cancer cell line. The main 
aim was to conduct a structure activity relationship on two key moieties of the molecules, the 
difference of the substitution pattern around the aromatic benzoyl moiety and also the 
attachment of the various aminoalkanes, in hope that the biological activity will show a 
greater anti-proliferative effect against cancer cell lines. The synthesis of the N-{(ferrocenyl)-
benzoyl}-aminoalkanes derivatives involved the coupling of the free N-terminus of the amine 
group of the aminoalkanes to the carboxylic acid group of the ferrocenyl-benzoic acid (ortho-
, meta- and para-) using N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
(EDC) and N-hydroxysuccinimide (NHS) coupling protocol. All compounds were also 
characterised by the spectroscopic methods as mentioned above. 
For the biological evaluation of the N-(ferrocenylmethylamino acid) fluorinated benzene 
carboxamide series of compounds, were tested on the estrogen positive (ER+) breast cancer 
cell line, MCF-7. Three libraries of novel ferrocene compounds were prepared by 
incorporating the glycine, L-alanine and β-alanine amino acids and the fluorobenzoyl moiety 
with the fluorine at the positions 2, 3, 4, (2,6), (2,4), (3,5), (3,4,5) and (2,3,4,5,6). All three 
libraries were tested in vitro. For comparative reasons, N-(ferrocenylmethyl)-4-fluorobenzene 
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carboxamide, the most active compound from a previous SAR study on the MBA-MD-435-
SF, ER(+) breast cancer cell line was also tested to observe the effect from the addition of the 
amino acid into the model structure. In total of the three libraries tested, there were four 
active compounds, with N-(ferrocenylmethylalanine)-3,4,5-trifluorobenzene carboxamide 
being the most active giving an IC50 value of 2.4 µM. This derivative also induced a block in 
the G2/M phase of the cell cycle. This series of compounds were also screened in vitro for 
their anti-proliferative effect against the non-small cell lung cancer cell line, H1299 at two 
concentrations, 10 µM and 1 µM. There was no activity below either of the concentrations 
and the study was stopped. The biological evaluation of N-{(ferrocenyl)-benzoyl}-
aminoalkanes were screened in vitro on the MCF-7 breast cancer cell line. Preliminary 
screens showed that this type of compound had an anti-proliferative effect on MCF-7 breast 
cancer cell line. From 27 derivatives synthesised, IC50 data values were achieved. The ortho- 
series produced eight derivatives having an anti-proliferative effect, six of which were in the 
range of 2 µM to 6 µM. The meta- series produced two derivatives, with IC50 values of 51.5 
µM and 51.2 µM. The para- derivatives also produced eight derivatives having an anti-
proliferative effect, three of which were in the range of 2 µM to 6 µM. The most active 
derivative synthesised was N-{para-(ferrocenyl)-benzoyl}-aminooctane, with an IC50 of 1.10 
µM. 
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Chapter 1 
Cancer, bioorganometallic chemotherapeutics as anti-cancer agents. 
1.1. Cancer and chemotherapy. 
1.1.1 Introduction 
Cancer is a leading cause of worldwide death in economically developed countries and the 
second cause of death in developing countries.
[1]
 In  2008, the World Health Organisation 
reported that cancer claimed 13% of deaths in total, a loss of just over 7.6 million people.
[2]
   
Cancer is a class of diseases characterised by the uncontrolled cell proliferation and the 
ability to invade other tissues and organs. 
[2][3]
 The word cancer originates from the Latin 
term meaning   “crab”.  The term is known historically because of the swollen blood vessels 
around a tumour was thought to resemble the limbs of a crab.  The study of cancer was 
known since the Egyptians and ancient Greeks, but was not fully investigated until the 16
th
 
century. The renaissance period brought about a change not only in culture but also in science 
and diagnosis. Scientists developed greater understanding of the human body in this period.  
Notable scientists such as Galileo and Isaac Newton, began to use scientific methods which 
was later used it study disease. In 1628, William Harvey was the first to perform human 
autopsies and animal dissections, 
[3]
 which led to the understanding of the circulation of the 
blood vessels around different organs of the body and heart while Giovanni Moragi in 1761, 
performed autopsies to relate patients’ deaths and illnesses to pathologic findings .[4] The 
results of these investigations laid the foundation for the study of scientific oncology, the 
study of cancer. 
In economically developed countries, the three most commonly diagnosed cancer types are 
prostate, colorectal, and lung amongst males, and breast, colorectal and lung amongst 
females. 
[1]
   Cancer cases are on the increase with over 12.8 million cases estimated in 2008, 
a total of 7.6 million deaths. Each year in Ireland, there are over 20,000 new cases of cancer 
and over 7,500 cancer deaths, accounting for almost one quarter of the annual death toll. 
[5][6]
 
Cancer is a major cause of death and disease in this country as in all western communities as 
statistics estimate for 2030, cancer related deaths will total to 11million. 
[4][7]
 The main causes 
of cancer are  
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 Tobacco use 
 Hereditary cancers  
 Infectious diseases 
 Nutrition. 
The use of tobacco continues to be the leading global cause of preventable death, causing the 
death of millions of people worldwide and also hundreds of millions of dollars of economic 
damage each year. The number of cancers attributable to tobacco continues to increase 
globally because of the expansion of the world’s population and the increase in long term 
exposure and cigarette consumption. 
[7]
 A large number of cancer cases reported have shown 
that cancer is hereditary or passed from one generation to the next. HBOC (hereditary breast-
ovarian syndrome) occurs in the female population at a rate of between 1 in 500. HBOC 
patients exhibit early onset breast cancer and have an elevated risk for other cancers such as 
pancreatic stomach and fallopian tube cancer. 
[3]
 Infectious etiologies are the second leading 
causes of cancer. Gastric, liver and cervical cancer are a result of infectious etiologies. 
Approximately 15% of all cancers are attributable to infectious disease. 
[7]
 Another growing 
problem not only in cancer, but in other diseases in the other organs of the body is nutritional 
factors. Calorific imbalance, weight gain in adults and children, obesity, and physical 
inactivity are often the causes of breast, colon, stomach and liver cancer. 
[4-7]
 The global 
burden of cancer continues to increase largely because of the rapid growth and aging of the 
world’s population.  
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1.1.2 The cancer cell versus the normal cell. 
All life begins on a cellular level, and has evolved from a single eukaryotic cell (animal, plant 
or fungi).  A cells cycle is dependent on growth, maturity, and function. The combination of 
all these factors gives rise to different cells types e.g., nerve cells, bone cells, blood cells.  
Each of these types of cells then come together to form organs, the brain from nerve cells, the 
skeleton from bone cells and blood vessels and heart from blood cells. Cancer cells also are 
evolved from one single cell.  However, unlike cells in the human body, an unknown 
malfunction has occurred resulting in a different cell or mutated form, which from this a 
cancer forms. 
[8]
  
The life cycle of a cell is extremely complex.  Cell division occurs in the M phase (mitotic 
phase) and lasts for one hour.  This is followed by a gap phase, G1 (pre-synthetic interphase). 
The synthetic phase or S phase is where chromosomal DNA is replicated. It is here that the 
function of all cells is organised and most often the cancer cell will originate.  The S phase is 
then followed by a second gap phase (G2) in which the cells prepare for mitosis. (pre-mitotic 
interphase).
[9]
 (Figure 1) 
 
Figure 1.1: Cell cycle; M-phase (mitosis), G1 (pre-synthetic interphase), S phase (DNA 
synthesis), G2 (pre-mitotic interphase) 
[9]
  
DNA (deoxyribonucleic acid) is packaged into chromosomes. Replication of DNA occurs in 
the synthesis phase (S) of the cell cycle. From a certain sequence of DNA nucleotide base 
pairs, that cell will have a certain function, e.g. nerve cells will form nerves, and bone cells 
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will form the skeleton. Over time, cells get damaged, and need repairing. It is here where they 
are synthesised and divided to keep that cell and organ working efficiently. Therefore the cell 
cycle allows the replication and regeneration of the damaged cell.  With cancer cells, this is 
where they differ. Cancer cells develop a different DNA sequence, a mutation of genes. As a 
result of this genetic instability, it causes an uncontrollable growth of cells and in an 
unorderly fashion. 
[8] 
These mutated genes will continue to replicate and divide and new cells 
will form, not allowing apoptosis to occur. Apoptosis is programmed cell death of damaged 
or ineffective normal cells.  The continuing replication and multiplication of cancerous cells 
will continue to divide rapidly, therefore form a mass of cells called a tumour. The cells 
energy is also another contribution. The mitochondria (cells battery) only delivers the right 
amount of energy to give that cell function, while in cancerous cells, it uses all of its energy 
on multiplication. 
[9]
  
There are two types of tumours categorized by their growth , benign or malignant. Benign 
tumours cause problems within the organ which they occur, but do not spread. These tumours 
may be removed via surgery, radiation or chemotherapy. Malignant tumours cause the 
cancerous cells to spread away from the original site. This can be done via the lymph system, 
blood stream or by direct extension where cells will invade nearby organs. Once this happens, 
the cancer cells migrate to other distant sites and organs in the body. These cancers are 
known as secondary cancers or metastatic cancers. In terms of naming the cancers, it is often 
the location of the cancer that gets prefixed to that type, e.g. liver cancer and skin cancer. 
Carcinoma refers to cancers that begin in the skin, or in the tissues that line or cover other 
internal organs. Similarly, cancers that originate in bone, cartilage fat or muscle are classified 
as sarcomas. Lymphoma and multiple myeloma arise from cells of the immune system, while 
leukaemia develops from blood forming tissue such as bone-marrow.
[10]
  
1.1.3 Most common cancers 
In Ireland, the most common forms of cancer in males are cancers of the prostate, colon, lung 
and lymphoma whereas amongst women cancer of the breast, colon, lung and uteri are the 
most common.
[5][11]
  The possibility of developing cancer is dependent on a number of risk 
factors which vary according to the tumour location. Melanoma cancers can develop from too 
much exposure to ultraviolet (UV) radiation. Tobacco is the greatest risk factor to the 
development of lung cancers (lung, larynx, oesophagus, stomach, pancreas, kidney, liver and 
bladder). The lack of physical activity, a person’s diet, life style, alcohol consumption, and 
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exposure to certain cancer causing chemicals, including asbestos, benzene and radon gases 
also contribute to the development of cancer. 
Survival rates of cancer are based on five year survival rate statistics. The survival rates are 
primarily dependant on the location of the tumour, since this influences the ease with which 
the tumour can be detected, which in turns aids detection and treatment and also the stage of 
the cancer at diagnosis is also dependant on survival of the cancer patient. Lung cancer is the 
leading cause of cancer death, with the survival rate remaining critically low while breast 
cancer is the most common cancer diagnosed in women in Ireland.
[5][7][11]
  Women have a 1 
in 13 chance of developing breast cancer  in their lifetime. Breast cancer was the cause of 624 
deaths to women in 2007 who had being diagnosed. 
[6]
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1.1.4 Breast cancer 
Breast cancer develops in the ducts or lobules of the breast. The lobules produce milk when 
woman breastfeeds and the milk moves down to the milk ducts in the nipple. If cells in the 
ducts or lobules start to multiply uncontrollably, they are known as a cancer or malignant 
cells. When cancer cells are confined within the ducts or lobules, it is known as ductal 
carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS). If the cancer cells spread from 
the ducts or lobules into the surrounding tissue, it is known as invasive breast cancer.  Breast 
cancer is often referred to as a hormonal cancer. Estrogen receptors are over-expressed in 
around 70 % of breast cancer cases. These cases are referred to as Estrogen Receptor positive 
(ER+). Other breast cancer types early breast cancer is defined as breast cancer that is 
contained only in the breast and hasn’t spread to the lymph nodes. The lymph nodes are part 
of the human body’s natural defences against infection, and are connected throughout the 
body. 
[6][14]
    
Endocrine therapy is a treatment involving selective estrogen receptor modulators (SERMS) 
which behave as ER antagonists in breast tissue or aromatase inhibitors. Hormonal therapies 
work by decreasing the amount of estrogen in the body or by stopping cancer cells from 
getting estrogen. 
[13]
 Although there are many treatment options, surgery and chemotherapy 
are the most employed. In most developed countries, breast cancer is second only to lung 
cancer as the leading cause of cancer – related death in women, and thus represents a serious 
health care problem. Worldwide 40 % - 70 % of patients ultimately develop metastatic breast 
cancer. In 2007, there were 2,463 new cases of breast cancer diagnosed in Ireland making it 
the most common invasive cancer (in Irish women).
[5][6][13]
 Statistics show that over half of 
all breast cancer cases are estimated to occur in economically developing countries are due to 
contributing factors such as the use of oral contraceptives, the late age of first birth, and also 
a long menstrual history. 
1.1.5 Lung cancer. 
One of the leading causes of cancer relating death is lung cancer. 
[1]
 Statistically it has been 
the leading cancer diagnosed since 1985 in the western world.  Among females, it was the 
fourth most common diagnosed cancer and the second leading cause of cancer death. Lung 
cancer accounts for 18 % (1.4 million) of the total deaths in 2008.
[4]
 In Ireland, it is the 3
rd
 
most common cancer amongst in men and women with only a 10.4 % survival rate based on a 
five year relative survival (2000-2004).
[11]
 Low survival rates can be attributed to poor 
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detection of the cancer at an early stage and exposure to certain cancer causing agents, 
carcinogens.  One of the attributed causes is the use of tobacco and smoking. Smoking 
accounts for 80 % of the worldwide lung cancer burden. The attempt to obtain a reduction in 
cigarette consumption has been a long and frustrating undertaking. It is one of the most 
successful industries in the world, profiting hundreds of millions of dollars per annum. 
Tobacco companies have exploited all means to undermine the evidence of carcinogenicity of 
tobacco products. Other sources are exposure to cancer causing chemicals such as asbestos, 
as well as the naturally occurring radioactive gas radon are other sources of lung cancer. 
Lung cancer can be divided into two major types, small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC). Approximately 20 % of all lung cancers are SCLC, which is 
very aggressive form of cancer due to early metastasis.
[15]
 Chemotherapy is the most common 
treatment for SCLC because of its early metastatic spread. However, even with treatment, 
long term survival remains poor. The remaining 80% of lung cancers are NSCLC, comprising 
of adenocarcinomas, squamous cell and large cell carcinomas. 
[16]
 One of the principal 
treatment options is surgery, however nearly 75 % of the NSCLC tumours are inoperable at 
the time of diagnosis. The option of surgery with the conjunctional use of chemotherapy and 
radiotherapy has increased the survival rates of these metastatic cancers. 
[17][18]
  
1.1.6 Melanoma 
Worldwide, malignant melanoma of the skin accounts for 160,000 new cases annually, with 
slightly more cases occurring in women than in men.
[4]
  In Ireland the number of melanoma 
cancer cases rose steeply by 50 % between 1994 and 2004. 
[11]
 The main risk factor 
associated with this type of cancer, is the exposure to ultra-violet (UV) radiation from the sun 
or UV emitting tanning devices. The risk level of developing melanoma through over 
exposure depends on skin type, where those of fairer skin are more at risk. Malignant 
melanoma has the potential to metastasise to any organ within the body. Common areas of 
dissemination include the skin, lymph nodes, bone and lungs. Advanced melanoma is fatal in 
most cases, as patients with advance melanoma have a poor prognosis, with a one year 
survival rate of less than 5 %. This is due to the fact that the melanoma cancer is particularly 
resistant to all current forms of treatment. 
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1.2 Role of drugs in cancer treatment: chemotherapy 
The ultimate clinical effectiveness of any drug used for the treatment of cancer is that it kills 
malignant tumour cells in vivo at doses that allow enough cells in the patients critical tissues 
(i.e., bone marrow, GI tract) to survive so that recovery can occur.  Surgery, radiotherapy and 
chemotherapy are all effective treatments for cancer and have been used alone and in 
combination. Surgery and radiation therapy can often eradicate primary or localized disease 
but may ultimately fail because the cancer has metastasised to other areas of the body. In 
such instances, chemotherapy is the most common and more viable option for patients for 
these types of cancer. The combination of chemotherapy with other therapies is known as 
adjuvant therapy.  
Although the use of chemicals for the treatment of cancer dates back 500 years, when 
preparations of mercury and silver were used, the first chemotherapeutic drug used was used 
in 1865. Lissauer administered potassium arsenite, (Fowlers solution, KAsO2) to a patient 
with leukaemia and noted a positive effect.
[20]
  Systemic cancer chemotherapy was not really 
developed until 80 years later. One of the first effective anti-cancer drugs, nitrogen mustard 
was tested in 1942 on a clinical trial patient suffering from lymph sarcoma. 
[21]
 Its sulphur 
precursor, mustard gas was ironically used not in medicine, but during the first world war, in 
chemical warfare. The anti-cancer effect of nitrogen mustards was later published by Koelle 
& Gilman in 1946.
[22]
  Most conventional chemotherapeutic drugs are cytotoxic agents, 
where they elicit cancer cell death and not normal cell death. Chemotherapeutic drugs can 
interfere with the replication of DNA, either by acting on DNA or by inhibiting enzymes 
involved in the synthesis of DNA. Chemotherapeutic drugs can also interfere with the 
mechanics of cell division, where, cytotoxic agents aim to target cells in a selective manner. 
Their selectivity is based on the fact that cancerous cells divide faster than normal cells. 
However, there are also cells in the body that divide rapidly under normal circumstances, i.e., 
bone marrow and hair follicle cells. Most cytotoxic agents also act on these cells as well as 
the cancer resulting in certain side effects, myelosuppression (decrease in blood cells) and 
alopecia (hair loss) to name but a few side effects are most common with patients with cancer 
.
[23]
 
One of the biggest problems in chemotherapy is cancer resistance.  There are two types of 
cancer resistance, intrinsic resistance is present at the time of diagnosis in tumours that fail to 
respond to first line chemotherapy. In contrast, drug acquired drug resistance occurs in 
 
20 
tumours that can often be highly responsive to initial treatment, but present with strong 
resistance to the original treatment upon tumour recurrence.  
Multiple drug resistance (MDR) is defined as cellular resistance to multiple anti-cancer 
agents due to a decreased concentration of the active drug at the target sites. MDR is a major 
obstacle in cancer chemotherapy as tumour cells become resistant to a range of diverse drugs 
after exposure to a single cytotoxic agent. A brief overview of the anti-cancer drugs and their 
target areas is described. 
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1.2.1 Anti-cancer drugs: 
The current types of anti-cancer drugs fall under several categories as, each category of anti-
cancer chemical  has a different target area of the cancer disease. These categories are  
1. Alkylating agents 
2. Anti-metabolites 
3. DNA topoisomerase inhibitors 
4. Anti-microtubule agents 
5. Organometallic agents. 
1.2.2 Alkylating agents: 
The alkylating agents are a diverse group of anti-cancer agents. They have the commonality 
that they act by covalently binding of an electrophilic alkyl group or substituted alkyl group 
to cellular nucleophilic sites. Alkylating agents react with cells in all phases, however their 
efficacy and toxicity is most active on proliferating cancers.  Historically, the first alkylating 
agent, Mechlorethamine, (1) was developed as a result of effects seen from the use of 
mustard gas during World War 1. 
[21] 
 
A number of related drugs has been developed, and have been successful in the treatment of 
leukaemia, lymphomas and solid tumours.  Nitrogen mustards, such as mechlorethamine and 
cyclophosphamide (2) for the treatment Hodgkin’s lymphoma  and lymphomas , and 
melphalan (3) for the treatment of ovarian cancers and malignant melanomas are such 
examples of the analogues synthesised post WW1 .
[22]
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Other forms of alkylating agents are also used to treat different forms of cancers. The alkyl 
sulfonates such as Busulfan (4) used to treat leukaemia, is the most common alkyl sulfonate.  
Azridines, such as triethylenemelamine (5) used in ovarian and breast cancer treatment, 
nitroureas such as carmustine (6) used in the treatment of glioma and astrocytoma,  and 
triazines, dacarbazine (7) (DTIC) for the treatment of melanoma are all different subgroups of 
alkyating agents.  However, the alkylating agents are frequently used as combination drugs. 
Cyclophosphamide being the most versatile, while the other drugs mentioned above are 
restricted to clinical use. Because of early successes, many disease states are managed with 
drug combinations that contain several alkylating agents. 
[3]
  
              
                                          
 
1.2.3. Anti-metabolites: 
Dihydrofolate reductase (DHFR) is a critical enzyme in folate metabolism, its role is 
maintaining the folate pool in its reduced form as tetrahydrofolates, which serve as one 
carbon carriers for the synthesis of purine nucleotide bases in DNA replication, as well as 
other amino acids used in DNA synthesis.  In 1940, aminopterin (8), an anti-metabolite 
demonstrated cytotoxic activity against children’s leukaemia.[23]  However, due to toxicity of 
the drug, it was replaced by the less toxic, methotrexate, or MTX (9). The methotrexate, is a 
tight binding DHFR inhibitor. However in 1957, Heidleberger synthesised 5-fluorouracil 
(10). To this day, 5-fluorouracil remains one of the most widely used anti-cancer drugs 
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showing activity in a wide range of cancers and solid tumours. It acts by interfering with the 
replication of RNA strands in DNA synthesis and thus not allowing the repair of DNA in 
cancerous cells. 
 
                         
1.2.4 DNA topoisomerase interacting agents 
DNA topoisomerase is a class of enzyme that alters the topology of DNA and they are found 
in all living organisms. The importance and functional need for DNA topoisomerase in all 
cells is due to the double helical structure of DNA. Access to DNA during processes such as 
replication (copying of the DNA),  transcription (creating a complentary sequence of RNA in 
DNA synthesis) and recombination (connecting the two strands to form DNA) requires 
 
24 
double helical DNA to be separated which results in tortional stress that is resolved by 
topoisomerase. 
[25]
  
DNA topoisomerases are classified by type 1 and type 2. They are distinguishable by the 
number of breaks made during catalysis.
[26]
 Anthracyclines are natural products produced by 
Streptomyces species.  The most common examples of anthracyclines are doxorubicin (11) 
daunorubicin (12) and epirubicin (13).  These drugs target topoisomerase type 2 and have an 
extremely broad range of therapeutic activity and clinical use. 
[27]
 Other topoisomerase 
inhibitors include the DNA intercalator mitoxantrone (anthrancenedione) and etoposide. 
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1.2.5 Anti-microtubule agents 
Anti-microtubule agents prevent cell mitosis by interfering with the formation of the 
microtubule spindle required for cell division. The main cellular target of these compounds is 
the structural protein tubulin. During the mitotic cycle of a cell, tubulin undergoes 
polymerisation to form the mitotic spindle (strands of tubulin that pull the chromosomes apart 
during division). The vinca alkaloids of which vinblastine (14) and vineristine (15) are the 
main examples which bind to tubulin and prevent the polymerisation from occurring.
[28]
 
Taxanes such as paclitaxel (16) and docetaxel bind to the beta (β)  subunit of tubulin, 
accelerating polymerisation and stabilising the resultant microtubules to prevent 
depolymerisation.  
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1.3 Metal based drugs 
For over 5000 years, metal based compounds were commonly used as folklore remedies and 
by ancient civilisations for medicinal purposes. 
[25]
 The metal based compounds were largely 
present in ancient medicine, side by side with drugs of natural origin as metal based drugs 
have limited selectivity due to their centres being positively charged. They are thus favoured 
to bind to negatively charged biomolecules such as proteins and nucleic acids, which offer 
excellent ligands for binding to metal ions. The pharmaceutical use of metal complexes 
therefore has excellent potential. 
[29][30]
   
Metal based compounds enlarge the possibility of building up molecules better suited for 
binding to specific biological agents (targets). 
[31]
 Indeed metal ions exhibit a wide range of 
coordination numbers and geometric characteristics, which allow the most different anions 
and organic ligands (with their chemical and biological properties) in more appropriate 
spatial distributions, affording better modalities of attack to target molecules. The redox 
potential of the metal can interact with the balanced cellular redox state, modifying cell 
viability either directly or through the conversion of an inert compound to an activated one, 
thus changing the inherent toxicity of the drug. In the last decade there have been an increase 
of interest in compounds of organometallic nature and their biological applications. 
Biologists have realized that certain organometallic compounds are stable and active under 
physiological conditions while chemists have shown the diverse applications that new 
compounds may have. 
1.3.1 Platinum agents. 
One of the most important drugs to be used in medicine is the platinum based drug cisplatin.           
Cisplatin (17) or cis-diaminedichloro-platinum was first discovered by Dr. Michele Peyrone 
in 1844 however it was not until a discovery was made by Rosenberg et al in 1965 of its anti-
cancer activity.
[3][32]
 The anti-proliferative activity of a platinum complex, cisplatin, was 
successfully introduced in the therapy of testicular cancer (1978). This fostered a renewed 
and growing interest in metal-based drugs, particularly organometallic complexes as anti-
cancer agents. Platinum based anti-cancer drugs play an essential role in the clinic today and 
a number of coordination compounds with other metals are in current development as 
promising anti-cancer drugs. 
[33]
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Cisplatin (17) is among the most active anti-cancer agents producing DNA damage similar to 
alkylating agents. The accidental discovery of cisplatin led to the development of modern 
organometallic medicinal chemistry. It is the most used of all platinum based drugs and is the 
prototype of this family of agents, having the broadest range of clinical activity and the most 
substantial toxicity profile. 
[33]
  
 
Cisplatin, is a square planar complex containing two relatively inert ammonia molecules and 
two chlorine atoms coordinated to the platinum molecule in the cis transfiguration. Cisplatin 
based therapy is curative in testicular cancer and is very active in gynaecologic cancers, 
gastrointestinal malignancies , genitourinary cancers and cancers of the neck and back. The 
activity and variety of use is due to the 70-80% efficacy rate against cancer. 
[35]
 The cisplatin 
induces its cell killing through the development of covalent bifunctional DNA adducts with 
cellular DNA. 
[36][37]
   
The ability of cisplatin to form adducts with nucleotide bases of DNA gives it a unique mode 
of action. Once the drug penetrates the cell the chloride ligands are replaced with neutral 
water ligands to give reactive positively charged species. This process is facilitated within the 
cell by the relatively low cellular concentration of chloride atoms. These positively charged 
species coordinate with the N7 atoms of the guanine residues forming intra-strand bridges. 
The result of these bridges causes distinct bends in the DNA at the point of where it allows 
the binding of proteins which contain the high mobility group (HMG). Once the protein is 
bound to the DNA, it inserts a phenyl group of phenylalanine 37 into the widened minor 
groove of the bend formed by the double helix of DNA. The tightly bound protein causes 
destacking of the nucleotide bases forming a “kink”. (Figure 2) As a result of this bending 
and protein binding, the cell dies. 
[35][36] 
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Figure 1.2: Mode of action of cisplatin.
[35][36] 
The adverse side effects with the usage of cisplatin have led to the synthesis of other platnium 
based analogues. At present, cisplatin, carboplatin (18) and oxaliplatin (19) are the only metal 
based anti-cancer agents currently established in therapy. 
[37]
 Today cisplatin is used in half of 
all cancer cases (usually in combination with other drugs) and has a cure rate in testicular 
cancer of over 70 %.  
 
Carboplatin shows a reduced toxicological profile compared to cisplatin, yet has a similar 
spectrum of activity, while oxaliplatin is active against metastatic colorectal cancer. Two very 
important features of the platinum compounds include the nature of the leaving groups and 
the nature of the carrier ligands. The leaving groups for cisplatin are the chloride atoms 
located in the cis-configuration form. The leaving group for carboplatin is the 
dicarboxylatocyclobutane moiety, which does not dissolve readily under conditions where 
cisplatin readily dissociates (a physiologic pH). Oxaliplatin has a leaving group and a carrier 
ligand. The diaminocyclohexane carrier ligand of oxaliplatin gives the compound a unique 
intracellular characteristic once the drug is covalently bound to DNA. 
[37]
 The different carrier 
and ligand varieties aid solubility, increase stability and also reduce the toxicity of the 
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complexes. The platinum agents are one of the most employed cancer agents, and can be 
administered either singly or together. Typical combination agents include, gemicitabine, 
paclitaxel, vinorelbine and docetaxel. 
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1.4 Bioorganometallic anti-cancer agents 
1.4.1 Non platinum metal compounds: 
Though the cisplatin molecular motif has led to the discovery of successful drugs, further 
significant research into the improvement in metal based cancer therapy might be achieved 
from the study of unconventional structures. Following the end of World War II, the 
investigation into metallic compounds with increased stability and greater availability was 
prompted, with the goal of developing potential agents to combat diseases such as cancer.  
Several thousand compounds, derived from about thirty metals have been prepared and 
tested. 
[42]
  
Bioorganometallic chemistry is a term that describes the discipline dedicated to the study of 
biomolecules or biological active molecules that contain at least one direct metal-carbon 
bond.
[46]
 The interest of the biological activity of compounds that incorporates a metal at its 
center rapidly increasing. Gainferrara et al 
[38]
 proposed a system of categorizing the range of 
metal anti-cancer compounds according to their mode of action. The five categories involve 
the metal and its role in the compound. 
1. The metal has a functional role 
2. The metal has a structural role 
3. The metal is a carrier for active ligands for delivery in vivo 
4. The metal compound is photoactive and behaves as a photo sensitizer 
5. The metal behaves as a catalyst in vivo. 
1.4.2 Ruthenium 
Some of the bioorganometallic complexes that are currently being researched have reached 
clinical trials. 
[39]
 Ruthenium complexes appear particularly promising despite their lower 
cytotoxicity compared to cisplatin; as they are better tolerated in vivo. Ru (III) complexes 
maintain the metal oxidation state until they reach the tumour, where the low oxygen level 
permits their activation by reduction to Ru (II). Anti-tumour activity of ruthenium complexes 
involves binding to DNA. The strong binding capacity for albumin and transferrin greatly 
influences the bio distribution of these complexes. Of great interest is the ability to inhibit 
angiogenesis and matrix metalloproteinase and hence metastasis in vivo. 
[40] 
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The most common Ru (III) complexes are KP418 (20), KP1019 (21), and NAMI-A (22). 
KP1019 and NAMI-A are currently in clinical trials. 
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1.4.3 Titanium 
Despite the success of cisplatin and other platinum based anti-tumor agents, the progression 
of other transition-metal anti-cancer drugs towards clinical trials has been exceptionally slow. 
The most noteworthy of the metallocene compounds is titanocene dichloride (23), as it was 
the first non-platnium organometallic compound to enter clinical trials since 1993.
[43]
 
Unfortunately, phase II clinical trials of the titanocene dichloride were abandoned as its 
efficacy as an anti-cancer agent against metastatic renal cell carcinoma and metastatic breast 
cancer proved too low to warrant further trials.  
                                                                  
Tacke et al has developed achiral titanocene drugs that may have anti-cancer potential, 
namely titanocene C, ((bis-(N,N-dimethylamino-2(N-
methylpyrrolyl)methylcyclopentadienyl) titanium (IV) dichloride) (24), and titanocene Y 
(bis-[(p-methoxybenzyl)cyclopentadienyl] titanium dichloride) (25). The anti-proliferative 
effects of these titanocenes were screened in vitro and also in vivo. The results showed that 
prostate, cervix, and renal cancers are primary target regions for these types of compounds. 
Compound 24 showed an IC50 value of 36 µM against the LLC-PK renal cell lines.
[44] [45]
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1.4.4 Iron 
The metallocene ferrocene has several novel applications and is a promising candidate for 
biological applications due to its ease of derivatization, stability, redox properties and its 
spectroscopic properties. It was one of the first of the “metallocene” compounds to be 
discovered, which transformed the area of bioorganometallic chemistry. 
[46]
 
In 1951, Kealy and Pauson carried out a reaction on cyclopentadienyl magnesium bromide 
with anhydrous iron (III) chloride in an attempt to synthesize fulvalene via the oxidation of 
cyclopentadienyl Grignard 
[47]
. However upon reduction of the iron (III) to iron (II) the group 
obtained a crop of orange crystals that analyzed for C10H10Fe. 
Miller et al, who were investigating the preparation of amines, formed the orange compound 
C10H10Fe by direct reduction of cyclopentadiene with iron, in the presence of aluminium at 
300 
0
C .
[48]
 Both of the groups noted that this new compound was completely unique. The 
orange crystalline iron incorporated structure was air stable and had a melting point of 173 
0
C. 
[47] [48]
 Structures originally proposed for the dicyclopentadienyl iron featured two flat 
planar cyclopentadiene rings, where one of the five carbon atoms of each ring was linked by 
a single α bond to the central iron atom (Figure 3). However it was not until the 
breakthrough of Geoffrey Wilkinson and Ernst Fischer that a correct formulation was 
identified.  
 
                        Figure 1.3: An early representation of the ferrocene molecule 
[46] 
 
Wilkinson used chemical, physical and spectroscopic methods to elucidate the correct 
structure of dicyclopentadienyliron, whilst independently Fischer used X-ray crystallography 
to structurally characterize the compound .
[49][50]
 Wilkinson realized that the five 
electronically equivalent carbons (five in the cyclopentadienyl ring) must all contribute in an 
equal way to the bonding of the iron atom. From infra red spectral analysis, he noticed a 
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single stretch in the carbon – hydrogen region, thus concluding that all five carbons to 
hydrogen bonds (C-H) are equivalent. He sketched a structure where the iron atom was 
placed between the two cyclopentadienyl (Cp) ligands. The bonding appeared very strong 
due to the excellent overlap of the metal d orbitals and the π electrons in the p orbitals of the 
Cp ligands. Fischer on the other hand, was using X-ray diffraction studies to propose a 
structure. Completely unaware of Wilkinson’s previous discoveries, Fischer’s studies gave 
unequivocal evidence of the sandwich structure and predicted a double-cone shape. It has 
become obvious the double ring structure with the iron atom centre of the two (sandwich 
structure) was due to good orbital overlap of the π electrons of the p orbitals of the Cp ligands 
and the d orbitals of the iron with the compounds high stability. 
[46][49][50]
 The discovery and 
recognition of this new type of bonding between metals and unsaturated organic molecules 
gave organometallic chemistry and new lease of life and shaped the future for ferrocene 
research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37 
1.4.5 Chemical bonding of ferrocene  
The bonding in ferrocene involves ring to metal donation of the π electrons from the p filled 
molecular orbital on the ring bonds into the vacant d orbital on the metal atom (M-Cp).  Also 
there is a degree of metal to ring back bonding from the field orbitals on the metal to the π* 
orbital on the cyclopentadiene ring. 
[46]
  
In the class of metallocenes, ferrocene is the most stable. It is a result of having the ideal 
number of electrons for a (η5-C5H5) – Metal – (η
5
-C5H5) complex, i.e., 18 electrons. As 
shown in Figure 4, the energy levels on the left hand side of the diagram belong to the pair of 
free cyclopentadienyl rings and the energy levels on the right belong to that of the free iron 
atom. Consequently the orbitals in the middle represent the metal to ring construct.  Nine pair 
of electrons is accommodated by filling all the bonding and non-bonding molecular orbitals 
and none of the anti-bonding molecular orbitals. The chemically relevant frontier orbitals are 
neither strongly bonding nor anti-bonding, and thus allow the existence of metallocenes that 
diverge from the 18 electron rule. Such examples include cobaltocene (19 electrons) and 
nickelocene (20 electrons). 
[46][48][49]
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Figure 1.4: The bonding diagram of ferrocene. 
[46] 
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1.4.6 Ferrocene and its role in bioorganic chemistry. 
The aromatic nature of and ease of derivatization allow ferrocene to undergo various organic 
reactions. More importantly, chemists are able to predict the chemistry of ferrocene and its 
derivatives based on  ferrocenes ability to maintain the metal – ligand (M-L) bond under 
harsh conditions. In general, metallocenes are far more reactive towards electrophilic 
substitution than benzene, indicating that more electrons are readily available. Electrophilic 
substitution reactions dominate the chemistry of ferrocene and some possible reaction 
mechanisms have been proposed 
[46]
.  
It is thought that for the first mechanism, the electrophilic subsituents (E
+
) interact with the 
weakly bonding electrons of the iron atom and then transfer to the C5H5 ring with proton 
elimination. 
FeFe Fe FeE
E+ -H+
E
H
E
 
Figure 1.5:  possible “endo” route for the bonding of the electrophile directly to iron in 
ferrocene 
Reactions where the electronic substituent electrophile is bonded directly to the iron atom 
have also been proposed. The intermediate cation with the electrophile (E
+
) bound to the 
metal rearranges to the cyclopentadiene complex with E in the endo position of the metal 
then losing a proton to give the substituted ferrocene.  
It has also been proposed that the attack takes place on the ring and not the metal as 
previously shown. It does not involve direct participation of the metal. This route involves the 
direct addition of the electrophile to the less hindered exo face of the ligand, which gives the 
intermediate. Losing a proton on the intermediate results in the product. 
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H
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Fe Fe
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Figure 1.6: possible “exo” route for the bonding of the electrophile directly to iron in 
ferrocene 
All reaction routes probably occur but it has been suggested that it is dependent on the 
stereochemistry of the electrophilic substitution, and the kinetic features of the electrophile 
determines which route it takes .
[51]
 However the more electrophilic the substituent is the 
more it will favour the endo side where deprotonation is the rate determining step. 
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1.5 The use of ferrocene in medicine 
 
Figure 1.7: The use of ferrocene in medicine 
Since the discovery of ferrocene in the early 1950s, it has been of particular interest into the 
inclusion of biological systems due its redox properties and also its non-toxicity to mammals. 
The use of  ferrocene to combat medical diseases has caused the development of various 
analogues which have shown anti-malarial 
[53]
, anti-bacterial 
[54]
 and anti-cancer activity. 
[55]
 
Malaria is a tropical disease that causes approximately 3 million fatalities per annum.
[1]
 Since 
the 1960’s, over 30 million cases of malaria occurs annually with just over 10% fatality rate. 
However, research has switched to the development of new anti-malarial drugs that combat 
this increasingly growing threat of malarial resistance. 
Brocard et al have developed a number of ferrocene containing chloroquine analogues. 
[52]
 
They incorporated a ferrocene molecule as part of the side chain to the existing malaria drug, 
chloroquine (26) to yield a ferrocene-chloroquine analogue (27).  The role and length of the 
methylene spacers between the two nitrogen atoms in chloroquine analogues has been shown 
to have an influence on efficacy in chloroquine – resistant strains of Plasmodium falciparum. 
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Krogstad et al increased the length of the methylene spacer in which was previously reported 
by  Brocard et al. Their results have shown aminoquinolines with short (2-3 CH2 units) and 
long (10-12 CH2 units) methylene side chains are equipotent against chloroquine sensitive, 
chloroquine resistance, and multidrug resistant strains of Plasmodium falciparum.
 [53]
 
Beagley et al also synthesized ferrocene-chloroquine analogs with both long and short chain 
methylene groups (28). The results showed that the length of the methylene spacer influenced 
anti-plasmodial activity.
[54]
 
 
Krieg et al have synthesized a series of N-ferrocenyl amino steroid molecules in an attempt to 
develop novel anti-microbial agents (29). They were screened in vitro against a broad 
spectrum of test organisms. These organisms included fungi, mycobacteria, and 
Staphylococci. 
[55]
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1.5.1 The use of ferrocene to treat cancer: 
The first ferrocene compounds to show anti-proliferative active were ferricenium salts.  The 
anti-tumor properties of ferricenium salts were first reported by Kopf-Maier et al, in 1984.
[56]
  
These ionic, water soluble complexes were shown to exhibit high cure rates, against fluid 
Ehrlich ascites tumour. Ferricenium picrate and trichloroacetate salts were found to elicit 
100% cure rates (30). This was achieved using the optimal dosage, of 220-300 mg kg 
-1
. 
[57] 
           
Osella et al reported the potential importance of a ferricenium cation under physiological 
conditions.  They prepared salts such as [FcCOOH]
+
 [BF4]
-
 for in vivo studies on Ehrlich 
ascites tumours. 
[58][59]
 Their observations showed that the oxidation state of the iron in the 
ferrocene played a vital role to cytotoxicity. Complexes with Fe 
3+
 showed a cytotoxic effect, 
as Fe 
2+
 centres were unable to inhibit tumour cell growth.  Another characteristic was also 
observed, that the ferricenium salts do not intercalate with DNA. A series of 
1
H NMR and 
13
C 
NMR studies suggest that interaction with DNA occurs primarily via an electrostatic 
interaction with the phosphate backbone. Using ESR experiments (Electron Spin Resonance), 
it was proposed that the ferricenium salts produced hydroxyl radicals under physiological 
conditions, which led to DNA damage. The success of this work led to the preparation of 
different ferricenium salts for screening against the human breast cancer cell line MCF-7. The 
most active of the ferricenium salts, decamethylferricenium tetrafluoroborate (31) gave an 
IC50 value of 35µM .
[2]
    
ESR experiments confirmed that the compound decamethylferricenium tetrafluoroborate (31) 
was producing a reactive oxygenated species (ROS) as a consequence of degradation in 
aqueous media. From the ESR pattern it is suggested there is a Haber-Weiss like process 
followed by a Fenton type reaction to yield a hydroxyl radical, OH. 
[59]
 Bleomycin (32) is 
known to be activated in the presence of iron. A rough synergistic effect between the two 
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drugs was seen as the activated bleomycin adducts which is responsible for the final oxidative 
damage of DNA, is produced from Fe (II) and Fe (III). 
[58][59] 
 
 
 
 
 
 
 
 
 
 
 
 
45 
One of the key factors for the use of ferrocene, is it has the ability to donate an electron from 
an essentially non-bonding high energy molecular orbital, transforming the neutral, 
diamagnetic compound to a positively charged, paramagnetic ferricenium ion radical.  
 
 
                                      Figure 1.8: Ferrocene in a biological environment 
[60]
. 
In a one-electron reduction step, B reverts back under different conditions to the uncharged 
parent compound. For example, ferrocene is readily oxidised to stable ferricenium by 
hydroxyl radicals. These radicals are reduced e.g. 
• 
OH to 
–
 OH.  The reverse reaction is 
shown through the generation of a superoxide anion radical.
 [60]
 
It is the ferricenium cation that is responsible for producing reactive oxygenated species in 
the body. In the development of the cancer and the carcinogenicity, the ROS and associated 
free radical reactions make a large contribution. In respiring aerobic cells, the reduction of the 
dioxygen species causes the production of ROS like the highly reactive hydroxyl radical. In a 
normal cell system, the oxygenated species will be controlled by cell protecting enzymes 
such as superoxide dismutase (SOD). This enzyme is present in vastly reduced concentrations 
in cancer cells so an elevated level of these reactive species may instigate pathological 
reactions leading to apoptosis and cell death.
 [60][61]
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1.5.2 Chemotherapies containing ferrocene. 
Perhaps no form of cancer is susceptible to such a variety of different types of drug therapy 
as is breast cancer. Over the last 40 years, our knowledge about the clinical behaviours of 
breast cancer has increased substantially. The ability to identify several prognostic subgroups, 
prediction of hormone sensitive and hormone resistant disease has led to a more rational 
utilisation of endocrine and cytotoxic treatments. 
[62] 
Early development in chemotherapy of 
breast cancer leads as far back as the 1950’s.  
 
TEPA (33) as well as methotrexate (9) were one of the first drugs to be used in combination 
therapy. This method showed to be a more effective treatment for metastatic breast cancer 
(MBC). To date, the taxanes such as paclitaxel (16) (taxol) and the anthracyclines are the 
most used chemotherapeutics against metastatic breast cancer. However, the most common 
form of breast cancer diagnosed amongst women is hormone dependant breast cancer, where 
the estrogen receptor (ER) is present. The introduction of tamoxifen and its analogues has 
paved the way for combating this form of breast cancer. 
Tamoxifen (34) is a widely prescribed selective estrogen receptor modulator (SERM), and is 
prescribed to patients with hormone dependant breast cancer, in which the estrogen receptor 
is present ER(+). SERMs are capable of interacting with estrogen binding sites despite their 
non-steroidal structure. The anti-proliferative action in the breast of the hydroxylated form of 
tamoxifen (OH-Tam) arises primarily from an anti-estrogenic effect caused by competitive 
binding to the ER, which represses estradiol-mediated DNA transcription. 
[63] 
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However, some breast cancer does not have estrogen receptors present. These are referred as 
estrogen receptor negative or ER(-). 
Jaouen et al have prepared a series of ferrocene substituted tamoxifen derivatives. Termed 
“ferrocifen”, a ferrocene moiety replaces the unsubstituted phenyl residue of the active 
metabolite of tamoxifen. This molecule is able to act on both estrogen receptor expressing 
ER(+) and non-expressing ER(-) human breast cancer cell lines. 
[64]
   These hydroxy-
ferrocifens (35), (n= 2, 3, 5) were screened on both positive and negative receptor cell lines. 
The results showed anti-proliferative behaviour in the (ER+) lines, with IC50 values as low as 
0.5 µM. 
[64-66] 
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A Ruthenocene analogue (36) of hydroxy-tamoxifen was synthesised by Pigeon et al 
[67]
 
where it was active against the ER(+) and negative against ER(-). The results showed a 
greater activity when the methylene chain was increased, when compared to tamoxifen. The 
activity of the compound had been attributed to intercellular oxidation resulting in the 
hydroxyl radical formation and in turn, cell death. However it was investigated using 
fluorescence activated cell sorting (FACS) that even at high concentrations ferrocifens caused 
negliable oxidative DNA damage. Fluorescence activated cell sorting monitors the presence 
of 8-oxo-guanine which is a marker for nucleobase oxidative damage.  From a series of 
voltametric experiments preformed by Hillard 
[63]
 and Jaouen 
[64-68]
, they showed that the 
cytotoxic effect was due to the formation of a quinone methide.  
This is a plausible explanation between the activity of the two derivatives. The activity of 
compound 35 is attributable to the intercellular oxidation resulting in hydroxyl radical 
formation and cell death.                                                                       Jaouen et al have 
prepared a series of diphenolic compounds derivatized with ferrocene and studied their anti-
cancer activity against dependant and independent ER cancer cell lines. Derivative 37 had a 
high anti-proliferative effect against the ER(+) MCF-7 and the ER(-) MDA-MD-231 cell line 
with IC50 values of 0.4 and 0.7 μM respectively. A regioisomer of derivative 37, derivative 
38, showed only a minor activity against both cell lines. There are two main differences 
between derivatives 37 & 38. Derivative 37, one of the two phenol groups is always 
orientated trans to the ferrocene, whereas in compound 38, there is a cis relationship and 
secondly, the two phenol rings are bonded to the same carbon on the alkene group in 
derivative 37, while in 38, each carbon of the alkene group is attached to the phenol ring. The 
different biological results illustrates that the ferrocene moiety is not solely responsible for 
activity. 
[66]
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The importance of the ferrocenyl moiety was investigated by Hillard et al, where a series of 
analogues was prepared and the ferrocenyl moiety was replaced by pentamethylferrocene, 
ruthenocene, cyclopentadienyl rhenium tricarbonyl and cyclopentadienyl manganese 
tricarbonyl units. The incorporation of these units resulted in the loss of activity on the ER(-) 
cell line, MDA-MB-231, and a loss in estrogenic effect on the MCF-7 cell line. 
[63]
  
Hillard et al also investigated the position of the ferrocene in the molecule using derivatives 
37 & 38. Only the compound with the ferrocene and ethyl groups attached to same carbon 
e.g. 37, showed irreversible redox activity. The postion of the ferrocene in relation to the 
ethyl group is therefore essential for the formation of the quinone methide derivative.  
Compound 37 has been incorporated into two types of nanoparticles, namely nanoparticles 
PEG/PLA nanospheres with the aim of finding an in vivo drug delivery model. The 
nanoparticles are extremely versatile and highly effective in relation to protection of the said 
drug or compound. These nano delivery models protect the drug against hydrolysis and 
oxidation and prevent degradation. After compound 37 was appended to these nano delivery 
models, cell cycle assays were performed in the presence of α-tocopherol (39). The α-
tocopherol is the vitamin E form that is preferentially absorbed by humans and is a well 
known anti-oxidant. In the presence of α-tocopherol, the anti-proliferative effect of 
compound, 37, was reversed as a drop of cells in the sub G1 phase of cell cycle was 
observed. This is the stage where damaged cells are found. The presence of an anti-oxidant 
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may prevent oxidation of ferrocene to ferricenium and therefore prevent the formation of the 
quinone methide, ultimately leading to a loss in anti-proliferative effect. 
 
The position of ferrocene, its efficacy and also the effect of the hydroxyl groups were 
accessed, but the importance of the phenolic groups was investigated in a number of studies. 
Heilmann et al 
[68]
 prepared both thio- and oxo- analogues of compound 37, for example 40 
and 41. When tested, compound 40 showed anti-proliferative effects on the ER(+) cell line, 
MCF-7. No activity was observed on the (ER-) cell line. The ester analogue showed similar 
results suggesting that the ester moiety was hydrolyzed by enzymes to generate 37 in situ. 
Since thioesterases are present in breast cancer cell lines, it can be expected that hydrolysis 
also occurs for compound 40. From the lack of anti-proliferative activity; it would suggest 
that the ferrocenyl thiophenol is also not cytotoxic.  
  
Investigation into the mechanism of action of hydroxytamoxifens is further complicated by 
the fact of having two estrogen receptor (ER) sub groups, ER α and ER β. A possible role of 
the ER β is the control of intercellular oxo-reduction. As the ferrocene moiety is easily 
oxidized to the ferricenium cation, further reduction of the ferricenium cation can yield O2•
-
 
and OH•. The superoxide radical is inactive against DNA unlike the highly reactive and 
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genotoxic hydroxyl radical. The assumption that hydroxy-ferrocifens are effective because of 
their ability to produce hydroxyl radicals was disproved. A technique was used to measure 
the amount of 8-oxo-guanine, which is used as a marker for oxidative damage on 
nucleobases. The ferrocifen did not increase the marker level, thus suggesting that the 
ferrocifen anti-proliferative effect is not due to oxidative stress on the DNA. 
[68]
  
 
Replacement of the phenol group with an acetanilide or aniline group was investigated by 
Pigeon et al, producing compounds 42 and 43 respectively. On testing on the MDA-MB-231 
cell line, both compounds showed anti-proliferative activity with IC50 values of 0.65 μM and 
0.8 μM respectively. [67][70]   
 
            
Zekri et al studied the effect of incorporating halogen groups such as, Br, Cl, and CF3 and 
also a cyano (CN) group in the place of the amino group of compound 43.
[71]
 No anti-
proliferative activity was observed for the Br, Cl and CF3 derivatives tested, but activity was 
present for the cyano derivative (44). IC50 values were in the range of 11 to 60 μM. 
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Plazuk et al prepared a series of ferrocenophane derivatives incorporated into the polyphenol 
structure. Upon analysis on the ER(+) MCF-7 cell line, compounds 45 and 46 exhibited IC50 
values of 4 and 11 μM. [72] In the ER(-) cell line MDA-MB-231 AND PC-3 the anti-
proliferative effect of compound 45 increases dramatically, with an IC50 value of 0.09 μM. 
This compound is ten times more active than compound 46, which IC50 of about 1 μM were 
observed on both cell lines. 
  
A monophenol analogue of compound 45 was synthesised by Gormen et al, namely 47. On 
the  ER(-) cell line, inhibition was recorded to be 0.47 μM, resulting in a fivefold increase in 
activity. Replacement of the phenol group with an acetanilide does not alter the activity 
however on replacement with an aniline group causes a further decrease in anti-proliferative 
activity, resulting in a decrease of IC5O to 0.21 μM.
 [73]
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Tamoxifen has also been appended to other known cytotoxic organometallic compounds. For 
example the cytotoxic (DACH)Pt fragment of oxaliplatin 19, has been attached to the β-
aromatic ring of the tamoxifen molecule. This compound had an IC50 of 4.0 μM compared to 
that of regular oxaliplatin 7.4 μM when tested on the ER(+) cell line, MCF-7. Therefore the 
anti-proliferative effect is similar to that observed for that parent platinum complex. 
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1.5.3 Other ferrocenyl conjugates. 
More recently, various ferrocenyl derivatives have been investigated with the aim of  
increasing the anti-proliferative effect. The incorporation of steroidal, carboxamide groups, 
phenyl dipeptide, multi ring systems and water soluble polymeric side chains have been 
appended to a ferrocene moiety in hope to increase the cytotoxicity.  
Payen et al have prepared ferrocenyl derivatives of the non steroidal anti-androgen 
nilutimide, used in the treatment of prostate cancer. 
[74]
 Analogues of nilutimide were 
prepared where the C-5 position of the hydantoin ring was substituted with ferrocene and a 
para-anisyl group respectively (49) & (50). 
 
From the analogues synthesised, neither showed binding affinity for the androgen receptor, 
which is claimed to play a vital role in prostate cancer development. The in vitro anti-
proliferative effect of both compounds was shown to be most active on the hormone 
dependant prostate cancer cell line, PC-3. The anti-proliferative activity is due solely to the 
aromatic character of ferrocene and is independent of its organometallic nature. Top et al 
have prepared ferrocenyl derivatives of the steroidal androgens, testosterone and 
dihydroxytestosterone. Substitution at the alpha 16 postion of the steroid with an 
ethynylferrocene unit was formed (51). However, all the derivatives synthesized showed 
negligible affinity to binding of the receptors. 
[75] 
 
55 
 
Neuse et al, have developed water soluble and biocompatible polymers with a ferrocene side 
chain for treatment of colon cancer. Cancers of the intestinal system are known to be 
insensitive to many treatments. These ferrocene conjugates have demonstrated excellent 
activity against colo320 DM colon cancer cells. The IC50 values represent the mean polymer 
concentration to achieve 50% cell growth inhibition. The cell growth inhibition is expressed 
as a function of polymer concentration in μg FER/ML. Compounds 52 and 53 displayed 
significant activity with IC50 values of 0.2 μM and 0.5 μM respectively. The activity of these 
conjugates was attributed to the tertiary amine side chain. This enables the polymer to 
become cationic at physicogical pH through nitrogen protonation. Cationic polymers of this 
type are known to enter cells more favourably than polymers in a neutral state. 
[76]
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1.5.4 Novel ferrocenyl conjugates. 
The inclusion of ferrocene into pre-existing analogues to combat fatal diseases such as cancer 
has been a well documented and well published area of research. The synthesis and research 
of novel analogues using the ferrocene as the backbone of the molecule is an area of growing 
interest. Analogues with subsituents that aid lipophilicity, stability, neutrality, while having 
anti-proliferative effects and non toxicity are key factors in this area. 
[2]
  
Long et al appended a ferrocene molecule to the 13-cis retinoic acid analogue, (54) which has 
been reported as a potential chemotherapeutic agent, but with adverse side effects upon 
treatment. 
[77]
 Their research showed that the inclusion of a ferrocene moiety on the 13-cis 
retinoic acid analogue via alkyl or aryl linkers gave a moderate anti-proliferative effect in the 
range, 18 to 42 µM.  
 
Kraatz et al prepared and evaluated a series of ferrocenyl derivatives as anti-cancer agents.  
These analogues incorporated ferrocene into pyrazole ligand 3-FC amp (55). Kraatz showed 
in vitro cytotoxicity profiles of the ferrocenyl ligand to be quite active and also exhibiting a 
dose dependant cytotoxicity relationship when tested on the MCF-7 breast cancer cell lines. 
[78]
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Joksovic et al attached a ferrocenyl pyrozole unit to the N-terminal of α amino acids (56). The 
in vitro anti-proliferative activity of these modified amino acids were evaluated on the cervix 
adenocarcinomas (HeLa), melanoma (Fem-x) cells and the myelogenous leukaemia (K562) 
cell lines. IC50 values were found to vary from 60 µM to 6 µM across the cell lines mentioned 
above. The incorporation of the L-tryptophan derivative showed an activity of 7.95 µM, 9.78 
µM, and 1.24 µM for the respective cell lines. 
[79] 
 
 
 
Subsequently Ratkovic et al prepared a series of compounds wherein the ferrocenyl pyrazole 
unit was appended to various modified chalcones.
[80] 
Evaluation in vitro on the same cell lines 
( HeLa, Fem-x, and K562) revealed that compound 57  to be the most active. The anti-
proliferative effect observed was in the myelogenous leukemia K562 cell line with a value of 
5.42 ± 0.53 µM. 
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1.5.5 Ferrocenyl fluoro-carboxamide & dipeptide conjugates: 
The investigation of the anti-cancer activity with the attachment of various amino acid, 
dipeptide and fluoro-carboxamide groups to different ferrocenyl moieties has been 
particularly fruitful within this research group.  
A series of novel N-(ferrocenylmethyl) fluorinated benzene carboxamide derivatives, with the 
general structure, 58, have been prepared by Kelly et al using standard peptide coupling 
procedures. 
[81]
 The strategic replacement of hydrogen with fluorine is a recognised strategy 
in the development of various drug types. This series was screened on the ER(+) MDA-MB-
435-SF breast cancer cell line. It revealed that the 4-fluoro derivative showed the strongest 
anti-proliferative effect. An IC5O value range between 11-14 μM was determined.  As the 
concentration of the compound increased, the anti-proliferative effect increased indicating a 
dose-dependant relationship.  
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 N-ferrocenyl dipeptide esters have also been synthesised and have been shown to be highly 
active in vitro.
[82-86]
 Initially, N-{ortho-(ferrocenyl)-benzoyl}-glycine ethyl ester was tested 
for in vitro anti-proliferative activity in the H1299 non small lung cancer (NSCLC) cell 
line.
[82]
 This compound was found to be cytotoxic, with an IC50 values of 48 μM. The starting 
material, which was also tested, ortho-ferrocenyl ethyl benzoate was inactive in the same cell 
line. Other derivatives were evaluated for their anti-proliferative effect on the H1299 cell 
line.  
Savage et al prepared a series of N-{meta-(ferrocenyl)-benzoyl}-dipeptide derivatives 
containing L-alanine as the first alpha amino acid in the dipeptide chain. The L-alanine-
glycine ethyl ester derivative (59) was found to have an IC50 of 26 μM in the H1299 cell line, 
whilst an IC50 value of 21 μM was observed for the corresponding ortho- analogue. 
[83]
 
 
A series of N-{ortho-(ferrocenyl)-benzoyl}-dipeptide conjugates containing glycine as the 
first amino acid in the dipeptide chain was prepared by Corry et al. The glycine-L-alanine 
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ethyl ester derivative was shown to exhibit a strong anti-proliferative effect in the H1299 cell 
line. An IC50 value of 5.3 μM was observed. Subsequently the in vitro activity of the 
corresponding meta- and para- analogues were also investigated to compare which was the 
optimal position of the benzoyl ring for cytotoxic activity.
[84]
 IC50 values of 4.0 μM and 6.6 
μM for the meta- and para- respectively were observed. This indicates that the orientation 
around the central benzoyl moiety is not a crucial factor for biological activity. However, the 
order of the amino acids in the dipeptide chain does indeed play a vital role for biological 
activity. N-(ferrocenyl)benzoyl-dipeptide derivatives (60) that contained glycine as the N-
terminal amino acid has a greater anti-proliferative effect in the H1299 cell line than that 
contained L-alanine as the N-terminal amino acid. 
 
 
 
A series of N-(ferrocenyl)benzoyl-tripeptide and tetrapeptide ethyl ester derivatives using 
standard coupling protocol were also prepared by Corry et al. 
[84]
 The N-{ortho-(ferrocenyl)-
benzoyl}-glycine-glycine-glycine ethyl ester was tested in vitro for its anti-proliferative effect 
in the H1299 cell line. An IC50 value of 63 μM was observed. The tetra glycine analogue was 
also tested; however, it did not register an IC50 value in the concentration range of 1-100 μM.  
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Mooney et al synthesized N-(3-ferrocenyl-2-naphthoyl) dipeptide ethyl esters and N-(6-
ferrocenyl-2-naphthoyl) dipeptide ethyl esters, which in vitro, had cytotoxic effects against 
the lung carcinoma cell line H1299. The IC50 values were in the range of 1.2 µM to 8.0 µM. 
The N-(6-ferrocenyl-2-naphthoyl) glycine-L-alanine ethyl ester, (61), was found to be the 
most active with an IC50 value of 1.3 ± 0.1µM compared to cisplatin 1.5 ± 0.1 µM on the 
same cancer cell line. 
[85][86]
 
 
The biological activity of these compounds is possibly due to their low redox potentials and 
their ability to form reactive oxygen species (ROS) under physiological conditions. The anti-
proliferative effect of compounds 58-61 is not solely due to the ferrocene, so it is plausible 
that the dipeptide chains, the fluorobenzoyl, benzoyl and naphthoyl subgroups are involved in 
a secondary mode of action. Cell cycle analysis was performed on a control sample and on 
cells treated with N-{ortho-(ferrocenyl benzoyl)}-glycine-L-alanine ethyl ester (62) at 
concentrations of 5, 10, 20, and 40. As the concentration of the compound increased the 
percentage of cells in the G1 phase of the cell cycle decreased, suggesting a block in the 
G2/M phase prevented the cells re-entering the G1 phase. 
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1.6 Conclusion:  
Research areas such as bioorganometallic chemistry is a flourishing area uniting both the 
discoveries and utilisations of the biological and chemical worlds. Metals have always been a 
prime source of medicinal interest for over 5 millennia. From the discovery of platinum based 
therapies, the research into new metal complexes with medicinal effect is a thriving subject 
that dominates the area of bioorganometallic chemistry. Of special interest it the use of iron 
complexes for malarial infections, bacterial and fungal disease, and also cancers of the breast, 
lung, and skin. Ferrocene is the archetypal of all the metallocenes. It is a small, rigid, 
lipophilic molecule capable of penetrating the cellular membrane. Since its discovery in 1951 
and its introduction into medicinal chemistry in the early 80’s, ferrocene has become one of 
the most utilized compounds in organometallic chemistry. It is a platform for the synthesis, 
development and design of new and more applicable pharmaceuticals and anti-cancer drugs, 
as well as anti-malarial, anti-fungal and anti-bacterial agents.  Ferrocene is also an important 
substitute for phenyl or heterocyclic rings, creating novel derivatives exerting a biological 
effect or creating analogues from pre-existing drugs.  
The reversible redox properties of ferrocene have being associated with the biological activity 
of ferrocenyl compounds. Ferricenium salts known to inhibit tumour growth have been 
shown to produce hydroxyl radicals via the Fenton reaction under physiological conditions. 
Ferrocenyl derivatives have shown to increase the levels of intracellular reactive oxygenated 
species (ROS) in vitro, which at high levels can lead to oxidative damage and cell death. The 
utilization and wide spectrum of medicinal diversity of ferrocene has resulted in the 
increasing popularity of biologically active molecules that include the ferrocene moiety, to be 
researched and pursued to possible treatments.  
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Chapter 2 
Synthesis and structural characterisation of N-(ferrocenylmethylamino acid)-
fluorinated benzene carboxamide derivatives. 
 
2.1 Introduction 
Over the last three decades, a new field of chemistry has emerged from the combination of 
biology and organometallic chemistry, called bioorganometallic chemistry. This area is 
devoted to the synthesis and discovery of new organometallic compounds that may possess  
biological activity. 
[1]
 The use of ferrocene in bioorganometallic chemistry has been the 
centre of interest for the last two decades due to its electrochemical properties, its stability 
and its non toxicity.
[2]
 Originally, ferrocene and ferrocenyl analogues were used as anion 
sensing agents. 
[1]
 However, the use of ferricenium salts known to inhibit tumour growth have 
been shown to produce hydroxyl radicals under physiological conditions, leading to 
oxidatively damaged DNA. Thus ferrocenyl derivatives that possess redox potentials are an 
attractive and alternative method to target and kill cancer cells. The design of ferrocenyl-
bioconjugates with amino acids, peptides and fluorinated aromatic moieties as unnatural 
drugs is an appealing approach. Not only will the combination of both aromatic moieties, 
increase the lipophilicity, but also the attachment of the amino acids, peptides and fluorinated 
species will lower the redox potential therefore making them easier to oxidise, and thus 
increasing their biological activity.
[3] 
Previous work in this laboratory has shown this approach to be quite effective. This study is  
based on the research conducted by Kelly et al, for the synthesis, structural characterisation 
and biological evaluation of N-(ferrocenylmethyl) fluorinated benzene carboxamide 
derivatives. 
[4] 
Their research gave IC50 data in the range of 11µM to 50µM on the MDA-MB-
435-SF breast cancer cell line. The position and also the number of fluorine atoms on the 
aromatic ring were investigated and several analogues were shown to have an anti-
proliferative effect. (Table 2.1) 
 
 
71 
Compound name Compound 
number 
% Inhibition 
(concentration 
10µM) 
N-(ferrocenylmethyl) benzene carboxamide 63 37 ± 3% 
N-(ferrocenylmethyl)-4-fluorobenzene carboxamide 64 41 ± 4% ** 
N-(ferrocenylmethyl)-2,6-difluorobenzene 
carboxamide 
65 27 ± 5% 
N-(ferrocenylmethyl)-2,3,4,5,6-pentafluorobenzene 
carboxamide 
66 35 ± 5% 
Note: {** compound was selected for IC50 studies (11-14µM)} 
Table 2.1: Most active N-(ferrocenylmethyl)-fluorobenzene carboxamide derivatives. 
[4]
 
The N-(ferrocenylmethyl)-fluorinated benzene carboxamide derivatives were previously 
tested and shown to exhibit an anti-cancer effect on the ER(+) breast cancer cell line, MDA-
MB-435-S-F.
[4]
  As this cancer cell line was no longer available, the use of the ER(+) breast 
cancer cell line, MCF-7 was used. For comparison of results, the most active derivative of the 
previous study, N-(ferrocenylmethyl)-4-fluorobenzene carboxamide, (64) was tested with the 
new series of N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide derivatives. 
 
1. A ferrocenylmethyl unit 
2. An amino acid moiety 
3. A fluorinated aromatic ring. 
 
Figure 2.1: Structure of N-(ferrocenylmethylamino acid) fluorinated benzene carboxamides. 
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The primary objective of this research was to explore the structure activity relationship 
(SAR) of these novel N-(ferrocenylmethylamino acid) fluorobenzene carboxamide 
derivatives in order to enhance their cytotoxic effect. This was carried out by substituting 
various amino acids between the ferrocene and the aromatic ring containing fluorine atoms. 
Thus the series of compounds synthesized and discussed in this chapter, have a ferrocenyl 
moiety (1) , linked to an amino acid moiety (2),  which is in turn, attached to a fluorinated 
aromatic ring (3). (Figure 2.1) The inclusion of ferrocene is vital to the mode of action to this 
class of drugs, due to its redox properties, but all of the derivatives incorporate two principle 
factors that increase the biological activity:  
 Use of amino acids 
 Use of fluorine  
 
2.1.1 Amino Acids 
Amino acids are one of nature’s most essential building blocks. They are naturally occurring 
organic compounds with two functional groups consisting of an amino group (-NH2), a 
carboxylic acid (-COOH)  and a variable R group. Both are attached to the central carbon, 
known as the alpha carbon (Cα). In nature, from bacteria to humans, individual α- amino acid 
units are linked together by an amide bond to form peptides and much longer 
macromolecules known as proteins. Peptide and polypeptides eventually form proteins and 
are an essential part of any biological system.  Proteins are involved in many processes in the 
cell, for example, enzymes catalyse chemical reactions within the cell, and also proteins are 
used for support and structure as some are embedded in the lipid bilayers. Proteins have 
multi-functions because of their amino acids. There are 20 essential amino acids with the 
same backbone structure, but variable R group. These R groups allow the proteins to 
diversify in function, as each functional group is different in size, shape, charge, and 
hydrogen bonding capacity 
[5].
 Molecules that contain amino acid or peptide drugs on the 
market today, (67) & (68) is a testament to the utilisation and versatility of these 
multifunctional units.  
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2.1.2 Role of fluorine 
For many years the addition of fluorine has been a fundamental approach to increase the 
biological activity of a drug. The importance of fluorine substitution in pharmaceutical 
development is evident in a large number of fluorinated derivatives approved by the FDA for 
uses as an anti-cancer, anti-viral, anti-depressant and anaesthetic agents. Fluorine has the 
ability to alter the electronic, lipophilic and steric parameters that can critically influence the 
pharmacological properties of a drug molecule. 
[6]
  
 
 
 
The first fluoro-organic substance isolated from natural sources was fluoro-acetic acid (69). 
[7] 
The low abundance of natural products containing fluorine ensures that drugs containing 
this element are processed as xenobiotics when they encounter biological systems. 
[6][7] 
Fluorine is the most electronegative element and the carbon fluorine (C-F) bond can cause the 
strengthening of adjacent carbon-carbon (C-C) single bonds, whereas carbon-carbon (C=C) 
double bonds are weakened by fluorine substitution. Fluorinated compounds are the least 
abundant natural halides. 
[7]
 Most terrestrial fluorine is bound in solution form, hindering 
uptake by bio organisms, however, there are  over 150 fluorinated drugs on the market,  
including the anti-cancer drug, 5-fluorouracil, (70) the anti-depressant fluoxetine (Prozac) 
(71), the cholesterol lowering drug atorvastatin (Lipitor) (72) and the anti-bacterial 
ciprofloxacin (Ciprobay) (73),  being the most used.
[8][9][10]
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The use of fluorine, due to its relatively low size, high electronegativity and lipophilic 
properties is an appealing approach in the investigation of fluorinated compounds with a 
greater biological effect. Fried and Sabo’s seminal preparation of 9-α-fluoro-hydrocortisone 
acetate (74) revealed how judicious introduction of fluorine into an existing biologically 
active molecule imparted beneficial properties to that compound. 
[11][12]
  
 
 
Fadeyi et al published research findings on novel fluorinated acridone derivatives that could 
have anti-cancer potential.
[13] 
Their research showed that trifluoromethyl fluorine subsituents 
(75), exhibited significant effects on the binding affinity in protein–ligand complexes. This 
effect can be direct by interaction of the fluorine with the protein, or it can be indirect by 
modulation of the polarity of other groups of the ligand that interact with the protein. 
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Frequently, it is found that a fluorine substituent leads to a slight enhancement of the binding 
affinity due to an increased lipophilicity of the molecule which results in an increased affinity 
for the protein.  
 
 
Moran et al synthesised a series of 3,4’,5-trifluoro-trans-stilbene derivatives (76) based on 
the parent compound known as resveratrol (3,4’,5- trihydroxy-trans-stilbene) (77). [14] The 
synthesised derivates were biologically evaluated on non small cell lung carcinoma cell lines, 
DKLP. Their results showed that substitution or replacement of the hydroxyl groups with 
fluorine atoms increased the anti-proliferative effect. 
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2.2 The synthesis of N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide 
derivatives. 
2.2.1 Preparation of ferrocenylmethylamine. 
The synthesis of ferrocenecarbaldoxime is outlined in figure 2.2. The amine of the 
hydroxylamine hydrochloride adds to the carbonyl group of the ferrocenecarboxaldehyde to 
form a dipolar tetrahedral intermediate. Intermolecular proton transfer from nitrogen to 
oxygen produces an amino alcohol. Protonation of the oxygen produces a good leaving 
group, and loss of water yields an oxime ion. Transfer of a proton to water produces the 
oxime. 
[15] 
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Figure 2.2: Reaction mechanism for the synthesis of ferrocenecarbaldoxime. 
Reaction yields of the ferrocenecarboaldoxime ranged between 80 – 90 %. Following 
complete drying of the ferrocenecarboaldoxime, it was reduced to ferrocenylmethylamine 
using lithium aluminium hydride.  
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Fe
N
HO
Fe
NH2
LiAlH4
THF
 
Scheme 2.1: Synthesis of ferrocenylmethylamine via reduction of ferrocenecarbaldoxime 
2.2.2 Coupling reactions involving protecting groups. 
For the synthesis of N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide 
derivates, two possible reaction routes were investigated.  For reaction route A, conventional 
coupling chemistry was employed between the amino group (-NH2) of the 
ferrocenylmethylamine and the carboxylic acid functional group of the protected amino acids. 
The protection of the amine group of the amino acid ensures that just the carboxylic acid and 
the ferrocenylmethylamine react. Subsequent deprotection of the protecting group using 
trifluoroacetic acid, which allows for the second coupling of carboxylic acid group of the 
fluorobenzoic  acids to the now free amino group of the ferrocenylmethylamino acid complex 
to yield the N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide derivatives. 
[16]
 
 
Scheme 2.2: Synthetic Route A; use of protected amino acids. 
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2.2.3 Amino protecting groups 
Characteristic amino protecting groups contain carbamate units that have a low degree of 
nucleophilicity and are easily deprotected. The most effective protecting groups are labile to 
mild cleaving conditions that would not affect the amide bond. Common carbamate 
protecting groups including the benzyloxycarbonyl (Z) (78) and t-butoxycarbonyl (BOC) (79) 
groups. These groups are introduced onto the amino acid using benzyl chloroformate and di-
t-butyl carbonate respectively. 
                         
These protecting groups are stable under basic conditions but are easily removed under acidic 
conditions. In each case, the carbamic acid is formed followed by the loss of carbon dioxide 
as illustrated in scheme 2.3. 
Scheme 2.3: Deprotection of BOC protecting group using trifluoroacetic acid 
Another variant is the use of (Bpoc) 2-(4-biphenyl)-isopropoxylcarbonyl (80). The Bpoc 
group is even more acid-labile than the BOC protecting group because the corresponding 
tertiary carbonium ion further stabilised by the biphenyl sub group.
[16]
 Treatment with 
chloroacetic acid removes the protected groups. A protecting group that is acid stable and 
base labile is 9-fluorenylmethoxycarbonyl (Fmoc) (81). It is introduced on the amino acid 
using its stable chloroformate derivative and removed using a base. i.e., piperdine. 
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2.2.4 Carbodiimides 
Carbodiimides are the most widely used carboxyl activating reagent since the introduction of 
dicyclohexylcarbodiimide (DCC) in 1955. DCC and other carboxyl activating reagents can be 
used to generate symmetrical anhydrides and active esters or as a direct coupling reagent. In 
each case, the primary activating event is the formation of an O-acylisourea intermediate. 
This O-acylisourea is a potent acylating agent and rapidly leads to peptide formation 
following aminolysis. However, this high reactivity can lead to the formation of the more 
inert N-acylurea following acyl transfer (Scheme 2.4). 
 
Scheme 2.4: Acyl transfer of O-acylisourea to N-acylurea 
Furthermore, the O-acylisourea intermediate is prone to racemisation (Scheme 2.5). This 
occurs when there is an intramolecular proton transfer from the chiral carbon atom to the 
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basic centre of the O-acylisourea. The chiral carbon is rehybridised from sp
3
 to sp
2
 and when 
the proton returns to its original position it is equally likely to return to either face of the sp
2
 
hybridized carbon. 
[17] 
 
Scheme 2.5: Proton transfer resulting in racemisation.  
These difficulties can be overcome by the addition of a secondary nucleophile, for example 
HOBt (1-hydroxybenzotriazole) or NHS, (N-hydroxysuccinimide) which has the ability to 
rapidly react with the O-acylisourea before side reactions can intervene. An acylating agent 
of lower potency, is formed but that is still highly reactive to aminolysis and less susceptible 
to side reactions and racemisation. EDC (N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride) was employed in the synthetic coupling steps of the N-
(ferrocenylmethylamino acid) fluorinated benzene carboxamide derivatives due to the 
problems associated with the removal of the DCU, urea by-product of DCC. EDC produces a 
water soluble urea by-product,1-(3-(dimethylamino)propyl)-3 ethyl urea, which is removed 
by washing with water. 
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2.2.5 The Schotten Baumann reaction for the synthesis of N-(fluorobenzoyl) amino acids 
The second route involved the reaction of fluorobenzoyl chlorides with free amino acids, 
under Schotten Baumann conditions and subsequent coupling to the ferrocenylmethylamine. 
[17]
 (Route B, Scheme 2.6).  
 
Scheme 2.6: Synthetic Route B; Use of Schotten Baumann conditions. 
The Schotten Baumann reaction involves a two-phase system of immiscible water and 
dichloromethane allowing the formation of the amino acid intermediates and also the 
neutralisation of the excess acid formed during the reaction. 
[18]
 In this instance, 
fluorobenzoyl chlorides are reacting with amino acids, to form N-(fluorobenzoyl) amino acid 
derivatives as outlined in figure 2.3.  Yields for the N-(fluorobenzoyl)-amino acids were in 
the range of 27 % to 46 % 
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Figure 2.3: Schotten Baumann reaction mechanism of fluorobenzoyl chlorides with the 
amino acids, glycine, L-alanine and β-alanine. 
For reaction route B, protection/deprotection was not required and therefore this route was 
employed in the synthesis of N-(ferrocenylmethylamino acid) fluorinated benzene 
carboxamide derivatives. 
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2.2.6 Coupling of ferrocenylmethylamine to N-(fluorobenzoyl) amino acids 
Coupling reactions were used to facilitate the attachment of the ferrocenylmethylamine to the 
various N-(fluorobenzoyl) amino acids. Ferrocenylmethylamine was treated with 1-
hydroxybenzatrizole (HOBt), N-(3diamethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDC) and triethylamine in dichloromethane at 0 
o
C in the presence of the 
various N-(fluorobenzoyl) amino acids. (Figure 2.4)  Subsequent to coupling, the crude 
compounds were purified via column chromatography. The eluant used in all the column 
chromatography was hexane : ethyl acetate mixture (2:1). 
Overall yields for the N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide 
varied from 12 % to 65 %. The varying percentage yield for derivatives is due to loss of 
product during the purification process and also the perfection the coupling method. The 
glycine derivatives were the first series to be synthesised. These yields are in the range of 12 
% to 44 %. In comparison with the other series, the L-alanine, and β-alanine derivatives, 
percentage yields are greater. The L-alanine derivatives range from 24 % to 47 %, and the β-
alanine derivatives range from 30 % to 65 %.  (Table 2.2) All spectroscopic data was in 
accordance with their proposed structures. 
Table 2.2 N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide derivatives 
Compound Number Name Percentage Yield (%) 
111 N-(ferrocenylmethylglycine) 
benzene carboxamide 
25.4 
112 N-(ferrocenylmethylglycine) 
-2-fluorobenzene 
carboxamide 
17.3 
113 N-(ferrocenylmethylglycine) 
-3-fluorobenzene 
carboxamide 
21.7 
114 N-(ferrocenylmethylglycine) 
-4-fluorobenzene 
carboxamide 
15.0 
115 N-(ferrocenylmethylglycine) 
-2,6-difluorobenzene 
carboxamide 
12.3 
116 N-(ferrocenylmethylglycine) 
-2,4-difluorobenzene 
carboxamide 
44.6 
117 N-(ferrocenylmethylglycine) 
-3,5-difluorobenzene 
carboxamide 
34.5 
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118 N-(ferrocenylmethylglycine) 
-3,4,5-trifluorobenzene 
carboxamide 
20.8 
119 N-(ferrocenylmethylglycine) 
-2,3,4,5,6-
pentafluorobenzene 
carboxamide 
29.8 
120 N-(ferrocenylmethyl-L-
alanine) benzene 
carboxamide 
35.4 
121 N-(ferrocenylmethyl-L-
alanine)-2-fluorobenzene 
carboxamide 
26.2 
122 N-(ferrocenylmethyl-L-
alanine)-3-fluorobenzene 
carboxamide 
26.1 
123 N-(ferrocenylmethyl-L-
alanine)-4-fluorobenzene 
carboxamide 
28.7 
124 N-(ferrocenylmethyl-L-
alanine)-2,6-difluorobenzene 
carboxamide 
28.6 
125 N-(ferrocenylmethyl-L-
alanine)-2,4-difluorobenzene 
carboxamide 
31.5 
126 N-(ferrocenylmethyl-L-
alanine)-3,5-difluorobenzene 
carboxamide 
24.7 
127 N-(ferrocenylmethyl-L-
alanine)-3,4,5-
trifluorobenzene 
carboxamide 
46.6 
128 N-(ferrocenylmethyl-L-
alanine)-2,3,4,5,6-
pentafluorobenzene 
carboxamide 
24.0 
129 N-(ferrocenylmethyl-β-
alanine) benzene 
carboxamide 
29.9 
130 N-(ferrocenylmethyl-β-
alanine)-2-fluorobenzene 
carboxamide 
35.5 
131 N-(ferrocenylmethyl-β-
alanine)-3-fluorobenzene 
carboxamide 
45.0 
132 N-(ferrocenylmethyl-β-
alanine)-4-fluorobenzene 
carboxamide 
30.8 
133 N-(ferrocenylmethyl-β-
alanine)-2,6-difluorobenzene 
42.6 
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carboxamide 
134 N-(ferrocenylmethyl-β-
alanine)-2,4-difluorobenzene 
carboxamide 
64.3 
135 N-(ferrocenylmethyl-β-
alanine)-3,5-difluorobenzene 
carboxamide 
55.6 
136 N-(ferrocenylmethyl-β-
alanine)-3,4,5-
trifluorobenzene 
carboxamide 
35.6 
137 N-(ferrocenylmethyl-β-
alanine)-2,3,4,5,6-
pentafluorobenzene 
carboxamide 
44.3 
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Figure 2.4: Coupling reaction mechanism of N-(fluorobenzoyl) amino acids and 
ferrocenylmethylamine using EDC and HOBt coupling reagents. 
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2.3 
1
H NMR studies of N-(ferrocenylmethylamino acid) fluorinated benzene 
carboxamide derivatives. 
All the 
1
H NMR experiments were performed in d6-DMSO as the N-(ferrocenylmethylamino 
acid) fluorinated benzene carboxamide derivatives showed limited solubility in other 
deuterated solvents. In d6-DMSO  the  amide protons of the amino acids appear at δ 9.20 to 
8.90 for the glycine derivatives, δ 9.30 to δ 8.40 for the L-alanine derivatives and δ 9.0 to δ 
8.5 for the β-alanine derivatives. The amide protons of the ferrocenylmethylamine moiety 
appear within the region of δ 8.20 to δ 8.0. The spectra have three signals in the ferrocenyl 
region which are typical of a mono-substituted ferrocene. The protons of the substituted 
cyclopentadienyl ring appear as fine triplets or singlets between δ 4.20 and δ 4.08. The 
unsubstituted cyclopentadienyl ring appears as a strong singlet at δ 4.15. For the glycine 
derivatives, the two methylene groups Fc-CH2 & glycine - CH2 respectively appear as 
doublets at δ 4.03 and δ 3.85. For the L-alanine derivatives, the methylene group (Fc- CH2) 
appears between  δ 4.05 and δ 4.00, while the methine group appears as a muliplet between δ 
4.60 - δ 4.55. The methyl group of the L-alanine derivatives appears as a doublet between δ 
1.41 and δ 1.30.  Three methylene groups are observed for the β-alanine spectra. The 
methylene of the Fc-CH2 appears as a doublet between δ 4.03 and δ 3.99. The methylene 
groups of the β-alanine appear as a quartet between δ 3.50 and δ 3.41 and a triplet between δ 
2.45 and δ 2.38. (Figure 2.5) 
 
91 
 
Figure 2.5 
1
H NMR spectra of the N-(ferrocenylmethyl glycine, L-alanine and β-alanine) 
fluorobenzene carboxamide derivatives (111, 120, & 129 respectively). 
 
Table 2.3 Selected 
1H NMR spectral data (δ, d6-DMSO) for N-(ferrocenylmethylamino acid) 
fluorinated benzene carboxamides. 
 
Compound NH’s (η5-C5H5) & Ortho 
(η5-C5H4) 
Meta (η5-C5H4) 
113 8.89, 8.07 4.18-4.15* 4.08 
118 9.02, 8.17 4.17-4.14* 4.08-4.06* 
123 8.62, 8.10 4.17-4.14* 4.07 
129 8.54, 8.13 4.16-4.05* 4.04 
135 8.79, 8.14 4.20-4.16* 4.10-4.09* 
137 9.05, 8.16 4.18-4.15* 4.08 
Note: * indicates that these peaks occur as a multiplet. 
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2.3.1 
1
H NMR spectroscopic study of N-(ferrocenylmethylglycine)-4-fluorobenzene 
carboxamide (114) 
 
In the 
1
H NMR spectrum of N-(ferrocenylmethylglycine)-4-fluorobenzene carboxamide 
(114), two amide protons occur at the relatively down field positions of  δ 8.80 and  δ 
8.01 respectively. Both amide groups appear as triplets due to the coupling of the nearby 
methylene groups of glycine amino acid and of the ferrocenylmethylamine moiety. The 
coupling constants observed for the amide protons at δ 8.80 and δ 8.0 were 6.0 Hz for 
both triplets.  The aromatic protons appear as two multiplets in the region δ 7.99 – δ 7.92 
and δ 7.35 – δ 7.28. This was observed in all fluorinated derivatives synthesized.  The 
splitting pattern of the two multiplets is a result of the position of the fluorine atom on 
the aromatic system. Each multiplet integrates as two hydrogens. The signal for the 
unsubstituted (η5C5H5) cyclopentadienyl ring and the protons in the ortho position on the 
substituted ring (η5C5H4) occur as a multiplet between δ 4.18 and δ 4.15. A multiplet 
with an integration of seven protons is observed due to the overlap of signals. The meta 
protons of the substituted (η5C5H4) cyclopentadienyl ring appears as a triplet at δ 4.07, 
integrating for two protons. The most upfield signals are due to the presence of the 
methylene protons attached to the ferrocenylmethylamine moiety and also the methylene 
of the glycine, which occur as doublets at δ 4.02 and δ 3.85 respectively.  
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Figure 2.6 
1
H NMR spectrum of N-(ferrocenylmethylglycine)-4-fluorobenzene 
carboxamide (114). 
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2.3.2 
1
H NMR spectroscopic study of N-(ferrocenylmethylglycine)-3,5-
difluorobenzene carboxamide (117)  
 
The amide protons of N-(ferrocenylmethylglycine)-3,5-difluoronbenzene carboxamide 
appear downfield at δ 8.97 and δ 8.10. Each of the amide protons is split into a triplet due 
to the neighbouring methylene protons of the amino acid and ferrocenylmethylamine 
group respectively. Both amide protons exhibit coupling constants of 5.6 Hz. The 
aromatic protons, integrating as two hydrogens appear as a multiplet between δ 7.63 and 
δ 7.58. The proton positioned at 4 on the aromatic ring is split as a triplet of triplets 
occurring between δ 7.51 and δ 7.46  (fig. 2.7).  This is due to the neighbouring fluorine 
atoms positioned at 3 and 5 on the aromatic ring. The unsubstituted (η5C5H5) 
cyclopentadienyl ring protons and the ortho protons of the substituted cyclopentadienyl 
ring occur as a multiplet between δ 4.18 and δ 4.15.  The meta protons of the substituted 
cyclopentadienyl ring occurs as a doublet at δ4.07. The methylene protons of the 
ferrocenylmethylamine moiety and the methylene protons of glycine appear at δ 4.02 and 
δ 3.85 respectively with coupling constants of 6.0Hz.  
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Figure 2.7: 
1
H NMR of N-(ferrocenylmethylglycine)-3,5-difluorobenzene carboxamide 
(117) 
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2.3.3 
1
H NMR spectroscopic study of N-(ferrocenylmethyl-L-alanine)-3,4,5- 
trifluorobenzene carboxamide (127). 
 
In the 
1
H NMR spectrum of N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene 
carboxamide, the amide protons appear at δ 8.78 and  δ 8.25. The splitting patterns have 
now changed, as the amide protons appear as a doublet and a triplet respectively. The 
presence of the doublet is due to the coupling interactions with the methine proton of the 
L-alanine amino acid in the molecule. The aromatic protons appear as a multiplet in the 
region of δ 7.93 to δ 7.85. The methine proton, integrating as one, occurs as a multiplet 
in the range of δ 4.53 to δ 4.46 The signal for the unsubstituted (η5C5H5) 
cyclopentadienyl ring and the protons in the ortho position on the substituted ring 
(η5C5H4) occur as a multiplet between δ 4.19 and δ 4.17. A multiplet with an integration 
of seven protons is observed due to the overlap of signals. The meta protons of the 
substituted ring occurs as a triplet at δ 4.10. The methylene group attached to the 
substituted cyclopentadienyl ring occurs as a muliplet between δ 4.05 - δ 3.95. The 
methyl group of the L-alanine amino acid appears as a doublet at δ 1.41 with a coupling 
constant of 6.0 Hz. 
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Figure 2.8: 
1
H NMR spectrum of N-(ferrocenylmethylalanine)-3,4,5-trifluorobenzene 
carboxamide (127). 
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2.3.4 
1
H NMR spectroscopic study of N-(ferrocenylmethyl-β-alanine)-2,3,4,5,6-
pentafluorobenzene carboxamide (137). 
 
 
In the 
1
H NMR spectrum of N-(ferrocenylmethyl-β-alanine)-2,3,4,5,6-
pentafluorobenzene carboxamide (137), two amide protons occur at δ 9.05 and  δ 8.16 
respectively.  Both amide groups appear as triplets due to the coupling of the nearby 
methylene groups of β-alanine amino acid and also of the ferrocenylmethylamine moiety. 
The coupling constants observed for the amide protons at δ 9.05 and δ 8.15 were 7.6 Hz 
and 6.0 Hz respectively. The signal for the unsubstituted (η5C5H5) cyclopentadienyl ring 
and the protons in the ortho position on the substituted ring (η5C5H4) occur as a multiplet 
between δ 4.18 and δ 4.15. A multiplet with an integration of seven protons is observed 
due to the overlap of signals. The meta protons of the substituted ring occurs as a triplet 
at δ 4.08. Two methylene proton groups of the amino acid occur upfield. These 
methylene groups are split into a quartet and a triplet. The quartet, occurs at δ 3.49  with 
a coupling constant of 6.8 Hz, while the triplet appears further upfield at δ 2.45. A 
coupling constant of 6.8 Hz is also observed. 
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Figure 2.9: 
1
H NMR spectrum of N-(ferrocenylmethyl-β-alanine)-2,3,4,5,6-
pentafluorobenzene carboxamide (137). 
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2.4 
13
C studies and DEPT 135 studies of N-(ferrocenylmethylamino acid) fluorobenzene 
carboxamide derivatives. 
In the 
13
C NMR spectra of N-(ferrocenylmethylamino acid) fluorinated benzene 
carboxamides the carbonyl carbon atoms of the amino acid and the benzene carbonyl carbon 
atoms appear in the region of δ 171 to δ 160 for all of the derivatives synthesized. 
The ferrocenyl carbon atoms appear in the region δ 86 to δ 67. The unsubstituted 
cyclopentadienyl ring (η5-C5H5) appears as a strong intense peak in the range of δ 68.5 to δ 
68.2 , while the other ferrocenyl peaks, the ortho and meta carbons of the substituted 
cyclopentadienyl ring (η5-C5H4) produce chemical shifts between δ 67.9 and δ 67.1 The ipso 
carbon on the substituted cyclopentadienyl ring appears in the range of  δ 86.4 to δ 85.0. As 
expected this peak does not appear in any of the DEPT 135 NMR spectra  
The methylene carbon atom of the glycine occurs in the region of δ 43.6 to δ 42.2 while the 
methylene carbon atom of ferrocenylmethylamine appears in the region of  δ 37.5 to δ 37.4. 
The methine carbon  of the L-alanine derivatives occur between δ 49.7 and δ 48.6 while the 
methyl carbon appears in the region of δ 18.5 to δ 17.9. The methylene carbon of the 
ferrocenylmethylamine moiety in the L-alanine derivatives occurs between δ 37.5 and δ 37.4. 
The methylene carbons of the β-alanine derivatives occur between δ 36.3 and δ 34.5 for the 
amino acid moiety, while the methylene carbon of the ferrocenylmethylamine moiety occurs 
between δ 37.5 and δ 37.2. The methylene peaks are easily identified in the DEPT 135 
spectra due to their negative resonances. 
The pattern observed in the aromatic region of the spectrum is dependent on where the 
fluorine atom is situated on the benzene ring. For the derivatives with fluorine located at 
position  4, (2,6),  (3,5), (3,4,5) and the penta derivatives give rise to four peaks, due to four 
unique carbons,  while the remaining derivatives with fluorine located at 2, 3, & (2,4) give 
rise to 6 peaks in the aromatic region due to the six non-equivalent carbons.  
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Table 2.4 Selected 
13
C NMR data (δ d6 DMSO) of N-(ferrocenylmethylglycine) fluorinated 
benzene carboxamides. 
Compound No. C=O Ipso (η5-C5H4) (η5-C5H5) Amino acid 
CH2 & CH2NH 
115 168.6, 166.4 86.0 68.3 42.2 & 37.5 
117 168.5, 163.5 86.3 68.3 42.9 & 37.4 
119 168.3, 165.0 85.9 68.4 42.6 & 37.5 
 
Table 2.5 Selected 
13C NMR data (δ d6 DMSO) of N-(ferrocenylmethyl-L-alanine) 
fluorinated benzene carboxamides. 
 
Compound 
No. 
C=O Ipso (η5-
C5H4) 
(η5-C5H5) (η5-C5H4) 
CH2 
Amino acid 
CH3 
122 171.7, 164.8 86.2 68.3 37.4 17.9 
124 171.1, 165.8 86.0 68.4 37.5 18.3 
126 171.5, 163.5 86.2 68.3 37.5 17.9 
 
Table 2.6 Selected 
13C NMR (δ d6 DMSO) N-(ferrocenylmethyl-β-alanine) fluorinated 
benzene carboxamides. 
 
Compound No. C=O Ipso (η5-C5H4) (η5-C5H5) Amino acid CH2 
& CH2NH 
130 169.7, 162.5 86.1 68.3 37.4, 36.0, 34.9 
132 169.7, 163.5 85.9 68.2 37.2, 36.3, 34.9 
135 169.3, 168.3 86.0 68.5 37.5, 35.8, 34.9 
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2.5 
13
C NMR and DEPT-135 study of N-(ferrocenylmethylglycine)-3-fluorobenzene 
carboxamide (113) 
 
            
The 
13
C NMR spectrum of N-(ferrocenylmethylglycine)-3-fluorobenzene carboxamide (113), 
displays two carbonyl carbon atoms between δ 168.2 and δ 163.0. These signals are not 
present in the DEPT-135 spectrum. The aromatic region displays six carbon peaks (splitting 
of the peaks occurs due to the presence of fluorine on the molecule) due to the 6 non-
equivalent carbons on the benzene ring. The carbon located at δ 85.9, is the ipso carbon. The 
5 equivalent carbons of the unsubstituted (η5C5H5) cyclopentadienyl ring occurs at δ 68.3. 
The carbons of the substituted cyclopentadienyl ring, in the positions of ortho and meta, 
occur at δ 67.7 and δ 67.2 respectively. The methylene groups of the ferrocenylmethylamine 
and the amino acid moiety are easily assigned, as they show negative resonance in the DEPT-
135 spectrum at δ 43.6 & δ 37.5 respectively. 
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Figure 2.10 
13
C NMR spectrum of N-(ferrocenylmethylglycine)-3-fluorobenzene 
carboxamide (113) 
 
Figure 2.11 DEPT-135 spectrum of N-(ferrocenylmethylglycine)-3-fluorobenzene 
carboxamide (113) 
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2.6 
1
H COSY studies of N-(ferrocenylmethyl-L-alanine)-4-fluorobenzene carboxamide 
(123). 
                    
A two dimensional experiment which indicates all the spin – spin coupled protons in one 
spectrum is called a COSY (COrrelated SpectroscopY). In the COSY spectrum, two 
essentially identical chemical shift axes are plotted orthogonally. There are two coordinate 
axes each representing chemical shift range. The data is plotted as a grid with both chemical 
shift ranges and the third dimension shows the intensity of the observed signal. 
[38]
 For the 
1
H 
COSY of N-(ferrocenylmethyl-L-alanine)-4-fluorobenzene carboxamide, (123),  the proton 
spectrum is plotted along each axis. The spectrum (figure 2.13) shows spots on the diagonal, 
as each individual spot corresponds to the same peak on each coordinate axis. The amide 
proton of the L-alanine amino acid a (δ 8.62) correlates with the methine group of the amino 
acid b (δ 4.54 – 4.47), while the amide proton of the ferrocenylmethylamine d (δ 8.10) 
correlates with the methylene group of adjacent to it e (δ 4.03). The methine group  b (δ 4.54 
– 4.47) also correlates with the methyl group  c (δ 1.35). There is correlation between the 
aromatic protons, as the two hydrogens of the aromatic ring (δ 8.0- 7.97) and (δ 7.35 – 7.26) f 
& g, correlate with each other. Correlation is also present between the ortho and meta protons 
of the substituted (η5-C5H4), h & i. 
                       
Figure 2.12 N-(ferrocenylmethyl-L-alanine)-4-fluorobenzenecarboxamide (123) 
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Figure 2.13 
1
H COSY spectrum of N-(ferrocenylmethyl-L-alanine)-4-fluorobenzene 
carboxamide (123). 
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2.7 HMQC study of N-(ferrocenylmethyl-β-alanine)-3,5-difluorobenzene carboxamide 
(135).  
HMQC (Heteronuclear Multiple Quantum Coherence) is a 2D NMR technique that correlates  
each 
13
C atom to the proton to which it is directly attached. Thus HMQC allows for complete 
assignment of proton and carbon spectra, and therefore total structure elucidation. For 
complex spectra, this technique is often used to resolve peaks that may be overlapping in the 
proton spectra. This technique only correlates carbon to hydrogen peaks, as quarterany 
carbons are not shown in this type of spectra. The structure of N-(ferrocenylmethyl-β-
alanine)-3,5-difluorobenzene carboxamide (135) and HMQC spectrum are shown in figure 
2.14 and table 2.7. 
                       
Figure 2.14 N-(ferrocenylmethyl-β-alanine)-3,5-difluorobenzene carboxamide (135) 
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Table 2.7 HMQC (δ d6 DMSO) data for N-(ferrocenylmethyl-β-alanine)-3,5-difluorobenzene 
carboxamide  
Site 
1
H NMR 
13
C NMR HMQC 
1  85.9  
2 & 3 4.20  67.2 
4 & 5 4.10  67.8 
6-10 4.19 – 4.15*  68.5 
11 4.08   
12 8.14   
13  169.3  
14 2.41 – 2.37*  35.8 
15 3.49 – 3.39*  34.8 
16 8.79   
17  168.3  
18  143.7  
19 7.54 – 7.46*  111.9-111.8 
20  141.1  
21 7.18 – 7.12*  101.4-101.3 
22  132.1  
23 7.54 – 7.46*  126.2-126.1 
* these peaks appear as multiplet 
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2.8 
19
F NMR spectroscopic studies of N-(ferrocenylmethylamino acid) fluorinated 
benzene carboxamide derivatives. 
The introduction of single fluorine atoms can have an effect, physically, chemically, and 
spectometically.
[20] 
For the characterisation of N-(ferrocenylmethylamino acid) fluorinated 
benzene carboxamide derivatives, fluorine was identified via 
19
F NMR spectroscopy. The 
position and also the number of fluorine atoms on the aromatic moiety of the N-
(ferrocenylmethylamino acid) fluorobenzene carboxamide derivative played a vital role in the 
characterisation of the compounds. the fluorine resonances for the mono fluorinated and 
equivalent difluorinated derivatives appeared as singlet’s, while for disubstituted and 
trisubstituted, two peaks were observed, three peaks were present in the 
19
F NMR, for the N-
(ferrocenylmethylamino acid)-2,3,4,5,6-pentafluorinated benzene carboxamide derivatives. 
The chemical shifts appear in the negative region within the range of δ -100 to δ -150. 
 
Figure 2.15 
19
F NMR spectrum of  N-(ferrocenylmethyl-β-alanine)-2,3,4,5,6-
pentafluorobenzene carboxamide derivative. (137) 
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2.9 Infra Red studies of N-(ferrocenylmethylamino acid) fluorinated benzene 
carboxamide derivatives. 
The energy of most molecular vibrations corresponds to that of the infrared region of the 
electromagnetic spectrum. Infra red (IR) spectroscopy is a technique used to identify the 
functional groups in a molecule.  Compounds can absorb IR radiation and compounds that 
are highly complex have a large number of vibrational modes that involve the whole 
molecule. While some vibrations within the molecule are due to functional groups, others are 
due these various modes  e.g. stretching, bending and rocking. These various vibrational 
modes are extremely useful in the identification of the functional groups in a molecule. The 
region of the spectrum above 1500 cm
-1
 gives the most information regarding the functional 
groups present. The lower region, known as the fingerprint region, is a useful region in the 
detection of substitution patterns of aromatic system where characteristic bands can show 
whether an aromatic system is mono-, ortho-, meta- or para- disubstituted. 
[19]
 
The IR spectra of N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide 
derivatives were obtained using potassium bromide discs or as pure solids. The spectra of 
these compounds shows weak sharp bands in the region of ~3400 to 3200 cm 
-1
. This 
corresponds to the N-H stretching of the amides in the molecule. The region of ~ 1650 to 
1580 cm 
-1
 refers to the stretching of the carbonyl groups, (C=O) in the molecule. Bands 
observed in the region of ~2960 to 2850 cm 
-1
 correspond for the saturated C-H stretches in 
methylene and methyl groups. The two or three bands  in the 1600-1500 cm 
-1
 region are 
shown by most six membered aromatic ring systems. 
[19]
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Figure 2.16 IR Spectrum of N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene 
carboxamide (127). 
Table 2.8: Selected IR data for N-(ferrocenylmethylamino acid) fluorinated benzene 
carboxamide derivatives. (values are quoted in cm 
-1
) 
Compound 
No, 
N-H stretch of 
amide 
C-H stretching C=O stretch of 
-CONH- 
Aromatic 
Stretching 
112 3325 3112 1689 1645-1516 
115 3344 3244 1653 1623-1559 
123 3345 3222 1655 1636-1507 
122 3340 3261 1647 1633-1525 
134 3263 3079 1635 1552 
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2.10 UV-Vis spectroscopic studies of N-(ferrocenylmethylamino) fluorinated benzene 
carboxamide derivatives. 
The ultraviolet and visible spectra of organic compounds are associated with the transitions 
between the electronic energy levels. The transitions are usually between a bonding or lone 
pair orbital and an unfilled non-bonding or anti-bonding orbital. The wavelength of 
absorption is then a measure of the separation of the energy levels of the orbitals concerned. 
The highest energy of separation is found when the electrons in σ-bonds are excited, giving 
rise to absorption in the 120-200 nm range. Attention should be focused on the region greater 
than 200 nm where the excitations of electrons of the p and d orbitals, π orbitals and 
especially π conjugated systems lead to informative and very useful spectra. [19] 
The UV-Vis spectra of N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide 
derivatives differ quite significantly. The N-(ferrocenylmethyl-L-alanine) fluorinated benzene 
carboxamide derivatives give the strongest absorbance bands. This is due to the amino acid 
being on the same plane of the aromatic linker and also the ferrocene unit, therefore creating 
a larger chromophore. The general rule is the larger the chromophore the better the 
absorbance. The L-alanine derivatives have maxima at approximately 320 nm to 430 nm 
corresponding to the π and π* transitions of the amide of the amino acid and of the metal to 
ligand charge transfer (MLCT) of the ferrocene respectively.  
The glycine and β-alanine derivatives have absorbance bands between 320 nm to 400 nm. 
These absorbances are not as intense and appear shorter to those of the L-alanine derivatives.  
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Table 2.9. UV-Vis data (nm) for N-(ferrocenylmethylamino acid) fluorinated benzene 
carboxamide derivatives. 
Compound λ MAX 1 ε 1 λMAX2 ε2 
118 426 984 321 1338 
119 420 1436 327 2720 
124 436 1078 322 1003 
127 436 2483 322 2940 
136 432 838 321 828 
137 436 965 321 753 
 
 
Figure 2.17: UV-Vis spectra of N-(ferrocenylmethyl (glycine), (L-alanine) & (β-alanine)) 
fluorinated benzene carboxamides 118, 119, 124, 127, 136 and 137. 
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2.11 Mass spectrometric studies of N-(ferrocenylmethylamino acid) fluorinated benzene 
carboxamide derivatives. 
Mass spectrometry enables the determination of the relative molecular mass of many 
different classes of compounds. The mass spectrometer is composed of three distinct parts, 
namely the ion source, the analyser and the detector. After the sample has been introduced 
into the ion source, ionisation occurs. The ions are then extracted into the analyser, where 
they are separated according to their mass (m) to charge (z) ratios (m/z). The separated ions 
are detected and displayed as a mass spectrum. 
[19][21]
 The N-(ferrocenylmethylamino acid) 
fluorinated benzene carboxamide derivatives are non volatile, therefore a soft ionisation 
technique such as ESI (Electrospray ionisation) mass spectrometry must be  employed in 
their analysis. The N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide 
derivatives  114, 117, 119, 127 & 128  were analysed by ESI mass spectrometry. 
Examination of the mass spectra revealed the presence of both radical cations [M]
+.
 as well as 
[M+H] 
+
 species.  Sequence specific fragment ions were not observed, with the exception of 
one fragment, the ferrocenylmethylene moiety appearing at m/z 199. This fragment is clearly 
present in the mass spectrum of N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene 
carboxamide (127). 
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Figure 2.18  ESI-MS of N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene  carboxamide 
(127) 
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2.12 Conclusions 
N-(Ferrocenylmethyl)-fluorobenzene carboxamide derivatives have been identified as 
potential anti-cancer agents on the MDA-MB-435-S-F breast cancer cell line. 
[4]
 This project 
sought to investigate and explore the structure activity relationship of these derivatives in 
order to enhance the anti-proliferative effect. The primary focus of this project was to 
incorporate various amino acids as well as various fluorine atom subsituents in order to 
increase this effect. Thus, three series of novel N-(ferrocenylmethylamino acid) fluorinated 
benzene carboxamide derivatives have been prepared in good yield, following a number of 
synthetic steps. These novel compounds have been characterised by a range of spectroscopic 
techniques including 
1
H NMR, 
13
C NMR, DEPT-135, HMQC, IR, UV, MS and 
19
F NMR. 
Each compound gave spectra in accordance with their proposed structures. All compounds 
were then screened for the anti-proliferative activity on the estrogen receptor positive, ER(+), 
breast cancer cell line. The N-(ferrocenylmethyl)-fluorobenzene carboxamide derivatives 
were tested on the MDA-MB-435-S-F breast cancer cell line 
[4]
, however, this cell line was 
no longer available when testing, and therefore, the MCF-7 breast cancer cell line was used.  
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    Experimental 
 
                                                  General procedures. 
 
All chemicals were purchased from Sigma-Aldrich, Lennox Chemicals, Fluorochem limited 
or Tokyo Chemical Industry UK limited; and used as received. Commercial grade reagents 
were used without further purification. When necessary, all solvents were purified and dried 
prior to use. Riedal-Haën silica gel was used for thin layer chromatography and column 
chromatography.  Melting points were determined using a Griffin melting point apparatus 
and are uncorrected. Optical rotation measurements were made on a Perkin Elmer 343 
Polarimeter and are quoted in units of 10
-1
 deg cm
2
 g
-1
.  Infrared spectra were recorded on a 
Nicolet 405 FT-IR spectrometer or a Perkin Elmer Spectrometer 100 FT-IR with ATR.  UV-
Vis spectra were recorded on a Hewlett-Packard 8452A diode array UV-Vis 
spectrophotometer. NMR spectra were obtained on a Bruker AC 400 NMR spectrometer 
operating at 400 MHz for 
1
H NMR, 376 MHz for 
19
F NMR and 100 MHz for 
13
C NMR. The 
1
H and 
13C NMR chemical shifts (δ) are relative to tetramethylsilane and the 19F NMR 
chemical shifts (δ) are relative to trifluoroacetic acid. All coupling constants (J) are in Hertz 
(Hz). The abbreviations for the peak multiplicities are as follows: s (singlet), d (doublet), t 
(triplet), q (quartet), qt (quintet), st (sextet) and  m (multiplet). Electrospray ionization mass 
spectra were performed on a Micromass LCT mass spectrometer or a Brűker Daltonics 
Esquire-LC ion trap mass spectrometer. Elemental analysis was carried out by the 
microanalytical laboratory at University College Dublin. 
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General procedure for the preparation of starting materials for N-(ferrocenylmethylamino 
acid)-fluorinated benzene carboxamides. 
 
Ferrocenecarbaldoxime 82 
 
 Ferrocenecarboxaldehyde (4.03 g, 18.83 mmol) was dissolved in 
warm ethanol (10 ml). Sodium acetate (4.55 g, 55.45 mmol) and hydroxylamine hydrochloride (3.50 
g, 50.37 mmol) were dissolved thoroughly in distilled water (15 ml). The solutions were combined 
and refluxed at 100 
o
C for 5 hr. After cooling to room temperature, diethyl ether (100 ml) was added. 
The ether layer was washed with water and dried over MgSO4. The solvent was removed in vacuo to 
yield an orange/ red solid.
 
 (3.50g, 46.5 %), mp 135-136 
o
C 
[1]
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 
11.01  (1H, s, CHN-OH), 7.30 (1H, s, Fc CH), 4.83 {2H, t,  J = 1.6 Hz, ortho on (η5-C5H4)}, 4.35, 
{2H, t, J = 1.6 Hz, meta on (η5-C5H4) }, 4.15 (5H, s, (η
5
-C5H5)}. 
13C NMR (100 MHz) δ (DMSO-d6): 
144.9, 73.4, 70.9, 69.3, 68.7 
 
Ferrocenylmethylamine via reduction with lithium aluminum hydride 83 
Lithium aluminum hydride (2.40 g, 63.24 mmol) was dissolved in 
anhydrous tetrahydrofuran (20 ml) under nitrogen. Ferrocenecarbaldoxime (2.71 g, 11.83 mmol) was 
dissolved in anhydrous tetrahydrofuran and added to the LiAlH4 via syringe. The reaction was stirred 
for 48 hr. The reaction flask was cooled to 0 
o
C. Ethyl acetate (5 ml) and 3 M  sodium hydroxide (5 
ml) were added. The reaction mixture was filtered and diethyl ether (100 ml) was added. The ether 
layer was washed with water and dried over MgSO4. The solvent was removed in vacuo to yield the 
crude product as an orange oil.
 [1]
  (1.10 g, 40.5 %), 
1H NMR (400 MHz) δ (DMSO-d6): 8.16 - 8.04 
{2H, m, (η5-C5H4)-CH2-NH2}, 4.19 -4.15 {7H, m, (η
5
-C5H5) and ortho on (η
5
-C5H4)}, 4.08 {2H, t, J = 
 
120 
5.6 Hz, meta on (η5-C5H4)}, 3.95 - 3.90 {2H, m, FcCH2 }. 
13C NMR (100 MHz) δ (DMSO-d6): 86.0, 
68.4, 67.8, 67.2, 37.5. 
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General procedure for the synthesis of N-(fluorobenzoyl) amino acids: 
N-(benzoyl)-glycine 84 
 Glycine (1.03 g, 13.72 mmol) was dissolved in 
dichloromethane (20 ml). Benzoyl chloride (1.50 ml, 12.96 mmol) was added slowly via a syringe.  1 
M sodium hydroxide (10 ml) was added, and the reaction mixture was stirred for 3 hr. Concentrated 
hydrochloric acid was added to the aqueous layer until a precipitate formed. Vacuum filtration yielded 
a white crystalline product. (0.54 g, 19.01 %), mp 154-155 
0
C;  
1
H NMR (400 MHz) δ (DMSO-d6): 12.70 (1H, s, -COOH), 8.88 (1H, t, J  = 5.6 Hz, Ar-CO-NH), 
7.88-7.86 (2H, m, Ar-H), 7.57-7.53 (2H, m, Ar-H), 7.48-7.46 (1H, m, Ar-H), 4.02 (2H, d, J  = 5.2 Hz, 
NH-CH2-COOH). 
13
C NMR (100 MHz) δ (DMSO-d6): 171.3, 166.5, 133.7, 131.4, 128.3, 127.2, 41.17 
N-(2-fluorobenzoyl)-glycine 85 
The synthesis followed that of 84 using the following 
reagents: glycine (1.01 g, 13.45 mmol), 2-fluorobenzoyl chloride (1.6 ml, 13.11 mmol).  The product 
was obtained as white crystals. (0.79 g, 25.2 %), mp 166-168 
0
C. 
 
1
H NMR (400 MHz) δ (DMSO-d6): 12.50 (1H, s, -COOH), 8.55 (1H, t, J  = 5.6 Hz, Ar-CO-NH), 
7.75-7.72 (1H, m, Ar-H), 7.61-7.53 (1H, m, Ar-H), 7.35-7.27 (2H, m, Ar-H), 3.90 (2H, d, J  = 4.4 Hz, 
NH-CH2-COOH). 
13C NMR (100 MHz) δ (DMSO-d6): 170.9, 163.7, 158.1, 132.9-132.8, 130.4-130.3, 124.6-124.5, 
122.9-122.7, 116.3-116.1, and 41.2 
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N-(3-fluorobenzoyl)-glycine 86 
 The synthesis followed that of 84 using the 
following reagents: glycine (1.25 g, 16.65 mmol), 3-fluorobenzoyl chloride (2.0 ml, 16.39 mmol).  
The product was obtained as white crystals. (0.83 g, 21.5 %), mp 165-167 
0
C. 
 
1
H NMR (400 MHz) δ (DMSO-d6): 12.66 (1H, s, -COOH), 8.97 (1H, t, J = 5.6 Hz, Ar-CO-NH), 7.75-
7.74 (1H, m, Ar-H), 7.67-7.64 (1H, m, Ar-H), 7.58-7.52 (1H, m, Ar-H), 7.44-7.39 (1H, m, Ar-H), 
3.94 (2H, d, J = 5.6 Hz,  NH-CH2-COOH). 
13
C NMR (100 MHz) δ (DMSO-d6): 171.4, 163.13, 160.7, 136.2-136.1, 130.5-130.4, 123.3-123.2, 
118.3-118.2, 114.1-113.9, 41.5 
 
N-(4-fluorobenzoyl)-glycine 87 
 The synthesis followed that of 84 using the 
following reagents: glycine (1.01 g, 13.45 mmol), 4-fluorobenzoyl chloride (1.5 ml, 12.29 mmol).  
The product was obtained as white crystals. (0.86 g, 29.0 %), mp 166-169
0
C. 
1
H NMR (400 MHz) δ (DMSO-d6): 12.60 (1H, s, -COOH), 8.97 (1H, t, J = 5.6 Hz, Ar-CO-NH), 8.00-
7.90 (2H, m, Ar-H), 7.38-7.29 (2H, m, Ar-H), 3.95 (2H, d, J = 2.4 Hz, NH-CH2-COOH). 
13
C NMR (100 MHz) δ (DMSO-d6): 171.3, 165.3, 162.7 130.8-130.3, 129.9-129.8, 115.7-115.5, 41.2 
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N-(2,6-difluorobenzoyl)-glycine 88 
 The synthesis followed that of 84 using the following 
reagents: glycine (1.02 g, 13.58 mmol), 2,6-difluorobenzoyl chloride (1.75 ml, 13.88 mmol).  The 
product was obtained as white crystals. (0.85 g, 24.7 %), mp 174-176 
0
C. 
 
1
H NMR (400 MHz) δ (DMSO-d6): 13.60 (1H, s, -COOH), 9.08 (1H, t, J = 5.6 Hz, Ar-CO-NH), 7.62-
7.48 (1H, m, Ar-H), 7.22-7.14 (2H, m, Ar-H), 3.95 (2H, d, J = 5.6 Hz, NH-CH2-COOH). 
13
C NMR (100 MHz) δ (DMSO-d6): 170.5, 160.5, 157.9, 133.0-132.8, 131.8-131.7, 114.8-114.6, 41.0 
N-(2,4-difluorobenzoyl)-glycine 89 
 The synthesis followed that of 84 using the 
following reagents: glycine (1.01 g, 13.45 mmol), 2,4-difluorobenzoyl chloride (1.70 ml, 13.77 
mmol).  The product was obtained as white crystals. (0.85 g, 24.2 %), mp 179-181 
0
C. 
1
H NMR (400 MHz) δ (DMSO-d6): 13.00  ( 1H, s, -COOH), 8.58 (1H, t, J = 5.2 Hz, Ar-CO-NH), 
7.81-7.73 (1H, m, Ar-H), 7.42-7.35 (1H, m, Ar-H), 7.29-7.16 (1H, m, Ar-H),  3.98 (2H, d, J = 6 Hz, 
NH-CH2-COOH). 
13
C NMR (100 MHz) δ (DMSO-d6): 170.1, 164.8, 158.7, 132.1-132.0, 119.6-119.5, 112.0-
111.9,112.0-111.7, 105.0-104.9, 41.2 
 
 
 
 
124 
N-(3,5-difluorobenzoyl)-glycine 90 
 
 
The synthesis followed that of 84 using the following reagents: glycine (1.03 g, 13.72 mmol), 3,5-
difluorobenzoyl chloride (1.60 ml, 13.59 mmol).  The product was obtained as white crystals. (0.80 g, 
23.3 %), mp 179-181 
0
C. 
1
H NMR (400 MHz) δ (DMSO-d6): 13.30 (1H, s, -COOH), 8.23 (1H, t, J = 5.6 Hz, Ar-CO-NH), 7.66-
7.65 (2H, m, Ar-H), 7.39-7.37 (1H, m, Ar-H), 3.90 (2H, d, J = 5.6 Hz, NH-CH2-COOH). 
13
C NMR (100 MHz) δ (DMSO-d6): 171.6, 163.3, 137.7, 114.6-114.5, 110.5-110.3, 106.8-106.3, 42.7 
N-(3,4,5-trifluorobenzoyl)-glycine 91 
 
The synthesis followed that of 84 using the following reagents: glycine (1.03 g, 13.72 mmol), 3,4,5-
trifluorobenzoyl chloride (1.75 ml, 13.32  mmol).  The product was obtained as white crystals. (0.88 
g, 24.3 %), mp 184-185 
0
C. 
1
H NMR (400 MHz) δ (DMSO-d6): 12.47 (1H, s, -COOH), 9.08 (1H, t, J = 5.6 Hz, Ar-CO-NH), 7.92-
7.84 (2H, m, Ar-H), 3.95-3.93 (2H, m, NH-CH2-COOH). 
13
C NMR (100 MHz) δ (DMSO-d6): 170.2, 168.7, 157.3, 142.5-142.3, 135.8-135.7, 112.0-111.9, 41.8 
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N-(2,3,4,5,6-pentafluorobenzoyl)-glycine 92 
 The synthesis followed that of 84 using the 
following reagents: glycine (1.29 g, 17.18 mmol), 2,3,4,5,6-pentafluorobenzoyl chloride (2.50 ml, 
17.36 mmol).  The product was obtained as white crystals. (0.75 g, 14.2 %), mp 188-190 
0
C. 
 
1
H NMR (400 MHz) δ (DMSO-d6): 11.80 (1H, s, -COOH), 9.44 (1H, t, J = 5.6 Hz, Ar-CO-NH), 3.95 
(2H, d, J = 4.8 Hz, NH-CH2-COOH). 
13
C NMR (100 MHz) δ (DMSO-d6): 171.4, 163.0, 151.3-151.2, 148.8-148.7, 130.4-130.3, 112.3-
112.2, 42.2 
 
N-(benzoyl)-L-alanine 93 
 The synthesis followed that of 84 using the following 
reagents: L-alanine (1.01 g, 11.34 mmol), benzoyl chloride (1.50 ml, 12.92 mmol).  The product was 
obtained as white crystals. (0.70 g, 24.9 %), mp 177-178 
0
C. 
 
1
H NMR (400 MHz) δ (DMSO-d6): 10.50 (1H, s, -COOH), 8.68 (1H, d, J = 7.2 Hz, Ar-CO-NH), 
7.91-7.89 (2H, m, Ar-H), 756.-7.50 (2H, m, Ar-H), 7.48-7.35 (1H, m, Ar-H), 4.45 (1H, qt, J = 7.2 Hz,  
NH-CH(CH3)-COOH), 1.43 (3H, d, J = 7.2 Hz, NH-CH(CH3)-COOH) 
13
C NMR (100 MHz) δ (DMSO-d6): 174.3, 166.0, 133.9, 131.3, 128.3, 127.3, 48.2, 16.9 
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N-(2-fluorobenzoyl)-L-alanine 94 
 The synthesis followed that of 84 using the following 
reagents: L-alanine (1.01 g, 11.34 mmol), 2-fluorobenzoyl chloride (1.50 ml, 12.29 mmol).  The 
product was obtained as white crystals. (0.65 g, 21.9 %), mp 181-183 
0
C. 
 
1
H NMR (400 MHz) δ (DMSO-d6): 12.65 (1H, s, -COOH),  8.55 (1H, d, J = 5.6 Hz,  -CO-NH-), 7.64-
7.60 (1H, m, Ar-H), 7.59-7.51 (1H, m, Ar-H), 7.39-7.26 (2H, m, Ar-H), 4.44 {1H, qt, J = 7.2 Hz NH-
CH(CH3)}, 1.38 {3H, d, J = 7.2 Hz,  NH-CH(CH3)}. 
13
C NMR (100 MHz) δ (DMSO-d6): 173.8, 165.0, 157.9, 134.6-134.5, 130.1-130.0, 124.5-124.4, 
119.3-119.2, 116.2-116.1, 48.1, 16.9 
 
N-(3-fluorobenzoyl)-L-alanine 95 
 The synthesis followed that of 84 using the 
following reagents: L-alanine (1.07 g, 12.01 mmol), 3-fluorobenzoyl chloride (1.50 ml, 12.29 mmol).  
The product was obtained as white crystals. (0.67 g, 22.2 %), mp 181-183 
0
C. 
 
1
H NMR (400 MHz) δ (DMSO-d6): 12.30 (1H, s, -COOH), 8.87 (1H, d, J = 5.6 Hz, Ar-CO-NH), 
7.83-7.77 (1H, m, Ar-H), 7.66-7.64 (1H, m, Ar-H), 7.63-7.58 (1H, m, Ar-H), 7.49-7.44 (1H, m, Ar-
H), 4.52 {1H,  qt, J = 5.6 Hz, NH-CH(CH3)}, 1.4 {3H, d, J = 5.6 Hz, NH-CH(CH3)}. 
13
C NMR (100 MHz) δ (DMSO-d6): 174.2, 165.1, 162.7, 132.1-132.0, 130.3-130.0, 127.3-127.2, 
115.6-115.0, 115.2-115.0, 48.2,16.8 
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N-(4-fluorobenzoyl)-L-alanine 96 
 The synthesis followed that of 84 using the 
following reagents: L-alanine (1.00 g, 11.22 mmol), 4-fluorobenzoyl chloride (1.50 ml, 12.67 mmol).  
The product was obtained as white crystals. (0.69 g, 22.9 %), mp 186-189 
0
C. 
 
1
H NMR (400 MHz) δ (DMSO-d6): 12.60 (1H, s, -COOH), 8.75 (1H, d, J = 7.2 Hz,  Ar-CO-NH), 
8.04-7.87 (2H, m Ar-H), 7.41-7.34 (2H, m, Ar-H), 4.50 {1H, qt, J = 7.2Hz, NH-CH(CH3)}, 1.43 {3H, 
d, J = 7.2 Hz,  NH-CH(CH3)}. 
13
C NMR (100 MHz) δ (DMSO-d6): 174.1, 164.7, 130.6-130.5, 123.6-123.5, 118.4-118.3, 114.3-
114.2, 48.3, 16.8 
 
N-(2,6-difluorobenzoyl)-L-alanine 97 
 The synthesis followed that of 84 using the following 
reagents: L-alanine (1.50 g, 16.83 mmol), 2,6-difluorobenzoyl chloride (2.00 ml, 15.86 mmol).  The 
product was obtained as white crystals. (0.81 g, 18.8 %), mp 190-191 
0
C. 
 
1
H NMR (400 MHz) δ (DMSO-d6): 12.00 (1H, s, -COOH), 9.16 (1H, d, J = 5.6 Hz, Ar-CO-NH), 
7.59-7.49 (1H, m, Ar-H), 7.20-7.09 (2H, m, Ar-H), 4.45 {1H, qt, J = 7.2 Hz, NH-CH(CH3)}, 1.38 
{3H, d, J = 4 Hz, NH-CH(CH3)}. 
13
C NMR (100 MHz) δ (DMSO-d6): 171.5, 163.0, 156.4, 131.3-131.2, 127.4-127.3, 116.3-116.2, 48.2, 
16.9 
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N-(2,4-difluorobenzoyl)-L-alanine 98 
 The synthesis followed that of 84 using the 
following reagents: L-alanine (1.55 g, 17.39 mmol), 2,4-difluorobenzoyl chloride (2.00 ml, 16.20 
mmol).  The product was obtained as white crystals. (0.95 g, 21.5 %), mp 189-191 
0
C. 
 
1
H NMR (400 MHz) δ (DMSO-d6):12.50 (1H, s,-COOH),  8.55 (1H, d, J = 6 Hz, Ar-CO-NH), 7.79-
7.73 (2H, m, Ar-H), 7.01-6.95 (1H, m, Ar-H), 4.50-4.45 {1H, m, NH-CH(CH3)}, 1.35 {3H, d, J = 6 
Hz, NH-CH(CH3)}. 
13
C NMR (100 MHz) δ (DMSO-d6): 170.1, 166.1, 160.2, 134.0-133.9,129.2-129.1, 116.0-115.9, 
112.0-111.8, 105.6-105.1, 48.1, 16.9 
N-(3,5-difluorobenzoyl)-L-alanine 99 
 The synthesis followed that of 84 using the 
following reagents: L-alanine (1.13 g, 12.68 mmol), 3,5-difluorobenzoyl chloride (1.50 ml, 12.74 
mmol).  The product was obtained as white crystals. (1.04 g, 30.7 %), mp 193-195 
0
C. 
 
1
H NMR (400 MHz) δ (DMSO-d6): 12.70 (1H. s,-COOH), 8.88 (1H, d, J = 7.2 Hz, Ar-CO-NH), 7.62-
7.59 (2H, m, Ar-H), 7.53-7.42 (1H, m, Ar-H), 4.44-4.41 {1H, m, NH-CH(CH3)}, 1.41 {3H, d, J = 7.2 
Hz, NH-CH(CH3)}. 
13
C NMR (100 MHz) δ (DMSO-d6): 173.8, 163.4, 137.3, 112.4-112.3, 110.9-110.8, 106.9-106.6, 48.4, 
16.7 
 
129 
N-(3,4,5-trifluorobenzoyl)-L-alanine 100 
 The synthesis followed that of 84 using the 
following reagents: L-alanine (1.01 g, 11.34 mmol), 3,4,5-trifluorobenzoyl chloride (1.50 ml, 11.42 
mmol).  The product was obtained as white crystals. (0.70 g, 21.7 %), mp 199-201 
0
C. 
1
H NMR (400 MHz) δ (DMSO-d6): 12.29 (1H,s, -COOH), 8.92 (1H, d, J = 7.2 Hz, Ar-CO-NH), 7.90-
7.78 (2H, m, Ar-H), 4.43 {1H, qt, J = 7.2Hz  NH-CH(CH3)}, 1.39 {3H, d, J = 7.2 Hz, NH-CH(CH3)}. 
13
C NMR (100 MHz) δ (DMSO-d6): 173.9, 162.8, 151.3, 148.8-148.7, 130.1-130.0, 112.5-112.4, 48.7, 
16.7 
 
N-(2,3,4,5,6-pentafluorobenzoyl)-L-alanine 101 
 The synthesis followed that of 84 using the 
following reagents: L-alanine (2.02 g, 22.67 mmol), 2,3,4,5,6-pentafluorobenzoyl chloride (3.00 ml, 
20.82 mmol).  The product was obtained as white crystals. (1.27 g, 18.6 %), mp 200-203 
0
C. 
1H NMR (400 MHz) δ (DMSO-d6): 12.01 (1H, s, -COOH), 9.31 (1H, d, J = 7.2 Hz, Ar-CO-NH), 4.43 
{1H, qt, J = 7.2 Hz  NH-CH(CH3)}, 1.41 {3H, d, J = 5.6 Hz,  NH-CH(CH3)}. 
13C NMR (100 MHz) δ (DMSO-d6): 171.6, 156.5, 144.4-144.3, 141.9-141.8, 138.3-138.2, 135.6-
135.5, 48.4, 16.9 
 
 
130 
N-(benzoyl)-β-alanine 102 
 The synthesis followed that of 84 using the 
following reagents: β-alanine (1.01 g, 11.34 mmol), benzoyl chloride (1.50 ml, 12.85 mmol).  The 
product was obtained as white crystals. (0.70 g, 24.9 %), mp 145-147 
0
C.  
 
1
H NMR (400 MHz) δ (DMSO-d6): 12.75 (1H, s, -COOH), 8.64 (1H, t, J = 5.6 Hz, Ar-CO-NH), 7.89-
7.87 (2H, m, Ar-H), 7.79-7.75 (1H, m, Ar-H), 7.62-7.55 (2H, m, Ar-H), 3.57-3.53 (2H, m, -CH2-CH2-
COOH), 2.55-2.50 (2H, m, CH2-CH2-COOH). 
13
C NMR (100 MHz) δ (DMSO-d6): 173.0, 166.3, 134.3, 131.1, 128.2, 127.2, 35.6, 33.8 
 
N-(2-fluorobenzoyl)-β-alanine 103 
 The synthesis followed that of 84 using the 
following reagents: β-alanine (1.01 g, 11.34 mmol), 2-fluorobenzoyl chloride (1.50 ml, 12.29 mmol).  
The product was obtained as white crystals. (0.69 g, 23.3 %), mp 151-153 
0
C. 
 
1
H NMR (400 MHz) δ (DMSO-d6): 12.47 ( 1H,s,-COOH), 8.68 (1H, t, J = 5.2 Hz, Ar-CO-NH), 7.71-
7.68 (2H, m, Ar-H), 7.57-7.50 (1H, m, Ar-H), 7.37-7.30 (1H, m, Ar-H), 3.50 (2H, q, J = 7.2 Hz, -
CH2-CH2-COOH), 2.55 (2H, t, J = 4.8 Hz, - CH2-CH2-COOH). 
13
C NMR (100 MHz) δ (DMSO-d6): 172.8, 164.8, 1, 160.7, 136.7-136.6, 130.4-130.3, 123.3-123.2, 
118.1-117.9,114.0-113.9, 35.6, 33.6 
 
 
131 
N-(3-fluorobenzoyl)-β-alanine 104 
 The synthesis followed that of 84 using the 
following reagents: β-alanine (1.01 g, 11.33 mmol), 3-fluorobenzoyl chloride (1.50 ml, 12.29 mmol).  
The product was obtained as white crystals. (0.85 g, 28.7 %), mp 151-154 
0
C. 
 
1
H NMR (400 MHz) δ (DMSO-d6): 12.46 (1H, s, -COOH), 8.76 (1H, t, J = 5.2 Hz, Ar-CO-NH), 7.71-
7.69 (1H, m, Ar-H), 7.65-7.60 (1H, m, Ar-H), 7.52-7.45 (1H, m, Ar-H), 7.35-7.31 (1H, m, Ar-H), 
3.02-2.97 (2H, m, -CH2-CH2-COOH), 2.64-2.61 (2H, m, -CH2-CH2-COOH). 
13
C NMR (100 MHz) δ (DMSO-d6): 173.1, 164.9, 160.7, 136.7-136.5, 130.4-130.3, 123.3-123.2, 
118.1-117.9,114.1-113.9, 35.5, 33.8 
N-(4-fluorobenzoyl)-β-alanine 105 
 The synthesis followed that of 84 using the 
following reagents: β-alanine (1.00 g, 11.22 mmol), 4-fluorobenzoyl chloride (1.50 ml, 12.67 mmol).  
The product was obtained as white crystals. (0.85 g, 28.2 %), mp 150-153 
0
C. 
1
H NMR (400 MHz) δ (DMSO-d6): 10.29 (1H, s, -COOH), 8.65 (1H, t, J = 5.2 Hz, Ar-CO-NH), 7.95-
7.84 (2H, m, Ar-H), 7.30 – 7.24 (2H, m, Ar-H), 3.49 (2H, q, J = 5.6 Hz, CH2-CH2-COOH), 2.50 (2H, 
t, J = 6 Hz  -CH2-CH2-COOH). 
13
C NMR (100 MHz) δ (DMSO-d6): 173.0, 165.3, 162.5, 130.7-130.6, 129.8-129.7, 115.2-115.0, 35.6, 
33.8 
 
 
132 
N-(2,6-difluorobenzoyl)-β-alanine 106 
 The synthesis followed that of 84 using the 
following reagents: β-alanine (1.05 g, 11.78 mmol), 2,6-difluorobenzoyl chloride (1.50 ml, 11.89 
mmol).  The product was obtained as white crystals. (0.70 g, 27.5 %), mp 160-161 
0
C. 
1
H NMR (400 MHz) δ (DMSO-d6): 10.50 (1H, s, -COOH), 8.86 (1H, t, J = 5.6 Hz, Ar-CO-NH), 7.55-
7.45 (2H, m, Ar-H), 7.22-7.12 (1H, m, Ar-H), 3.54 (2H, q, J = 7.2 Hz, CH2-CH2-COOH), 2.51 (2H, t, 
J = 6.8 Hz, -CH2-CH2-COOH). 
13
C NMR (100 MHz) δ (DMSO-d6): 172.7, 160.1, 157.5, 131.5-131.4, 115.6-115.5, 111.9-111.8, 35.3, 
33.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
N-(2,4-difluorobenzoyl)-β-alanine 107 
 
 The synthesis followed that of 84 using the 
following reagents: β-alanine (1.02 g, 11.44 mmol), 2,4-difluorobenzoyl chloride (1.50 ml, 12.15 
mmol).  The product was obtained as white crystals. (0.70 g, 22.1 %), mp 169-171 
0
C. 
1
H NMR (400 MHz) δ (DMSO-d6): 12.30 (1H, s,-COOH), 8.38 (1H, s, Ar-CO-NH), 7.73-7.70 (1H, 
m, Ar-H), 7.57-7.40 (1H, m, Ar-H), 7.24-7.21 (1H, m, Ar-H) 3.47 (2H, q, J = 5.6 Hz, -CH2-CH2-
COOH), 2.52 (2H, t, J = 4.8 Hz  CH2-CH2-COOH). 
13
C NMR (100 MHz) δ (DMSO-d6): 172.9, 162.7, 158.4, 131.9-131.8, 120.5-120.4, 111.8-111.7, 
105.1-104.9, 104.5-104.2, 35.4, 33.6 
 
 
 
133 
N-(3,5-difluorobenzoyl)-β-alanine 108 
 The synthesis followed that of 84 using the 
following reagents: β-alanine (1.00 g, 11.22 mmol), 3,5-difluorobenzoyl chloride (1.50 ml, 12.74 
mmol).  The product was obtained as white crystals. (0.70 g, 21.5 %), mp 169-172 
0
C. 
1
H NMR (400 MHz) δ (DMSO-d6): 12.40 (1H, s, -COOH), 8.92 (1H, t, J = 5.6 Hz, Ar-CO-NH), 7.65-
7.56 (2H, m, Ar-H), 7.33-7.19 (1H, m, Ar-H), 3.30 (2H, q, J = 7.2 Hz, CH2-CH2-COOH), 2.45 (2H, t, 
J = 6.4 Hz , CH2-CH2-COOH). 
13
C NMR (100 MHz) δ (DMSO-d6): 172.1, 163.7, 137.6, 112.3-112.1, 110.6-110.5, 106.8-106.6, 35.7, 
33.4 
 
N-(3,4,5-trifluorobenzoyl)-β-alanine 109 
 The synthesis followed that of 84 using the 
following reagents: β-alanine (1.04 g, 11.67 mmol), 3,4,5-trifluorobenzoyl chloride (1.60 ml, 12.17 
mmol).  The product was obtained as white crystals. (0.80 g, 23.6 %), mp 189-191 
0
C. 
1
H NMR (400 MHz) δ (DMSO-d6): 12.06 (1H, s, -COOH), 8.69 (1H, t, J = 5.2 Hz, Ar-CO-NH), 7.82-
7.70 (2H, m, Ar-H), 3.51-3.49 (2H, m, CH2-CH2-COOH), 2.51-2.48 (2H, m, CH2-CH2-COOH). 
13
C NMR (100 MHz) δ (DMSO-d6): 172.7, 162.9, 151.3, 148.8-148.7, 131.8-131.9, 112.3-112.1, 35.8, 
33.4 
 
 
134 
N-(2,3,4,5,6-pentafluorobenzoyl)-β-alanine 110 
 The synthesis followed that of 84 using the 
following reagents: β-alanine (1.05g, 11.78 mmol), 2,3,4,5,6-pentafluorobenzoyl chloride (1.75 ml, 
12.14 mmol).  The product was obtained as white crystals. (0.88 g, 22.9 %), mp 196-198 
0
C. 
1
H NMR (400 MHz) δ (DMSO-d6): 12.39 (1H, s, -COOH), 9.10 (1H, t, J = 6 Hz, Ar-CO-NH), 3.44-
3.41 (2H, m, CH2-CH2-COOH), 2.50-2.45 (2H, m, CH2-CH2-COOH). 
13
C NMR (100 MHz) δ (DMSO-d6): 172.8, 164.7, 151.2-151.1, 148.8-148.7, 114.2-114.1, 112.3-
112.1, 35.8, 33.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
135 
General procedure for the synthesis of N-(ferrocenylmethylamino acid)-fluorinated benzene 
carboxamides. 
 
N-(ferrocenylmethylglycine)-benzene carboxamide 111 
 
1-Hydroxybenzotriazole (0.55 g, 4.07 mmol) was added to a solution of ferrocenylmethylamine (1.15 
g, 5.34 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (0.61 g, 3.18 mmol) 
and triethylamine (2 ml) in dichloromethane (40 ml) at 0 
o
C. After 30 min, N-(benzoyl)-glycine (1.00 
g, 5.56 mmol) was added and the reaction was stirred at room temperature for 72 h. Diethyl ether (100 
ml) was then added.  The organic layer was then washed with water, dried over MgSO4 and the 
solvent was removed in vacuo. The compound was purified by column chromatography (eluant 2:1 
hexane:ethyl acetate) to give the title compound as bright orange crystals. ( 0.58 g, 26.9 %),  mp 108 – 
110 
0
C ; UV-VIS λmax ACN: (337, 418) IR: υmax (KBr): 3408, 3302, 1680, 1641, 1577, 1548, 1433, 
1334, 1296 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.81 (1H, t, J = 5.6 Hz, Ar-CO-NH), 8.80 (1H, 
t, J = 5.6 Hz, FcCH2NH), 7.92-7.87 (2H, m, Ar-H), 7.54-7.52 (1H, m, Ar-H), 7.50-7.43 (2H, m, Ar-
H), 4.18-4.13 {7H, m, (η5-C5H5) and ortho on (η
5
-C5H4)}, 4.10-4.07 {2H, m, meta on (η
5
-C5H4)},  
4.02 (2H, d, J = 5.6 Hz, FcCH2), 3.89 (2H, d, J = 5.6 Hz, CO-CH2-NH) ; 
13
C NMR (100 MHz) δ 
(DMSO-d6): 168.3, 168.0, 136.5, 130.5, 123.5, 118.3, 85.9, 68.3, 67.7, 67.2, 42.6(-ve DEPT),  37.5 (-
ve DEPT).  
 
 
 
 
 
 
 
136 
N-(ferrocenylmethylglycine)-2-fluorobenzene carboxamide 112   
 
For compound 112 N-(2-fluorobenzoyl)-glycine (1.15 g, 5.83 mmol) was used as a starting material. 
The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) and isolated 
as yellow crystals. ( 0.41 g, 17.9 %) , mp 155 – 158 0C ; UV-VIS λmax ACN: (321, 434)  IR: υmax 
(KBr):  3325, 3112, 1689, 1645, 1516, 1480, 1248, 1105 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 
8.90 (1H, t, J = 6 Hz, Ar-CO-NH), 8.08 (1H, t, J = 6 Hz, FcCH2NH), 7.77-7.74 (1H, m, Ar-H), 7.71-
7.68 (1H, m, Ar-H), 7.57-7.52 (1H, m, Ar-H), 7.43-7.38 (1H, m,  Ar-H), 4.19-4.15 {7H, m, (η5-C5H5) 
and ortho on (η5-C5H4)}, 4.08 {2H, t, J = 2 Hz, meta on (η
5
-C5H4)}, 4.03 (2H, d, J = 6 Hz, FcCH2), 
3.88 (2H, d, J = 6 Hz, CO-CH2-NH) ; 
13
C NMR (100 MHz) δ (DMSO-d6): 168.2, 165.2-165.1, 160.7 
136.4-136.3, 130.5-130.4, 123.6-123.5, 118.3-118.1, 114.2-114.0, 86.0, 68.3, 67.7, 67.2, 42.6 (-ve 
DEPT),  37.5 (-ve DEPT). 
19
F (376 MHz, DMSO): δ -112.90 (1F, m). 
 
 
 
 
 
 
 
 
 
 
 
 
137 
 
N-(ferrocenylmethylglycine)-3-fluorobenzene carboxamide 113  
 
For compound 113 N-(3-fluorobenzoyl)-glycine (1.00 g, 5.07 mmol) was used as a starting material. 
The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) and isolated 
as orange crystals.  ( 0.41 g, 19.9 %) , mp 153 – 155 0C; UV-VIS λmax ACN: (323, 436)  IR: υmax 
(KBr):  3345, 3134, 1700, 1684, 1644, 1559, 1549, 1517, 1477, 1104, 910 cm
-1
 ;  
1
H NMR (400 MHz) 
δ (DMSO-d6): 8.89 (1H, t, J = 5.6 Hz, Ar-CO-NH), 8.07 (1H, t, J = 5.6 Hz, FcCH2NH), 7.76-7.74 
(1H, m,  Ar-H), 7.71-7.68 (1H, m,  Ar-H), 7.57-7.52 (1H, m, Ar-H), 7.43-7.38 (1H, m, Ar-H), 4.18-
4.15 {7H, m, (η5-C5H5) and ortho on (η
5
-C5H4)}, 4.08 {2H, t, J = 2 Hz, meta on (η
5
-C5H4)}, 4.03 (2H, 
d, J = 6 Hz, FcCH2), 3.89 (2H, d, J = 6 Hz, CO-CH2-NH) ; 
13
C NMR (100 MHz) δ (DMSO-d6): 
168.2, 165.2-165.1, 163.0, 136.4-136.3, 130.5-130.4, 123.6-123.5, 118.3-118.1, 114.2-114.0, 85.9, 
68.3, 67.7, 67.2, 42.6 (-ve DEPT), 37.5 (-ve DEPT) ;
19
F (376 MHz, DMSO): δ -113.46 (1F, m). 
 
 
 
 
 
 
 
 
 
 
 
138 
 
N-(ferrocenylmethylglycine)-4-fluorobenzene carboxamide 114 
 
For compound 114 N-(4-fluorobenzoyl)-glycine (1.01 g. 5.12 mmol) was used as a starting material. 
The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) and isolated 
as bright orange crystals. (0.40 g, 19.8 %) , mp 172 – 174 0C ; UV-VIS λmax ACN: (318, 426)  IR: υmax 
(KBr):  3272, 3108, 1654, 1638, 1603, 1561, 1469, 1382, 1174, 998 cm
-1
 ; 
1
H NMR (400 MHz) δ 
(DMSO-d6): 8.80 (1H, t, J = 6 Hz, Ar-CO-NH), 8.01 (1H, t, J = 6 Hz, FcCH2NH), 7.99-7.92 (2H, m, 
Ar-H), 7.35-7.28 (2H, m, Ar-H), 4.18-4.15 {7H, m, (η5-C5H5) and ortho on (η
5
-C5H4)}, 4.07 {2H, t, J 
= 2 Hz, meta on (η5-C5H4) }, 4.02 (2H, d, J = 6 Hz, FcCH2 ), 3.85 (2H, d, J = 6 Hz, CO-CH2-NH) ; 
13
C NMR (100 MHz) δ (DMSO-d6): 168.2, 165.2, 136.3,  130.5-130.4, 118.3-118.1, 114.3-114.1, 
85.9, 68.3, 67.7, 67.2, 42.7 (-ve DEPT), 37.5 (-ve DEPT) ; 
19
F (376 MHz, DMSO): δ -109.2 (1F, m). 
Anal Calc. for C20H19FFeN2O2: C, 60.93; H, 4.86; N, 7.11. Found: C, 60.59; H, 4.77; N, 7.02. m/z 
(ESI) 394.44  [M]
+
 
•
 . C20H19FFeN2O2 requires 394.57. 
 
 
 
 
 
 
 
 
 
 
 
139 
N-(ferrocenylmethylglycine)-2,6-difluorobenzene carboxamide 115  
 
For compound 115 N-(2,6-difluorobenzoyl)-glycine (0.62 g, 2.88 mmol) was used as a starting 
material. The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) 
and isolated as orange crystals.  (0.25 g, 22.3 %),  mp 167 – 169 0C; UV-VIS λmax ACN: (306, 437)  
IR: υmax (KBr):  3200, 3187, 1700, 1681, 1653, 1623, 1559, 1434, 1279, 1024, 1001, 839 cm
-1
; 
1
H 
NMR (400 MHz) δ (DMSO-d6): 9.01 (1H, t, J = 6 Hz, Ar-CO-NH), 8.01 (1H, t, J = 6 Hz, FcCH2NH), 
7.55-7.48 (1H, m, Ar-H), 7.19-7.14 (2H, m,  Ar-H), 4.20-4.15 {7H, m, (η5-C5H5) and ortho on (η
5
-
C5H4) }, 4.10 { 2H, t, J = 2 Hz, meta on (η
5
-C5H4) }, 4.05 (2H, d, J = 5.6 Hz, FcCH2), 3.91 (2H, d, J = 
5.6 Hz, CO-CH2-NH);  
13
C NMR (100 MHz) δ (DMSO-d6): 168.6, 166.4, 131.3-131.2, 127.2-127.1, 
111.8-111.7, 104.5-104.4,  86.0, 68.3, 67.8, 67.2, 42.2 (-ve DEPT), 37.5 (-ve DEPT); 
19
F (376 MHz, 
DMSO): δ -113.27 (2F, m). Anal Calc. for C20H18F2FeN2O2: C, 58.27; H, 4.40; N, 6.80. Found: C, 
57.97; H, 4.56; N, 6.52 
 
 
 
 
 
 
 
 
 
 
 
140 
N-(ferrocenylmethylglycine)-2,4-difluorobenzene carboxamide 116 
 
For compound 116 N-(2,4-difluorobenzoyl)-glycine (0.55 g, 2.55 mmol) was used as a starting 
material. The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) 
and isolated as red crystals.  (0.50 g, 43.4 %),  mp 172 – 174 0C; UV-VIS λmax ACN: (307, 437)  IR: 
υmax (KBr):  3344, 3244, 1700, 1681, 1653, 1623, 1559, 1434, 1279, 1024, 1001, 839 cm
-1
; 
1
H NMR 
(400 MHz) δ (DMSO-d6): 8.98 (1H, t, J = 5.6 Hz, Ar-CO-NH), 8.03  (1H, t, J = 5.6 Hz, FcCH2NH), 
7.55-7.48 (1H, m, Ar-H), 7.19-7.15 (2H, m, Ar-H), 4.20-4.17 {7H, m, (η5-C5H5) and ortho on (η
5
-
C5H4)}, 4.09 { 2H, t, J = 2 Hz, meta on (η
5
-C5H4) }, 4.05 (2H, d, J = 6 Hz, FcCH2), 3.92 (2H, d, J = 6 
Hz, CO-CH2-NH);  
13
C NMR (100 MHz) δ (DMSO-d6): 167.4, 159.9, 149.9-149.8, 134.3-134.2, 
125.6-125.5, 120.8-120.7, 111.9-111.8, 104.3-104.2, 86.1, 68.4, 67.6, 67.3, 42.3 (-ve DEPT), 37.5 (-
ve DEPT); 
19
F (376 MHz, DMSO): δ -108.77 (2F, m).  
 
 
 
 
 
 
 
 
 
 
 
 
 
141 
N-(ferrocenylmethylglycine)-3,5-difluorobenzene carboxamide  117 
 
 
For compound 117 N-(3,5-difluorobenzoyl)-glycine (1.15 g, 5.35 mmol) was used as a starting 
material. The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) 
and isolated as bright yellow crystals. (0.50 g, 23.2 %), mp 148 – 150 0C; UV-VIS λmax ACN: (308, 
440)  IR: υmax (KBr): 3267, 3083, 1685, 1653, 1629, 1593, 1541, 1331, 1274, 986, cm
-1
. 
1
H NMR (400 
MHz) δ (DMSO-d6): 8.97 (1H, t, J = 5.6 Hz, Ar-CO-NH), 8.10 (1H, t, J = 5.6 Hz, FcCH2NH), 7.63-
7.58 (2H, m, Ar-H), 7.51-7.46 (1H, m,  Ar-H), 4.18-4.15 {7H, m, (η5-C5H5) and ortho on (η
5
-C5H4) }, 
4.07 {2H, t, J = 1.6 Hz, meta on (η5-C5H4)}, 4.02 (2H, d, J = 6 Hz, FcCH2), 3.85 (2H, d, J = 6 Hz, 
CO-CH2-NH-). 
13
C NMR (100 MHz) δ (DMSO-d6): 167.9, 166.7, 143.5-143.4, 137.7-137.5, 123.4-
123.2, 110.9-110.8, 85.9, 68.3, 67.8, 67.2, 42.7 (-ve DEPT), 37.5 (-ve DEPT).
19
F (376 MHz, DMSO): 
δ: -109.2 (2F, m). Anal Calc. for C20H18F2FeN2O2: C, 58.27; H, 4.40; N, 6.80. Found: C, 58.10; H, 
4.33; N, 6.40. m/z (ESI) 412.07 [M]
+
 
•
 . C20H18F2FeN2O2 requires 412.07 
 
 
 
 
 
 
 
 
 
 
142 
N-(ferrocenylmethylglycine)-3,4,5-trifluorobenzene carboxamide 118 
 
For compound 118 N-(3,4,5-trifluorobenzoyl)-glycine (1.20 g, 5.14 mmol) was used as a starting 
material. The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) 
and isolated as red crystals.  (0.49 g, 21.4 %), mp 134 –136 0C; UV-VIS λmax ACN: (321, 433) IR: 
υmax (KBr):  3360, 3329, 1684, 1647, 1525, 1364, 1408, 1239, 1048 cm
-1
; 
1
H NMR (400 MHz) δ 
(DMSO-d6): 9.02 (1H, t, J = 5.6 Hz, Ar-CO-NH), 8.17 (1H, t, J = 5.6 Hz, FcCH2NH), 7.89 – 7.79 
(2H, m, Ar –H ), 4.17-4.14 {7H, m, (η5-C5H5) and ortho on (η
5
-C5H4)},  4.08-4.06 {2H, m, meta on 
(η5-C5H4)}, 4.03 (2H, d, J = 6 Hz, FcCH2), 3.89 (2H, d, J = 6 Hz, CO-CH2-NH); 
13
C NMR (100 
MHz) δ (DMSO-d6): 168.5, 163.5, 151.5-151.2, 148.8-148.7, 130.5-130.4, 112.5-112.3, 86.3, 68.3, 
67.8, 67.2, 42.9,(-ve DEPT),  37.4 (-ve DEPT),; 
19
F (376 MHz, DMSO): δ -134.4 (2F, m), -156.9 (1F, 
m).  
 
 
 
 
 
 
 
 
 
 
 
 
143 
N-(ferrocenylmethylglycine)-2,3,4,5,6-pentafluorobenzene carboxamide  119 
 
For compound 119 N-(2,3,4,5,6-pentafluorobenzoyl)-glycine (1.21 g, 4.49 mmol) was used as a 
starting material. The compound was purified by column chromatography (eluant 2:1 hexane:ethyl 
acetate) and isolated as yellow crystals. (0.51 g, 22.6 %),  mp 138 – 140 0C ; UV-VIS λmax ACN: (377, 
426)  IR: υmax (KBr): 3311, 3067,  1693, 1653, 1559, 1539, 1506, 1461, 1437, 1328, 991, 827 cm
-1
 ; 
1
H NMR (400 MHz) δ (DMSO-d6): 9.20 (1H, t, J = 5.2 Hz, Ar-CO-NH), 8.20 (1H, t, J = 5.2 Hz, 
FcCH2NH), 4.20-4.17 {7H, m, (η
5
-C5H5) and ortho on (η
5
-C5H4)}, 4.10 {2H, t, J = 1.6 Hz, meta on 
(η5-C5H4)}  4.05 (2H, d, J = 5.6 Hz, FcCH2), 3.95 (2H, d, J = 5.6 Hz, CO-CH2-NH) ;
13
C NMR (100 
MHz) δ (DMSO-d6): 168.3, 165.0, 156.9, 133.7-133.6, 130.2-130.0, 115.4-115.3,  85.9, 68.3, 67.8, 
67.3, 42.6 (-ve DEPT), 37.5 (-ve DEPT) ; 
19
F (376 MHz, DMSO): δ -153.2 (2F, m), -153.6 (2F,m), -
161.6 (1F, m). m/z (ESI) 466.04[M]
+
 
•
 .C20H15F5FeN2O2 requires 466.04. 
 
 
 
 
 
 
 
 
 
 
 
 
144 
N-(ferrocenylmethyl-L-alanine)-benzene carboxamide  120 
 
For compound 120 N-(benzoyl)-L-alanine (0.90 g, 4.65 mmol) was used as a starting material. The 
compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) and isolated as 
brown crystals.  (0.79 g, 39.5 %), mp 127-130 
0
C. [α]D 
20
 = +15 º (c 0.005, ACN); UV-VIS λmax ACN: 
(323, 434) 
 
IR: υmax (KBr); 3256, 3074, 1629, 1553, 1466, 1435, 1369, 1189 cm
-1
; 
1
H NMR (400 
MHz) δ (DMSO-d6): 8.57 (1H, d, J = 7.6 Hz, Ar-CO-NH), 8.09 (1H, t, J = 2.8 Hz, FcCH2NH),  7.93-
7.91 (2H, m, Ar-H), 7.54-7.52 (1H, m, Ar-H), 7.49-7.45 (2H, m, Ar-H), 4.55-4.48 {1H, m, NH-
CH(CH3)}, 4.17-4.15 {7H, m, (η
5
-C5H5) and ortho on (η
5
-C5H4) }, 4.08{2H, t, J = 2 Hz, meta on (η
5
-
C5H4)}, 4.07 - 4.02 (2H, m,  FcCH2), 1.35 {3H, d, J = 7.2 Hz, NH-CH(CH3)}; 
13
C NMR (100 MHz) δ 
(DMSO-d6):171.8,170.3, 134.0, 131.3, 129.9, 128.2, 86.3, 68.3, 67.9, 67.2, 48.9,  37.4 (-ve DEPT), 
17.9 
 
 
 
 
 
 
 
 
 
 
 
 
145 
N-(ferrocenylmethyl-L-alanine)-2-fluorobenzene carboxamide 121 
 
 
For compound 121 N-(2-fluorobenzoyl)-L-alanine (1.30 g, 6.15 mmol) was used as a starting 
material. The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) 
and isolated as bright orange crystals. (0.55 g, 20.8 %), mp  129 – 131 0C. [α]D 
20
 = +13 º (c 0.005, 
ACN); UV-VIS λmax ACN: (325, 439) 
 
IR: υmax (KBr): 3321, 3301 1787, 1624, 1538, 1577, 1456, 
1438, 1370, 1303, 1149, 1017, 927 cm
-1
; 
1H NMR (400 MHz) δ (DMSO-d6): 8.42 (1H, d, J = 3.6 Hz, 
Ar-CO-NH), 8.13 (1H, t, J = 6 Hz, FcCH2NH),  7.71-7.67 (1H, m, Ar-H), 7.58-7.51 (1H, m, Ar-H), 
7.32-7.27 (2H, m, Ar-H), 4.55-4.48 {1H, m, NH-CH(CH3)}, 4.18-4.15 {7H, m, (η
5
-C5H5) and ortho 
on (η5-C5H4) }, 4.10{2H, t, J = 2 Hz, meta on (η
5
-C5H4)}, 4.02-4.00 (2H, m, FcCH2), 1.35{3H, d, J = 
7.2 Hz, NH-CH(CH3)}; 
13
C NMR (100 MHz) δ (DMSO-d6): 171.4, 165.9-165.8, 163.1, 132.6-132.5, 
130.3-130.2, 124.4-124.2, 117.5-117.3,  116.2-116.0,  86.1, 68.3, 67.9, 67.2, 48.8,  37.5(-ve DEPT), 
18.3. 
19
F (376 MHz, DMSO): δ -113.7 (1F, m). Anal Calc. for C21H21FFeN2O2: C, 61.78; H, 5.18; N, 
6.86. Found: C, 62.03; H, 5.35; N, 6.56 
 
 
 
 
 
 
 
 
 
 
146 
N-(ferrocenylmethyl-L-alanine)-3-fluorobenzene carboxamide 122 
 
For compound 122 N-(3-fluorobenzoyl)-L-alanine (1.10 g, 5.21 mmol) was used as a starting 
material. The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) 
and isolated as bright yellow crystals. (0.45 g, 19.6 %) , mp 118 – 120 0C. [α]D 
20
 = +28 º (c 0.005, 
ACN); UV-VIS λmax ACN: (318, 432) IR: υmax (KBr): 3200, 3095,  1737, 1700, 1634, 1588, 1559, 
1486, 1438, 1370, 1326, 1168, 1024, 948 cm
-1
. 
1
H NMR (400 MHz) δ (DMSO-d6): 8.72 (1H, d, J = 
7.2 Hz, Ar-CO-NH), 8.15 (1H, t, J =5.6 Hz,  FcCH2NH), 7.78-7.72 (2H, m, Ar-H), 7.56-7.50  (1H, m, 
Ar-H), 7.42-7.37 (1H, m, Ar-H), 4.54-4.47 {1H, m, NH-CH(CH3)}, 4.19-4.14 {7H, m, (η
5
-C5H5) and 
ortho on (η5-C5H4) } 4.08 {2H, t, J = 1.6 Hz meta on (η
5
-C5H4)}, 4.03-3.99 (2H, m, FcCH2), 1.30 
{3H, d, J = 7.2 Hz, NH-CH(CH3)}; 
13
C NMR (100 MHz) δ (DMSO-d6): 171.7, 164.8, 160.6, 136.4-
136.3, 130.4-130.3, 118.3-118.1, 114.4-114.2, 103.1-102.9, 86.2, 68.3, 67.4, 67.1, 49.1, 37.4 (-ve 
DEPT), 17.9; 
19
F (376 MHz, DMSO): δ -112.8 (1F, m). Anal Calc. for C21H21FFeN2O2: C, 61.78; H, 
5.18; N, 6.86. Found: C, 61.48; H, 5.26; N, 6.87 
 
 
 
 
 
 
 
 
 
 
 
147 
N-(ferrocenylmethyl-L-alanine)-4-fluorobenzene carboxamide  123 
 
For compound 123 N-(4-fluorobenzoyl)-L-alanine (1.30 g, 6.15 mmol) was used as a starting 
material. The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) 
and isolated as orange/yellow crystals. (0.89 g, 33.5 %), mp 134 – 136 0C. [α]D 
20
 = +23 º (c 0.005, 
ACN); UV-VIS λmax ACN: (318, 429) IR: υmax (KBr): 3345, 3222, 1655, 1636, 1629, 1507, 1225, 
1104, 815 cm
-1 
;
1H NMR (400 MHz) δ (DMSO-d6): 8.62 (1H, d, J = 7.2 Hz, Ar-CO-NH), 8.10 (1H, t, 
J = 6 Hz, FcCH2NH), 8.02-7.97 (2H, m, Ar-H), 7.35-7.26 (2H, m, Ar-H), 4.54-4.47 {1H, m, NH-
CH(CH3)}, 4.17-4.14 {7H, m, (η
5
-C5H5) and ortho on (η
5
-C5H4)}, 4.07 (2H, t, J = 1.6 Hz, meta on 
(η5-C5H4)}, 4.03 (2H, d, J = 6 Hz,  FcCH2), 1.35 (3H, d, J = 7.2 Hz, CH-CH3); 
13
C NMR (100 MHz) δ 
(DMSO-d6): 171.8, 166.1, 134.1-134.0, 131.3-131.2, 129.9-129.5, 127.5-127.4, 86.3, 68.3, 67.4, 67.2, 
48.9,  37.4 (-ve DEPT), 17.9; 
19
F (376 MHz, DMSO): δ -109.3 (1F,  m). Anal Calc. for 
C21H21FFeN2O2: C, 61.78; H, 5.18; N, 6.86. Found: C, 61.48; H, 5.36; N, 6.69 
 
 
 
 
 
 
 
 
 
 
 
 
148 
N-(ferrocenylmethyl-L-alanine)-2,6-difluorobenzene carboxamide 124 
 
For compound 124 N-(2,6-difluorobenzoyl)-L-alanine (1.14 g, 4.97 mmol) was used as a starting 
material. The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) 
and isolated as bright orange crystals.  (0.92 g, 41.4 %), mp 128 – 130 oC. [α]D 
20
 = - 17 º (c 0.005, 
ACN); UV-VIS λmax ACN: (328, 434) IR: υmax (KBr): 3301, 3100,  1700, 1631, 1559, 1553, 1466, 
1322, 1236, 1160, 1043, 895, 794 cm
-1
; 
1
H NMR (400 MHz) δ (DMSO-d6): 9.00 (1H, d, J = 7.6 Hz, 
Ar-CO-NH), 8.12 (1H, t, J = 6 Hz, FcCH2NH), 7.53-7.48 (1H, m, Ar-H), 7.18-7.13 (2H, m, Ar-H), 
4.60-4.52 {1H, m, NH-CH(CH3)}, 4.19-4.17{7H, m, (η
5
-C5H5) and ortho on (η
5
-C5H4)},  4.15 {2H, t,  
J = 1.6 Hz, meta on (η5-C5H4)}, 4.03-3.98 (2H, m, FcCH2), 1.35 {3H, d, J = 7.2 Hz, NH-CH(CH3)}; 
13
C NMR (100 MHz) δ (DMSO-d6): 171.1, 165.8, 157.6-157.5, 131.6-131.5, 115.2-115.1, 111.8-
111.6, 86.0, 68.4, 67.3, 67.2, 48.6, 37.5 (-ve DEPT), 18.3; 
19
F (376 MHz, DMSO): δ -113.6 (2F,  m). 
Anal Calc. for C21H20F2FeN2O2: C, 59.17; H, 4.73; N, 6.57. Found: C, 59.67; H, 4.94; N, 6.32 
 
 
 
 
 
 
 
 
 
 
 
149 
N-(ferrocenylmethyl-L-alanine)-2,4-difluorobenzene carboxamide 125 
 
For compound 125 N-(2,4-difluorobenzoyl)-L-alanine (1.10 g, 4.79 mmol) was used as a starting 
material. The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) 
and isolated as orange/red crystals.  (0.97g, 45.3 %), mp 128 – 130 oC. [α]D 
20
 = - 17 º (c 0.005, ACN); 
UV-VIS λmax ACN: (318, 431) IR: υmax (KBr): 3362, 3272, 1656, 1614, 1537, 1491, 1263, 1252, 1195, 
1149 cm
-1
; 
1H NMR (400 MHz) δ (DMSO-d6): 9.0 (1H, d, J = 7.6 Hz, Ar-CO-NH), 8.15 (1H, t, J = 
5.6 Hz, FcCH2NH), 7.52-7.48 (2H, m, Ar-H), 7.18-7.13 (1H, m, Ar-H), 4.56-4.49 {1H, m, NH-
CH(CH3)}, 4.18-4.15{ 7H, m, (η
5
-C5H5) and ortho on (η
5
-C5H4)},  4.10 {2H, t,  J = 1.6 Hz, meta on 
(η5-C5H4)}, 4.03-3.98 (2H, m, FcCH2), 1.35 {3H, d, J = 6.8 Hz, NH-CH(CH3)}; 
13
C NMR (100 MHz) 
δ (DMSO-d6): 171.5, 166.1, 134.1-134.0, 131.3-131.2, 129.9-129.6, 118.8-118.7, 112.7-112.5, 105.6-
105.5, 86.2, 68.3, 67.4, 67.1, 49.3, 37.5 (-ve DEPT), 17.9; 
19
F (376 MHz, DMSO): δ -113.4 (2F m). 
 
 
 
 
 
 
 
 
 
 
 
 
150 
N-(ferrocenylmethyl-L-alanine)-3,5-difluorobenzene carboxamide 126 
 
For compound 126 N-(3,5-difluorobenzoyl)-L-alanine (1.25 g, 5.45 mmol) was used as a starting 
material. The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) 
and isolated as brown crystals. (0.91 g, 37.4 %), mp 144 – 146 0C. [α]D 
20
 = + 27 º (c 0.005, ACN)
; 
UV-VIS λmax ACN: (320, 434) IR: υmax (KBr): 3256, 3081, 1635, 1594, 1555, 1439, 1403, 1340, 1296, 
1246, 1173, 1050, 986 cm
-1
; 
1
H NMR (400 MHz) δ (DMSO-d6): 8.88 (1H, d, J = 6 Hz, Ar-CO-NH), 
8.15 (1H, t, J = 6 Hz , FcCH2NH), 7.67-7.62 (2H, m, Ar-H), 7.5-7.45 (1H, m, Ar-H), 4.50-4.46 {1H, 
m, NH-CH(CH3)}, 4.17-4.14{ 7H, m, (η
5
-C5H5) and ortho on (η
5
-C5H4)  }, 4.08 {2H, t, J = 2 Hz , 
meta on (η5-C5H4)}, 4.03-3.95 (2H, m, FcCH2), 1.34 {3H, d, J = 7.2 Hz, NH-CH(CH3)}; 
13
C NMR 
(100 MHz) δ (DMSO-d6): 171.5, 163.5, 160.7-160.8, 137.5-137.4, 111.1-110.8, 106.7-106.5, 86.2, 
68.3, 67.4, 67.1, 49.2, 37.5 (-ve DEPT), 17.9; 
19
F (376 MHz, DMSO): δ -118.50 (2F,  m). Anal Calc. 
for C21H20F2FeN2O2: C, 59.17; H, 4.73; N, 6.57. Found: C, 59.17; H, 4.58; N, 6.64 
 
 
 
 
 
 
 
 
 
 
 
151 
N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide 127 
 
For compound 127 N-(3,4,5-trifluorobenzoyl)-L-alanine (1.27 g, 5.14 mmol) was used as a starting 
material. The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) 
and isolated as red crystals.  (1.10 g, 46.6 %), mp 134 –136 0C. [α]D 
20
 = +32 º (c 0.005, ACN); UV-
VIS λmax ACN: (320, 432) IR: υmax (KBr):  3279, 3075, 1641, 1621, 1559, 1455, 1232, 1043, 889 cm
-1
; 
1H NMR (400 MHz) δ (DMSO-d6): 8.78 (1H, d, J = 7.2 Hz, Ar-CO-NH), 8.25 (1H, t, J = 6 Hz, 
FcCH2NH), 7.93-7.85 (2H, m, Ar –H ), 4.53-4.46 {1H, m, NH-CH(CH3)}, 4.19-4.17 {7H, m, (η
5
-
C5H5) and ortho on (η
5
-C5H4)},  4.10 {2H, t, J = 2 Hz, meta on (η
5
-C5H4)}, 4.05-3.95 (2H, m, FcCH2), 
1.41 {3H, d, J = 7.2 Hz, NH-CH(CH3)}; 
13
C NMR (100 MHz) δ (DMSO-d6):  170.3, 167.7, 155.9-
155.7, 147.5-147.4, 130.2-130.0, 112.7-112.5, 86.2, 68.3, 67.4, 67.1, 49.7, 37.5 (-ve DEPT), 17.9.; 
19
F 
(376 MHz, DMSO): δ -134.6 (2F, m), -157.1 (1F, m) . Anal Calc. for C21H19F3FeN2O2: C, 56.78; H, 
4.31; N, 6.31. Found: C, 56.62; H, 4.28; N, 5.98. m/z (ESI) 444.07 [M]
+
 
•
 . C21H19F3FeN2O2 requires 
444.075. 
 
 
 
 
 
 
 
 
 
 
152 
N-(ferrocenylmethyl-L-alanine)-2,3,4,5,6-pentafluorobenzene carboxamide 128 
 
For compound 128 N-(2,3,4,5,6-pentafluorobenzoyl)-L-alanine (1.47 g, 5.19 mmol) was used as a 
starting material. The compound was purified by column chromatography (eluant 2:1 hexane:ethyl 
acetate) and isolated as bright orange/red crystals. (0.59 g, 23.0 %), mp 123 –125 0C. [α]D 
20
 = +41º (c 
0.005, ACN); UV-VIS λmax ACN: (324, 436) IR: υmax (KBr):  3286, 1653, 1559, 1506, 1371, 1260, 
1105, 995 cm
-1
; 
1
H NMR (400 MHz) δ (DMSO-d6): 9.24 (1H, d, J = 7.6 Hz, Ar-CO-NH), 8.32 (1H, t, 
J = 5.6 Hz, FcCH2NH), 4.60-4.53 {1H, m, NH-CH(CH3)}, 4.19-4.17 {7H, m, (η
5
-C5H5) and ortho on 
(η5-C5H4)},  4.10 {2H, t, J = 1.6 Hz, meta on (η
5
-C5H4)}, 4.05-3.95 (2H, m, FcCH2), 1.36 {3H, d, J = 
7.2 Hz, NH-CH(CH3)}; 
13
C NMR (100 MHz) δ (DMSO-d6): 170.6,  164.6-164.5, 162.9, 136.6-136.5, 
129.8-129.7, 115.3-115.1, 86.2, 68.3, 67.4, 67.2, 48.8, 37.5 (-ve DEPT), 18.5; 
19
F (376 MHz, DMSO): 
δ -141.5 (2F,  m), -153.4 (2F, m), -161.7 (1F, m) Anal Calc. for C21H17F5FeN2O2: C, 52.52; H, 3.57; 
N, 5.83. Found: C, 51.87; H, 3.68; N, 5.27. m/z (ESI) 480.06 [M]
+
 
•
 . C21H17F5FeN2O2 requires 480.06. 
 
 
 
 
 
 
 
 
 
 
 
153 
N-(ferrocenylmethyl-β-alanine)-benzene carboxamide 129 
 
For compound 129 N-(benzoyl)-β-alanine (1.00 g, 5.17 mmol) was used as a starting material. The 
compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) and isolated as 
bright orange crystals. ( 0.69 g, 32.4 %), mp 103 – 107 0C ; UV-VIS λmax ACN: (323, 436) IR: υmax 
(KBr): 3298, 3078, 1637, 1539, 1318, 1275, 1245, 1158, 1087, 1022 cm
-1
 ; 
1H NMR (400 MHz) δ 
(DMSO-d6): 8.54 (1H, t, J = 5.6 Hz, Ar-CO-NH), 8.13 (1H, t, J = 5.6 Hz, FcCH2NH), 7.83 (2H, d, J 
= 6.8Hz, Ar-H), 7.53- 7.50 (1H, m, Ar-H), 7.47-7.43 (2H, m, Ar-H), 4.16-4.05 {7H, m, (η5-C5H5) and 
ortho on (η5-C5H4)}, 4.04 {2H, t, J = 2 Hz, meta on (η
5
-C5H4)}, 4.03-3.96 (2H, m, FcCH2), 3.50-3.45 
(2H, m,  CO-CH2CH2-NH) 2.43 (2H, t, J = 7.2 Hz, CO-CH2CH2-NH) ; 
13
C NMR (100 MHz) δ 
(DMSO-d6): 169.8, 166.1, 134.3, 131.0, 128.2, 127.0, 86.1, 68.2, 67.8, 67.1, 37.4 (-ve DEPT),  36.1 (-
ve DEPT), 35.1 (-ve DEPT). 
 
 
 
 
 
 
 
 
 
 
 
154 
N-(ferrocenylmethyl-β-alanine)-2-fluorobenzene carboxamide 130 
 
 
For compound 130 N-(2-fluorobenzoyl)-β-alanine (1.18 g, 5.59 mmol) was used as a starting material. 
The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) and isolated 
as orange crystals.  ( 0.82 g, 35.5 %), mp 101 – 104 0C ; UV-VIS λmax ACN: (323, 432)  IR: υmax 
(KBr):  3315, 3091, 1634, 1614, 1534, 1481, 1367, 1314, 1103, 1024 cm
-1
 ; 
1H NMR (400 MHz) δ 
(DMSO-d6): 8.35 (1H, t, J = 2.4 Hz, Ar-CO-NH), 8.15 (1H, t, J =  5.6 Hz, FcCH2NH), 7.64-7.59 (1H, 
m, Ar-H), 7.55- 7.50 (1H, m, Ar-H), 7.30-7.26 (2H, m, Ar-H), 4.17 {2H, t, J = 1.6 Hz, ortho on (η5-
C5H4)}, 4.14 {5H, s, (η
5
-C5H5)}, 4.07 {2H, t, J = 1.6 Hz, meta on (η
5
-C5H4)}, 4.00 (2H, d, J = 1.6 Hz,  
FcCH2), 3.49 (2H, q, J = 6.8 Hz, CO-CH2CH2-NH) 2.42 (2H, t, J = 6.8 Hz, CO-CH2CH2-NH) ; 
13
C 
NMR (100 MHz) δ (DMSO-d6): 169.7, 162.5, 139.9-139.8, 132.4-132.3, 130.2-130.1, 123.7-123.6, 
124.5-124.4, 116.2-116.1,  86.1, 68.3, 67.8, 67.2, 37.4 (-ve DEPT),  36.0 (-ve DEPT), 34.8 (-ve 
DEPT). 
19
F (376 MHz, DMSO): δ -114.25 (1F, m). 
 
 
 
 
 
 
 
 
 
155 
N-(ferrocenylmethyl-β-alanine)-3-fluorobenzene carboxamide 131 
 
 
For compound 131 N-(3-fluorobenzoyl)-β-alanine (1.00 g, 4.73 mmol) was used as a starting material. 
The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) and isolated 
as bright yellow crystals. ( 0.83 g, 41.3%), mp 135 – 139 0C; UV-VIS λmax ACN: (316, 434)  IR: υmax 
(KBr):  3340, 3261, 1647, 1633, 1525, 1479, 1304, 1288, 1105 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-
d6): 8.23-8.12 (1H, m, Ar-CO-NH), 8.16 (1H, t, J =11.2 Hz, FcCH2NH), 7.66-7.63 (1H, m, Ar-H), 
7.55- 7.50 (1H, m, Ar-H), 7.30-7.25 (2H, m, Ar-H), 4.17-4.15 {7H, m, (η5-C5H5) and ortho on (η
5
-
C5H4)}, 4.07 {2H, t, J = 3.2 Hz, meta on (η
5
-C5H4)}, 4.00 (2H, d, J = 5.6 Hz,  FcCH2), 3.49 (2H, q, J 
= 6.8 Hz, CO-CH2CH2-NH) 2.42 (2H, t, J = 6.8 Hz, CO-CH2CH2-NH) ; 
13
C NMR (100 MHz) δ 
(DMSO-d6): 170.5, 163.8-163.6, 157.9, 132.4-132.2, 130.1-130.0, 124.5-124.4, 123.8-123.6, , 115.8-
115.7,  86.0, 68.3, 67.8, 67.2, 37.5 (-ve DEPT),  36.0 (-ve DEPT), 34.9 (-ve DEPT). 
19
F (376 MHz, 
DMSO): δ -113.9 (1F, m). 
 
 
 
 
 
 
 
 
 
156 
N-(ferrocenylmethyl-β-alanine)-4-fluorobenzene carboxamide 132 
 
For compound 132 N-(4-fluorobenzoyl)-β-alanine (1.01 g, 4.78 mmol) was used as a starting material. 
The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) and isolated 
as bright yellow crystals.  (0.82 g, 38.8 %), mp 135 – 138 0C ; UV-VIS λmax ACN: (367, 434)  IR: υmax 
(KBr):  3312, 1675, 1622, 1537, 1402, 1301, 1232, 1151, 1104 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-
d6): 8.59 (1H, t, J = 5.6 Hz, Ar-CO-NH), 8.12 (1H, t, J = 5.6 Hz, FcCH2NH), 7.91-7.87 (2H, m, Ar-
H), 7.31- 7.26 (2H, m, Ar-H), 4.15 {2H, t, J = 1.6 Hz, ortho on (η5-C5H4)}, 4.14 {5H, s, (η
5
-C5H5)}, 
4.05-4.03 {2H, m, meta on (η5-C5H4)}, 4.01 (2H, d, J = 7.2 Hz,  FcCH2), 3.49 (2H, q, J = 6.8 Hz, CO-
CH2CH2-NH) 2.42 (2H, t, J = 6.8 Hz, CO-CH2CH2-NH) ; 
13
C NMR (100 MHz) δ (DMSO-d6): 169.7, 
163.8, 132.4-132.2, 130.1-130.0, 124.5-124.4, 115.9-115.7,  85.9, 68.2, 67.7, 67.1, 37.2 (-ve DEPT),  
36.3 (-ve DEPT), 34.9 (-ve DEPT). 
19
F (376 MHz, DMSO): δ -109.60 (1F, m). 
  
 
 
 
 
 
 
 
 
 
157 
N-(ferrocenylmethyl-β-alanine)-2,6-difluorobenzene carboxamide 133 
  
 
For compound 133 N-(2,6-difluorobenzoyl)-β-alanine (1.19 g, 5.19 mmol) was used as a starting 
material. The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) 
and isolated as bright brown crystals. (1.06 g, 44.3 %), mp 128– 130 0C; UV-VIS λmax ACN: (318, 
429)  IR: υmax (KBr):  3361, 3267, 1658, 1632, 1537, 1490, 1433, 1301, 1194, 1090 cm
-1
 ; 
1
H NMR 
(400 MHz) δ (DMSO-d6): 8.79 (1H, t, J = 5.6 Hz, Ar-CO-NH), 8.14 (1H, t, J = 5.6 Hz, FcCH2NH), 
7.52-7.46 (1H, m, Ar-H), 7.18-7.12 (2H, m, Ar-H), 4.18 {2H, t, J = 2 Hz, ortho on (η5-C5H4)}, 4.16 
{5H, s, (η5-C5H5)}, 4.08 {2H, t, J = 2 Hz, meta on (η
5
-C5H4)}, 4.00 (2H, d, J = 5.6 Hz,  FcCH2), 3.47-
3.44 (2H, m, CO-CH2CH2-NH) 2.41 (2H, t, J = 7.2 Hz, CO-CH2CH2-NH) ; 
13
C NMR (100 MHz) δ 
(DMSO-d6): 169.3, 167.4, 159.6-159.5, 134.9-134.8, 131.6-131.5, 111.9-111.7,  86.0, 68.2, 67.8, 
67.2, 37.5 (-ve DEPT),  36.1 (-ve DEPT), 34.8 (-ve DEPT). 
19
F (376 MHz, DMSO): δ -114.11 (1F, m) 
-114.09 (1F, m). 
 
 
 
 
 
 
 
 
 
158 
N-(ferrocenylmethyl-β-alanine)-2,4-difluorobenzene carboxamide 134 
 
For compound 134 N-(2,4-difluorobenzoyl)-β-alanine (1.70 g, 7.41 mmol) was used as a starting 
material. The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) 
and isolated as orange/yellow crystals.  (0.72 g, 21.2 %), mp 128 – 132 0C; UV-VIS λmax ACN: (319, 
430)  IR: υmax (KBr):  3263, 3079, 1635, 1552, 1492, 1434, 1265, 1190, 1104, 1093 cm
-1
 ; 
1
H NMR 
(400 MHz) δ (DMSO-d6): 8.39 (1H, t, J = 4 Hz, Ar-CO-NH), 8.19 (1H, t, J = 4 Hz, FcCH2NH), 7.72-
7.66 (1H, m, Ar-H), 7.38-7.32 (1H, m, Ar-H), 7.19-7.13 (1H, m, Ar-H), 4.19-4.15 {7H, m, (η5-C5H5) 
and ortho on (η5-C5H4)}, 4.08-4.05 {2H, m, meta on (η
5
-C5H4)}, 3.95-3.85 (2H, m, FcCH2), 3.49-3.44 
(2H, m, CO-CH2CH2-NH) 2.42-2.38 (2H, m, CO-CH2CH2-NH) ; 
13
C NMR (100 MHz) δ (DMSO-d6): 
169.7, 162.6, 158.5-158.3, 144.6-144.5, 132.0-131.9, 120.3-120.2, 111.7-111.6,104.4-104.3, 86.0, 
68.3, 67.8, 67.2, 37.4 (-ve DEPT),  36.1 (-ve DEPT), 34.8 (-ve DEPT). 
19
F (376 MHz, DMSO): δ -
104.11 (2F, m). 
 
 
 
 
 
 
 
 
 
159 
N-(ferrocenylmethyl-β-alanine)-3,5-difluorobenzene carboxamide 135 
 
For compound 135 N-(3,5-difluorobenzoyl)-β-alanine (1.60 g, 6.98 mmol) was used as a starting 
material. The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) 
and isolated as bright orange crystals.  (0.75 g, 24.2 %), mp 144 – 146 0C; UV-VIS λmax ACN: (323, 
435)  IR: υmax (KBr):  3265, 3084, 1637, 1549, 1493, 1266, 1190, 1104 cm
-1
 ; 
1
H NMR (400 MHz) δ 
(DMSO-d6): 8.79 (1H, t, J = 5.6 Hz, Ar-CO-NH), 8.14 (1H, t, J = 5.6 Hz, FcCH2NH), 7.60-7.49 (2H, 
m, Ar-H), 7.18-7.12 (1H, m, Ar-H), 4.20-4.16 {7H, m, (η5-C5H5) and ortho on (η
5
-C5H4)}, 4.10-4.09 
{2H, m, meta on (η5-C5H4)}, 3.99 (2H, d, J = 5.6 Hz,  FcCH2), 3.46-3.41 (2H, m, CO-CH2CH2-NH) 
2.41 (2H, t, J = 7.2 Hz, CO-CH2CH2-NH) ; 
13
C NMR (100 MHz) δ (DMSO-d6): 169.3, 168.3, 159.6, 
132.2-132.1, 125.6-125.5, 111.9-111.8, 86.0, 68.5, 67.8, 67.2, 37.5 (-ve DEPT),  35.8 (-ve DEPT), 
34.9 (-ve DEPT). 
19
F (376 MHz, DMSO): δ -114.14 (2F, m). 
 
 
 
 
 
 
 
 
 
 
160 
N-(ferrocenylmethyl-β-alanine)-3,4,5-trifluorobenzene carboxamide 136 
 
 
For compound 136 N-(3,4,5-trifluorobenzoyl)-β-alanine (1.27 g, 5.14 mmol) was used as a starting 
material. The compound was purified by column chromatography (eluant 2:1 hexane:ethyl acetate) 
and isolated as bright yellow crystals.  (0.84 g, 35.6 %), mp 134 –136 0C; UV-VIS λmax ACN: (322, 
434)  IR: υmax (KBr):  3263, 1634, 1552, 1492, 1301, 1283, 1141, 1023, 1001 cm
-1
 ; 
1
H NMR (400 
MHz) δ (DMSO-d6): 8.79 (1H, t, J = 5.6 Hz, Ar-CO-NH), 8.14 (1H, t, J = 5.6 Hz, FcCH2NH), 7.18-
7.13 (2H, m, Ar-H), 4.20-4.15 {7H, m, (η5-C5H5) and ortho on (η
5
-C5H4)}, 4.10 {2H, t, J = 1.6 Hz, 
meta on (η5-C5H4)}, 4.00 (2H, d, J = 5.6 Hz, FcCH2), 3.46 (2H, q, J = 7.6 Hz  CO-CH2CH2-NH) 2.43 
(2H, t, J = 7.2 Hz, CO-CH2CH2-NH) ; 
13
C NMR (100 MHz) δ (DMSO-d6): 169.8, 164.8,157.5-157.3, 
14831-148.0,  131.4-131.3, 111.9-111.7, 86.3, 68.3, 67.8, 67.2, 37.5 (-ve DEPT),  35.9 (-ve DEPT), 
34.9 (-ve DEPT). 
19
F (376 MHz, DMSO): δ -114.42 (3F, m). 
 
 
 
 
 
 
 
 
 
161 
N-(ferrocenylmethyl-β-alanine)-2,3,4,5,6-pentafluorobenzene carboxamide 137 
 
 
 
For compound 137 N-(2,3,4,5,6-pentafluorobenzoyl)-β-alanine (2.00 g, 7.06 mmol) was used as a 
starting material. The compound was purified by column chromatography (eluant 2:1 hexane:ethyl 
acetate) and isolated as bright orange crystals. (1.20 g, 34.3 %), mp 123 – 125 0C ; UV-VIS λmax ACN: 
(322, 434)  IR: υmax (KBr):  3267, 1637, 1543, 1492, 1427, 1333, 1266, 1105 cm
-1
 ; 
1
H NMR (400 
MHz) δ (DMSO-d6): 9.05 (1H, t, J = 5.6 Hz, Ar-CO-NH), 8.16 (1H, t, J = 5.6 Hz, FcCH2NH), 4.18-
4.15 {7H, m, (η5-C5H5) and ortho on (η
5
-C5H4)}, 4.08 {2H, t, J = 2 Hz, meta on (η
5
-C5H4)}, 4.03 (2H, 
d, J = 7.6 Hz,  FcCH2), 3.49 (2H, q, J = 6.8 Hz,  CO-CH2CH2-NH) 2.42 (2H, t, J = 7.2 Hz, CO-
CH2CH2-NH) ; 
13
C NMR (100 MHz) δ (DMSO-d6): 169.2, 167.5, 132.4-132.1, 125.6-125.5, 115.6-
115.4, 106.6-106.4,  85.9, 68.3, 67.8, 67.2, 37.5 (-ve DEPT),  36.0 (-ve DEPT), 34.5 (-ve DEPT). 
19
F 
(376 MHz, DMSO): δ -142.2 (2F, m), -153.2 (2F, m), -161.5 (1F, m). 
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Chapter 3 
Biological evaluation of N-(ferrocenylmethylamino acid) fluorinated benzene 
carboxamide derivatives. 
3.1 Introduction 
Cancer is a class of diseases characterised by the uncontrolled cell proliferation and the 
ability to invade other tissues. In the most developed countries, lung cancer is the leading 
cause of cancer death worldwide (1.4 million deaths per year). 
[1]
 Breast cancer is second 
only to lung cancer as the most common cause of cancer related death in women and thus 
represents a serious health care problem. 
[2]
 On average, 1 in 8 women in America and 1 in 13 
women in Ireland have the chance of developing breast cancer in their lifetime.   Surgery, 
radiation and chemotherapy are the three categories in which cancer treatment is approached. 
The cancer of the breast is primarily treated with surgery and now more importantly, 
chemotherapy. For the development and testing of new chemotherapeutic agents, the 
cytotoxicity is evaluated on in vitro models. Their introduction in the 1940/50s  
revolutionised the area of drug discovery, as it is the first step in the biological evaluation of 
synthetic and natural compounds.  The use of in vitro models allows the reproducibility of 
results, low cost and reduced time to acquire more substantial information on drug activity
 
.
[4]
 
3.1.1 Miniaturised in vitro methods 
The uses of miniature in vitro colorimetric endpoint assays furnish information on the ability 
of the drug as to whether it is enhancing cell growth or promoting cell death. Assays 
performed in vitro involve the determination of cell number (the most common measure in 
cell growth) after the cells have been treated with the test substance for a specific period of 
time. 
[5]
 The substance for testing is considered to have an anti-proliferative effect on treated 
cells, if a reduction in cell number is evident when compared to untreated controls. 
Unfortunately, there is one considerable limitation to the use of miniaturised in vitro 
colorimetric end point assays; it is not possible to determine whether the test is cytostatic or 
cytotoxic. 
[5]
 Cytostatic agents only affect the growth of cells temporarily, in a reversible 
manner. The anti-proliferative activity of a drug is lost once the cytostatic agent is removed. 
Cytotoxic agents however cause irreversible cell damage, which in turn leads to cell death by 
either apoptosis or necrosis. 
[6]
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There are numerous techniques to choose from when it comes to in vitro model assays. The 
choice is dependent on a number of factors such as sensitivity and linear range of 
colorimetric assay, which vary depending on the cell line and the end point employed. The 
five most common assays used are  
 MTT assay 
 LDH assay 
 Neutral Red assay 
 Protein staining assay 
 Acid phosphatase assay. 
3.1.1.1 MTT assay 
MTT, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (138) is a tetrazolium 
salt that is yellow in colour and added to the cells at the end-point of the assay. The MTT is 
taken up only by metabolically active cells. If no proliferation of the cell has taken place, the 
MTT is cleaved by dehydrogenase enzymes in the mitochondria of the cells to form dark blue 
Formazan crystals (139) (figure 3.1). The Formazan crystals are then solubilised in DMSO to 
give a coloured solution which can be measured spectrophotometrically at 570 nm. 
[6]
 
 
Figure 3.1 The dehydrogenase enzyme conversion of the MTT dye to the formazan product. 
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3.1.1.2 Lactate dehydrogenase (LDH) assay. 
LDH or lactate dehydrogenase is used to determine the cytotoxicity of the compounds. This 
assay quantitatively measures lactate dehydrogenase (LDH) which is a stable cytosolic 
enzyme that is released upon cell lysis. Released LDH in culture supernatants is measured 
with a 30-minute coupled enzymatic assay, which results in the conversion of a tetrazolium 
salt (INT) into a red formazan product. The amount of colour formed is proportional to 
number of lysed cells. Traditionally, on performing an LDH assay, an MTT assay would be 
carried out prior to distinguish between the cytotoxic and cytostatic properties of the test 
compound. 
[7] 
 
3.1.1.3 Neutral red assay 
The neutral red assay is based on the accumulation of the neutral red dye in the lysosomes of 
viable cells. At the end point, a neutral red solution is added to the cells and incubated to 
allow accumulation (140). Following washing, an acetic acid/ethanol mixture is added to 
elute the bound dye and the absorbance of the coloured solution is measured at 570 nm. 
 
Figure 3.2 Neutral red dye used to determine cell number at the end-point of the assay 
3.1.1.4 Protein staining assays 
The crystal violet dye elution assay is a protein staining assay in which the cells are fixed 
with formalin and stained with crystal violet dye. Another example of a protein assay is the 
sulforhodiamine B assay. This assay was developed by Skehan et al in the National Cancer 
Institute for the use on the MCI60 cell drug line screen. 
[8]
 In this screen the cells are fixed 
with trichloroacetic acid before staining with the dye. Of the above two protein staining 
assays, both are very sensitive but they exhibit a loss of linearity of optical density versus cell 
number at higher densities. 
[6] 
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3.1.1.5 Acid phosphatase assay 
In the acid phosphatase assay, a solution of p-nitrophenyl substrate is added at the end-point 
of the assay. The p-nitrophenyl substrate is then dephosphorylated by the acid phosphatase 
enzyme, which is located in the lysosomes of the cells. This process yields p-nitrophenol. In 
the presence of strong alkaline conditions, the p-nitrophenol chromophore can be quantified 
by measuring the absorbance at 405 nm.  (Scheme 3.1) 
 
Scheme 3.1 Acid phosphatase end-point assay (i) phosphatase catalysed reaction (H2O), (ii) 
colorimetric reaction in strong alkaline conditions (NaOH). 
The acid phosphatase assay is highly sensitive but, as a consequence, it has a low range of 
linearity between OD and cell number. This assay is easier to perform that the natural red 
assay, as it involves fewer steps and use of few reagents. It is  more convenient than the MTT 
assay because of the inherent problem of removal of medium from the insoluble crystals. The 
reproducibility between replicate wells is excellent, and was one of the principle reasons in 
choosing the acid phosphatase assay as the colorimetric end-point assay for the in vitro 
biological evaluation of N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide 
derivatives. Because of the large amount of derivatives synthesised, a preliminary screen was 
preformed and IC50 data studies were obtained for the most active derivatives, on the estrogen 
receptor positive cell line, MCF-7. 
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3.2 In vitro study of N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide 
derivatives on the MCF-7 breast cancer cell line  
A series of N-(ferrocenylmethyl) fluorobenzene carboxamide derivatives have been 
synthesised and biologically evaluated on the estrogen receptor positive (ER+) breast cancer 
cell line, the MDA-MB-435-S-F. In total from the series of compounds synthesised, four 
compounds displayed efficacy on the breast cancer cell line when screened at a concentration 
of 10 µM. 
[10]
 (Figure 3.3) & (Table 3.1) 
Compound name Compound 
number 
Inhibitory 
concentration 
(10µM) 
N-(ferrocenylmethyl) benzene carboxamide 63 37 ± 3% 
N-(ferrocenylmethyl)-4-fluorobenzene 
carboxamide 
64 41 ± 4% * 
N-(ferrocenylmethyl)-2,6-difluorobenzene 
carboxamide 
65 27 ± 5% 
N-(ferrocenylmethyl)-2,3,4,5,6-pentafluorobenzene 
carboxamide 
66 35 ± 5% 
 
Table 3.1 Anti-proliferative activity of N-(ferrocenylmethyl) fluorobenzene carboxamide 
derivatives previously synthesised 
[10]
 (* Compound was selected for IC50 data studies). 
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Figure 3.3:  N-(ferrocenylmethyl) fluorobenzene carboxamide derivatives, 63-66. 
The most active compound was N-(ferrocenylmethyl)-4-fluorobenzene carboxamide (64) 
which showed inhibition of 41 ± 3 %. An IC50 value range of 11- 14 µM was achieved.  
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3.2.1 Effect of fluorine and position in N-(ferrocenylmethylamino acid) fluorinated 
benzene carboxamide derivatives. 
In order to increase the biological activity of these N-(ferrocenylmethyl) fluorobenzene 
carboxamide compounds, the addition of amino acids, with the position and amount of 
fluorine atoms on the phenyl moiety were proposed. These structural changes were to assess 
the effects on the growth of cells. In total 27 derivatives were synthesised and screened at two 
concentrations on the MCF-7 breast cancer cell line. The MCF-7 breast cancer cell line was 
used, as the MDA-MB-435-SF cell line was no longer available at the time of testing, 
however both cell lines are estrogen receptor positive cells. (ER (+)). The amino acids that 
were used in the synthesis were glycine, L-alanine and β-alanine. The screening 
concentrations were 10µM and 40µM. These two concentrations were chosen as they were 
the maximum and the most active concentrations of the previous N-(ferrocenylmethyl) 
fluorobenzene carboxamide derivatives screened. 
[10]
   
 
Figure 3.4: Percent inhibition of selected N-(ferrocenylmethylamino acid) fluorobenzene 
carboxamide derivatives. 
 
 
169 
Compounds 117, 119, 127 and 128 showed to be cytotoxic when tested at 10 µM on the 
MCF-7 breast cancer cell line. The β-alanine derivatives (129-137), did not show any activity 
at this concentration. The four most active compounds were selected for further IC50 study. 
Compound 64, N-(ferrocenylmethyl)-4-fluorobenzene carboxamide was also tested and used 
as a standard. To determine the IC50 value of the 5 compounds, individual 96-well plates 
containing MCF-7 cells were treated with the test compound at concentrations ranging from 
10µM to 90µM. The cells were incubated for 4-5 days until the cell confluency was reached. 
Cell survival was determined by performing the acid phosphatase assay. The data obtained is 
presented in Figure 3.5, showing a plot of cell survival versus compound concentration for 
the four N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide derivatives (117, 
119, 127 and 128) and N-(ferrocenylmethyl)-4-fluorobenzene carboxamide (64).  The four 
N-(ferrocenylmethylamino acid) fluorinated benzene carboxamides were shown to exert a 
strong anti-proliferative effect on the MCF-7 cell line, as three of the derivatives are 
considerably more active than that of the standard (64). 
 
Figure 3.5: IC50 plot of compounds 64, 117, 119, 127 and 128 on the MCF-7 cell line. 
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Table 3.2 IC50 values in the MCF-7 cell line 
Compounds Name No. IC50 value (µM) (RSD %) 
N-(ferrocenylmethyl)-4-
fluorobenzene 
carboxamide 
64 24.8  ± 12% 
N-
(ferrocenylmethylglycine)-
3,5-difluorobenzene 
carboxamide 
117 46.5 ± 11% 
N-
(ferrocenylmethylglycine)-
2,3,4,5,6-
pentafluorobenzene 
carboxamide 
119 11.1 ± 12% 
N-(ferrocenylmethyl-L-
alanine)-3,4,5-
trifluorobenzene 
carboxamide 
127 2.84 ± 10% 
N-(ferrocenylmethyl-L-
alanine)-2,3,4,5,6-
pentafluorobenzene 
carboxamide 
128 10.3 ± 12% 
 
The N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide derivatives which 
have shown anti-proliferative activity have more than one fluorine atom on the aromatic ring.  
This is best observed for N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide 
(127)  which displayed an IC50 value of 2.84 µM. This figure is almost 9 times lower to that 
of N-(ferrocenylmethyl)-4-fluorobenzene carboxamide (64) (24.8 µM) when screened on the 
MCF-7 breast cancer cell line.  
The N-(ferrocenylmethylglycine)-2,3,4,5,6– pentafluorobenzene carboxamide (119) and the 
N-(ferrocenylmethyl-L-alanine)-2,3,4,5,6– pentafluorobenzene carboxamide (128), show IC50 
data values of  11.1 µM and 10.3 µM respectively.  These results show that the inclusion of 
the amino acids, glycine and L-alanine, in combination with the positioning and amount of 
fluorine atoms plays a vital role in increasing the biological activity and anti-cancer effect of 
these compounds. 
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Figure 3.6: N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide (127) 
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3.2.2 Effect of amino acid addition in N-(ferrocenylmethylamino acid) fluorinated 
benzene carboxamide derivatives. 
The addition of amino acids into the N-(ferrocenylmethyl) fluorobenzene carboxamide 
structure, increases the anti-proliferative effect. The N-(ferrocenylmethyl-L-alanine) 
fluorinated benzene carboxamide compounds are more active compared to the glycine and β-
alanine compounds. The addition of the amino acid, L-alanine, into the molecule, increases 
the cytotoxicity, as compounds 127 (trifluoro derivative) and 128 (pentafluoro derivative) 
showed IC50 values of 2.84 µM and 10.3 µM respectively. These two compounds were the 
most active derivatives synthesised. The addition of an amino acid with a side chain, i.e. L-
alanine has thus the greater biological effect. Differing only by the structural orientation, the 
β-alanine derivatives were also screened on the MCF-7 breast cancer cell line. However only 
one derivative synthesised was put forward for IC50 study. The N-(ferrocenylmethyl-β-
alanine)-2,3,4,5,6-pentafluorobenzene carboxamide (137) displayed  an IC50 of 89 µM. In 
terms of biological activity, it is clear that with the addition the amino acid with a side chain 
shows a greater anti-proliferative effect. (Figure 3.7)  
 
Figure 3.7: In vitro anti-proliferative activity of N-(ferrocenylmethyl-glycine, L-alanine, β-
alanine)-2,3,4,5,6-pentafluorobenzene carboxamide derivatives (119, 128, 137) 
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Figure 3.8: N-(ferrocenylmethyl-β-alanine)-2,3,4,5,6-pentafluorobenzene carboxamide (137). 
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3.3 In vitro study of N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide 
derivatives on the NSCLC H1299 Lung Cancer cell line. 
The N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide derivatives were 
evaluated in vitro on the H1299 lung cancer cell line. Each compound was screened at a 
single dose of 10 µM. This approach follows that adopted by the National Cancer Institute of 
the NCI60 cell line drug screen. The compounds to which had an anti-proliferative effect 
greater to that of 50% would then be screened at 1 µM.  The screen was performed by 
treating individual wells of a 96-well plate with 10 µM of each test compound. The test 
compounds were prepared in 1 mM stock solutions in DMSO. These solutions were then 
added to the culture medium. Since DMSO can have such an adverse effect on cells, two 
controls were set up in order to compare the anti-proliferative effects of the compounds. One 
control involved just cells in the well, while the second control was that of cells and 0.2 % 
DMSO, as in previous studies any concentration higher that 1 % DMSO gave a high 
inhibitory effect. 
[6]
  
At the first concentration, 10 µM, almost all the compounds screened were shown to have an 
inhibitory effect. N-(ferrocenylmethylglycine)-2,3,4,5,6-pentafluorobenzene carboxamide 
(119) and N-(ferrocenylmethyl-L-alanine)-2,3,4,5,6-pentafluorobenzene carboxamide (128) 
showed inhibitory percentages of above 90 and 70 % respectively. Figure 3.9 shows selected 
compounds and the inhibition percentage (%) at the concentration of 10 µM. 
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Figure 3.9 Percentage inhibition of selected compounds at 10 µM concentration in the 
H1299 cell line. 
 
Following these results, the compounds were then tested at a lower concentration of 1 µM. 
Any compound that was shown to inhibit cell growth above 50% would then be selected for 
IC50 data studies. Unfortunately, when the same compounds were tested at a lower 
concentration, the inhibition values were too low to pursue further study.  
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3.4 Mediated DNA damage of N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene 
carboxamide (127). 
A potential mechanism by which N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene 
carboxamide may induce DNA damage is by the generation of a reactive oxygenated species 
via the Fenton reaction.  To investigate this,  the rate of Fenton reaction mediated 8-
oxoguanine formation from the DNA nucleotide base, guanine, was monitored.  
Guanine was chosen as it has the lowest oxidation potential of all the DNA bases and is 
considered the clinical biomarker for oxidative DNA damage. 
[12][13]
 Guanine was oxidised 
using N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide (127)  and H2O2 at 
37 °C. Samples were taken in duplicate over 15 minutes. Each sample was injected in 
triplicate and analysed by HPLC-EC using an electrochemical detector at +550 mV versus 
Ag/AgCl. 
The iron mediated Fenton oxidation of guanine and the kinetic profile of 8-oxoguanine 
formed as a result has previously been investigated, using FeSO4 as the model iron 
complex.
[12] 
To examine if the N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene 
carboxamide  induced guanine oxidation via a similar mechanism, kinetic 8-oxoguanine 
formation profiles were compared using both iron complexes.  
Control experiments were carried out utilising both the iron complexes in the absence of 
peroxide, and peroxide in the absence of iron, to verify that any oxidation was Fenton 
mediated. Additionally, they ensured that no artifactual oxidation was occuring from the 
sample preparation or analysis methodology.  For these experiments, deionised water was 
used to sequentially replace each of the reagents used. The highest background reading for 
these controls is plotted as the base line. (Figures 3.10 and 3.11) Error bars show the 
standard deviation of duplicate samples injected in triplicate.   
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Figure 3.10: 8-Oxoguanine concentration as a function of time after incubation of free 
guanine with reagents Fe(II) and H2O2 at 37 °C.  
 
Figure 3.11: 8-Oxoguanine concentration as a function of time after incubation of free 
guanine with N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide (127)  and 
H2O2 at 37 °C. 
Incubation of free guanine with FeSO4 and peroxide lead to oscillating concentrations of 8-
oxoguanine over the incubation as previously reported.
[12]
  The formation is significantly 
higher than the control baselines, confirming the oxidation is Fenton mediated. The 8-
oxoguanine concentration maxima were 1.39 µM at 6 minutes and 2.29 µM at 8.5 minutes. 
This trend is analagous to that reported previously.
[12]
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oscillation frequency, which can be attributed to differences in solution pH (previously these 
maxima were reported at 4 and 15 minutes respectively). Incubation of free guanine with N-
(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide and peroxide,  which was 
suspected to result in Fenton mediated oxidation, also resulted in the formation of oscillating 
concentrations of 8-oxoguanine over the incubation period, as found with FeSO4. Again, the 
formation is significantly higher than the control base lines, clearly illustrating that both the 
iron complex and peroxide are required to form this concentration of 8-oxoguanine, 
confirming that the oxidation of guanine was Fenton mediated.  
The maximum concentration of 8-oxoguanine was achieved when 0.62 µM N-
(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide was used. This value was 
recorded after 30 seconds. The concentration of 8-oxoguanine generated by N-
(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide is significantly lower than 
that of the FeSO4. Ferrocene may produce a weaker response than the FeSO4 due to the 
presence of the cyclopentadienyl ligands and the size of the molecule. However the 
generation of 8-oxoguanine by N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene 
carboxamide illustrates that the oxidation is occurring by Fenton chemistry and generating 
DNA damage via a reactive oxygenated species (ROS) mediated mechanism. 
The oscillation period for 8-oxoguanine mediated by the N-(ferrocenylmethyl-L-alanine)-
3,4,5-trifluorobenzene carboxamide differs from that of FeSO4. After the initial maxima at 
0.5 and 2 minutes, the 8-oxoguanine concentration continues to oscillate for the rest of the 
incubation period, with concentrations consistently higher than control levels, further 
confirming that oxidation is Fenton mediated.  
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3.5 Conclusions. 
In summary, 27 N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide 
derivatives were tested in vitro on the MCF-7 estrogen receptor positive breast cancer cell 
line. The addition of amino acids, glycine, L-alanine and β-alanine, into the pre-existing N-
(ferrocenylmethyl) fluorinated benzene carboxamide structure was addressed to observe the 
difference in anti-proliferative activity upon the addition of the amino acids.  
The incorporation of the first amino acid, glycine, (111-119) resulted in two compounds 
reaching IC50 data studies. Values of 46 µM (117) and 11.1 µM (119) were recorded. For the 
third series synthesised, the β-alanine derivatives (129-137), as the greatest anti-proliferative 
effect observed was 89 µM (IC50 data study of 137). However, the inclusion of the L-alanine 
amino acid showed different results (120-128). With the inclusion of the fluorine atoms at 
positions 3,4,5 on the benzene moiety , the anti-proliferative effect increased. An IC50 value 
of 2.84 µM (RSD 10%) was obtained for N-(ferrocenylmethyl-L-alanine)-3,4,5-
trifluorobenzene carboxamide (127), therefore making it the most active compound of the 
entire study. It was an almost 9 fold increase in activity compared to the most active 
compound of this type, N-(ferrocenylmethyl)-4-fluorobenzene carboxamide (64) (also tested 
on the MCF-7. With the inclusion of the fluorine atoms at positions, 2,3,4,5,6 on the benzene 
moiety, the biological activity decreased to 10.3 µM (128) (RSD 12%). These results show 
that the inclusion of the L-alanine amino acid as well as specific position of the fluorine 
atoms on the benzene moiety is vital for the anti-proliferative effect. The IC50 data studies 
was carried out over a concentration range of 10 µM to 90 µM. These studies proved, that 
like the N-(ferrocenylmethyl) fluorinated benzene carboxamide derivatives, that with the 
increase in the concentration resulted in an increase in anti-proliferative activity, therefore 
concluding that a dose-dependent relationship is observed. The N-(ferrocenylmethyl-L-
alanine)-3,4,5-trifluorobenzene carboxamide derivative (127) was also monitored for its 
oxidative damage on the DNA nucleotide base, guanine. This test showed that the use of N-
(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide (127), illustrates that the 
oxidation is occurring on the DNA base guanine is occurring by Fenton chemistry and 
generation damage on the DNA via a reactive oxygenated species (ROS) mediated 
mechanism. 
The synthesised compounds were also screened on the non small cell lung cancer cell line 
H1299. The derivatives tested, showed an anti-proliferative effect at a concentration of 10 
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µM on the NSCLC H1299, but further studies showed that this activity ceased when the 
concentration of the compounds decreased. 
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Materials and Methods 
Cell culture media, supplements and related solutions were purchased from Sigma-Aldrich 
(Dublin, Ireland) unless otherwise stated. The H1299 cell line was obtained from the 
American Type Culture Collection (ATCC). The MCF-7 breast cancer cell line was obtained 
from the Health Protection Agency. The cells were grown in modified eagles’ medium with 5 
% foetal bovine serum (FBS).  The cell medium used was RPMI-1640 medium supplemented 
with 10 % foetal calf serum (FCS) for the H1299 cells. Both lines were grown as a monolayer 
culture at 37 
0
C, under a humidified atmosphere of 95 % O2, and 5 % CO2 in 75 cm
2
 flasks). 
All cell culture work was carried out in a class II laminar airflow cabinet (Holten LaminAir). 
All experiments involving cytotoxic compounds were conducted in a cytoguard laminar 
airflow cabinet (Holten LaminAir Maxisafe). Before and after use the laminar airflow cabinet 
was cleaned with 70 % industrial methylated spirits (IMS). Any items brought to the airflow 
cabinet were swabbed using IMS. At any one time, only one cell line was used in the laminar 
airflow cabinet and after completion of work with the cell line, the laminar airflow cabinet 
was allowed stand for 15 minutes before use. This was to eliminate any possibility of cross 
contamination between cell lines. The Laminar Airflow was cleaned daily with industrial 
disinfectants (Virkon or Tego) and also with IMS. These disinfectants were alternated 
fortnightly. Cells were fed with fresh media or subcultured when confluency reached 70 % in 
order to maintain active cell growth. 
Subculture techniques of cell lines. 
Media and Trypsin/EDTA solution (0.25 % trypsin (Gibco), 0.01 % EDTA (Sigma Aldrich) 
solution in PBS) were incubated at 37 
0
C for 20 min in a water bath. The cell culture medium 
was removed from the tissue culture flask and discarded into a sterile bottle. The flask was 
then rinsed with PBS (7 ml) to ensure the removal of any residual media. Once removed to a 
sterile waste bottle, fresh trypsin/EDTA solution (4 ml) was added and incubated at 37 
0
C for 
the required time  (dependant on cell line) until all the cells were detached from the inside 
surface of the tissue culture flask. The trypsin was deactivated by adding PBS (6 ml). The cell 
suspension was removed from the flask and placed in a sterile universal container and 
centrifuged at 2000 rpm for 5 minutes. The supernatant was then removed and discarded 
from the universal container and the pellet was suspended in complete medium. A cell count 
was performed. Depending on number of tests, an aliquot of cells was used to reseed a flask 
at the required density, topping up the flask with fresh medium. 
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Assessment of cell number 
Cells were trypsinised, pelleted and resuspended in media. An aliquot (10 µL) of the cell 
suspension was then applied to a universal vial and dye was added. This was then applied to 
the chamber of a glass cover slip enclosed haemocytometer. Cells in the 16 squares of the 
four grids of the chamber were counted. The average cell number, per 16 squares, was 
multiplied by a factor of 104 and the relevant dilution factor to determine the number of cells 
per ml in the original cell suspension. 
Cryopreservation of cells. 
Cells for cryopreservation were harvested when the cells had reached the log phase of growth 
and counted as described above. Cell pellets were resuspended and the media was removed 
and discarded. The cells were resuspended in cryogenic freezing medium (3 ml) and then 
placed in a cryovial (Greiner). These were then placed in the -20 
0
C  freezer for a period of 1-
2 hrs and then in the -80 
0
C freezer overnight.  Following this period, the vials were removed 
from the -80 
0
C freezer and transferred to the liquid nitrogen tanks for storage (-196 
0
C).  
Removing cells from cryopreservation 
A volume of prepared culture media (8 ml) was placed in a hot water bath for 20 minutes. 
The cryovial was removed from the liquid nitrogen storage tanks (-196 
0
C) and placed in a 
hot water bath for 10 minutes at 37 
0
C. The cryopreserved cells were then resuspended in the 
prepared culture media in a 75 cm
2
 flask. The cells were observed at 12 hr, 24 hr and 48 hr 
intervals for adhesion and confluency and growth. Following substantial growth the cells 
were fed with fresh culture media. 
In vitro proliferation assays 
Confluent cells in the exponential growth phase were harvested by trypsination and a cell 
suspension of 5 x 10
4
 cells/ml was prepared in fresh culture medium. The cell suspension (40 
µL ) was added to a flat bottom 96 well plate (Costar 3599), followed by culture medium (60 
µL).  The plate was slightly agitated in order to ensure complete dispersion of the cells. The 
cells were then  incubated for an initial 24 hours in a 37 
0
C , 5 % CO2 incubator to allow the 
adhesion  of cells to flat bottom wells. The compounds for testing were prepared in 1 mM 
stocks. The different concentrations used in the preliminary scans and for the further IC50 
data studies were made up accordingly by adding the desired amount of compound stock 
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solution to fresh culture media.  Once the compounds and media were added to the 96 well 
flat bottom plates, the plate was gently agitated and then incubated at 37 
0
C, 5 % CO2, for 4-5 
days until cell confluency reached over 85 %. Assessment of cell survival in the presence of 
test sample was determined by the acid phosphatase assay. For the full comprehensive screen, 
cell growth percentage in the presence of each sample was calculated relative to the DMSO 
control cells. For the preliminary studies and IC50 data studies, the concentration of drug that 
causes 50 % growth inhibition was determined by plotting the percentage (%) survival of 
cells (relative to control cells) against the concentration of the test sample. In relation to IC50 
data studies, IC50 values were calculated using Calcusyn software (Biosoft, UK). 
Acid phosphatase assay of MCF-7 cells. 
Following an incubation period of 5-6 days, drug media was removed from the 96-well plate 
and each well was washed with 100 µL of PBS. This was then removed and 100 µL of 
freshly prepared phosphatase substrate (10 mM p-nitrophenol phosphate in 0.1M sodium 
acetate, 0.1% triton X-100, pH 5.5) was added to each well. The plate was then incubated at 
37 
0
C for 2 hours. The enzymatic reaction was stopped upon addition of 1M NaOH (50 µL) 
to each well. The absorbance of each well was read in a dual beam reader (Synergy HT, Bio-
Tek, USA) at 405 nm with a reference wavelength of 620 nm. 
DNA cleavage study 
Guanine was purchased from Sigma-Aldrich. 8-Oxoguanine was purchased from Cayman 
Chemicals. Deionised water was purified using an ELGA purelab ultra system to a specific 
resistance of greater than 18.2 MΩcm.  All other chemicals were of analytical grade and used 
without further purification. All buffers and HPLC mobile phases were filtered through a 47 
mm, 0.45 µm polyvinylidine fluoride (PVDF) micropore filter (Sartorius Stedim Biotech) 
before use. 
Oxidation of Guanine 
10 mM Guanine prepared in 84 % 50 mM ammonium acetate, 85 mM acetic acid buffer and 
16 % 1 M NaOH was incubated with 1 mM Iron (II) sulphate (FeSO4.6H2O) or  1 mM  N-
(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide and 0.5 M hydrogen 
peroxide (H2O2) at 37 °C with constant stirring. Aliquots of 100 µl were taken in duplicate at 
various incubation times. The reaction was quenched with 1 ml cold ethanol. The solution 
was dried immediately under a stream of nitrogen gas.  Samples were stored at -20 °C until 
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further use. Prior to analysis they were redissolved in 1 ml of  84 % 50 mM ammonium 
acetate, 85 mM acetic acid buffer and 16 % 1 M NaOH. Samples were injected in triplicate. 
HPLC-UV-EC analysis of 8-oxoguanine formation 
For 8-oxoguanine analysis, the HPLC system consisted of a Varian ProStar 230 solvent 
delivery module and a Varian ProStar 310 UV-VIS dectector.  A Phenomenex Onyn 
Monolithic C
18
 reversed phase column (100 x 4.6 mm) with 1 cm guard column was used. 
The eluent comprised 1.2 % acetonitrile (ACN), 50 mM ammonium acetate and was adjusted 
to pH 4.6 with glacial acetic acid. It was run at a flow rate of 4 ml min
-1
 with an injection 
volume of 20 µl. The column temperature was ambient and 8-oxoguanine formation was 
monitored using an electrochemical detector at a detection potential of +550 mV versus an 
Ag/AgCl reference electrode. 
Controlled experiments 
Control incubations were performed with guanine to ensure that no artificial oxidation was 
caused by the reaction conditions. Each of the reagents was replaced with deionised water to 
insure that none of them could generate 
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Chapter 4 
Synthesis and structural characterisation of N-(ferrocenyl)-benzoyl-aminoalkanes. 
4.0 Introduction 
The synthesis, structure characterisation and biological evaluation was undertaken as part of a 
secondary structure activity relationship (SAR) study, with the goal of developing new 
analogues with a greater anti-proliferative activity. The N-(ferrocenyl)-benzoyl aminoalkanes 
are composed of three key moieties: (Figure 4.1) 
1. A ferrocene unit  
2. An aromatic linker   
3. A short or long aliphatic aminoalkane. 
The attachment of peptide and dipeptide subgroups to ferrocenyl moieties has been quite 
fruitful in this laboratory as other related structure activity relationships has shown. The 
testing of N-(ferrocenyl)-benzoyl dipeptide ester compounds 
[1-3]
 and N-(ferrocenyl)-
naphthoyl dipeptide ester compounds 
[4][5]
 has exhibited a wide range of anti-proliferative 
activity  across numerous cell lines including the H1299 lung cancer cell line, SK-Mel skin 
cancer cell line.
[6] 
However research has switched to their biological activity following 
cytotoxicity upon in vitro screening. As reported in the first SAR study, the attachment of 
amino acids into an N-(ferrocenylmethyl) fluorobenzene carboxamide structure, increased the 
anti-cancer activity on the MCF-7 breast cancer cell line. It is hoped that the use of the 
ferrocenyl-benzoyl moiety with the attachment of aminoalkane chains of differing length will 
thus further increase the anti-cancer activity on this cell line.   
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Figure 4.1: Structure of N-(ferrocenyl)-benzoyl amino alkanes 
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4.1 Effect of alkane chain length on biological activity. 
4.1.1 Effect of alkane chain length on anti-bacterial and anti-fungal strains. 
The investigation into the attachment of short and long aliphatic alkanes onto various 
molecules has been extensively researched and reported to have an effect against bacterial
[7][8]
 
and fungal infections.
[9]
 The extension of the alkyl chain moiety  has also shown to increase 
the anti-cancer activity on various cancerous cell lines. 
[10] 
Green et al have reported the synthesis of new anti-microbial agents (141, 142, 143) based on 
the anacardic acid scaffold (144). SAR studies showed that the alkyl chains had an interactive 
function when tested against Staphylococcus aureus. It was proposed that the hydrophilic 
head moiety binds with an intermolecular hydrogen bond (resembling a ‘hook’). This bond 
allows it to attach itself to a hydrophilic portion of the membrane of the bacteria cell. Thus 
allowing the hydrophobic tail portion of the molecule to enter into the membrane lipid 
bilayer. As a result a disorder in the lipid bilayer is created allowing the molecule to have an 
anti-microbial effect. These results showed that attachment of differing hydrophobic groups 
and also varying the length of the alkyl chains increased the efficacy against the bacteria. 
[7] 
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Subsequently, Akinnusi et al have also showed that variation of the alkyl chain does increase 
the activity of a drug. 
[8]
 SAR studies were carried out on variations of alkyl groups on a 
series of anti-bacterial compounds. Increasing the chain length of N-substituted 
pantothenamides from a penta derivative (145) to a heptyl (146) or nonyl (147) derivative 
results in an increase in anti-bacterial activity.  
 
 
Obando et al showed the effect on activity when the chain length of a series of 
alkylphosphocholines (148) was increased. 
[9] 
The anti-microbial and anti-fungal activity of 
alkyl phospholipids was increased versus Staphylococcus aureus and Cryptococcus 
neoformans respectively. When the alkyl chain length was increased from a 12 carbon chain, 
with a minimal inhibitory concentration (MIC) of 2.8 µM, to an 18 carbon chain, the minimal 
inhibitory concentration decreased (MIC) to 1.4µM, showing the length of the chain plays a 
vital role to inhibitory activity. 
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4.1.2 Effect of alkane chain length on cancerous cell lines. 
The varying of alkyl chain length has been shown to be effective against cancerous cell lines. 
Kamal et al screened benzothiazole-pyrrolobenzodiazepine conjugates for their cytotoxic 
activity against 60 human cancer cell types.
[10]  
Compound 149, exhibited cytotoxicity against  
leukaemia cell lines and also against Hop-62, Hop-92, NCI-H23, NCI-H460, NCI-H522 
(non-small cell lung cancer),  and a variety of colon, melanomas and breast cancers. IC50 data 
studies were in the range of 15-25 nM when the alkane chain was increased 
 
 
Bai et al demonstrated the importance of chain length to increase the cytotoxicity of modified 
ceramide derivatives. Ceramides (150) are long chain molecules recognized for their 
important role as signaling molecules involved in regulation of survival, proliferation and cell 
death. 
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The derivatives were also screened against the MCF-7 breast cancer cell line for their anti-
proliferative activity. Compound 151, a compound based on a modified acid ceramidase 
inhibitor resulted in an IC50 value of 1.0 µM, whilst in comparison, when the alkyl chain was 
shortened it resulted in a decrease of anti-cancer activity, with an IC50 of 6.0 µM.
[11]
 
 
Lamoral-Theys et al synthesised a series of polyphenol compounds based on the vanillin 
(152) backbone.
[12] 
 The compounds synthesised consisted of di- and tri- vanillin moieties, 
which were screened for their inhibitory effects on lung (A545)  prostate (PC-3), melanoma 
(B16F10)  and breast (MCF-7)  cancer cell lines. Compound 153, with the longest alkyl chain  
(11 carbons) showed the greatest inhibitory effect with IC50 ranging from 21 µM  - 31 µM in 
all the cancer cell lines. The shorter chain lengths of 5 carbons, (154) and the 6 carbon chain 
(155) resulted in a decrease of cytotoxic activity.  IC50 values were in the range of 69 -144 
µM and 22 – 63 µM respectively. 
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The series of N-(ferrocenyl)-benzoyl-aminoalkane derivatives comprise of a ferrocene moiety 
attached to a aromatic benzoyl group in the ortho-, meta-, and para- substitution pattern. A 
series of amino alkanes ranging in length from 3 carbon atoms to 12 carbon atoms were 
directly attached to the aromatic benzoyl moiety. These compounds were synthesised in good 
yield via standard coupling protocol. All derivatives gave spectroscopic data in accordance 
with their proposed structures. The structure activity relationship of these compounds was  
investigated by screening each derivative on the estrogen receptor positive, ER(+), breast 
cancer cell line, MCF-7, to investigate the importance of the aromatic orientation of the 
benzoyl moiety and also the effect of modifying the alkane chain length. 
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4.2 The Synthesis of N-(ferrocenyl)-benzoyl aminoalkanes 
Ferrocenyl benzoic acid was added to a stirred solution of equimolar amounts of the aliphatic 
amino alkane, treated with triethylamine (Et3N), N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) at 0 
O
C in 
anhydrous dichloromethane. The procedure is similar to that used by Mooney et al in the 
synthesis of N-(ferrocenyl)naphthoyl dipeptide esters.
[4]
 The synthetic route employed in the 
synthesis of N-{para-(ferrocenyl)-benzoyl} aminoalkanes derivative is outlined in Scheme 
4.1.  
 
Scheme 4.1 The general reaction scheme for the synthesis of N-{para-(ferrocenyl)-benzoyl} 
aminoalkanes. (i) HCl / NaNO2 (ii) C19H42BrN / H2O 0 
0
C (iii) aminoalkanes, EDC, NHS, TEA 0 
0
C. (a similar protocol is used for the ortho- and meta- derivatives). 
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4.2.1 The preparation of ferrocenyl benzoic acid. 
The arylation of ferrocene is easily achieved by reaction of ferrocene with an aryl diazonium 
salt. In this case, 2-, 3- and 4- aminobenzoic acid were used to give the ortho-, meta- and 
para-ferrocenyl benzoic acids with the aid of a phase transfer catalyst.
[13]
  These compounds 
were isolated as red and brown solids. This procedure the para- derivative is outlined in 
scheme 4.2. 
 
Scheme 4.2 Reaction scheme for the preparation of N-{para-(ferrocenyl)} benzoic acid. (i) 
HCl / NaNO2 (ii) C19H42BrN / H2O 0 
0
C 
4.2.2 Coupling of N-(ferrocenyl)-benzoyl amino alkanes 
Coupling reactions were used to facilitate the inclusion of the ferrocenyl group to the amino 
alkane. The coupling of ferrocenyl benzoic acids and amino alkanes gave yields in the range 
of 17 to 38 %. The crude N-(ferrocenyl) benzoyl aminoalkanes were purified by column 
chromatography, using a mixture of hexane and ethyl acetate as the eluant. The pure N-
{meta-(ferrocenyl)} benzoyl amino alkanes and the N-{para-(ferrocenyl)}-benzoyl-
aminoalkanes furnished as orange, red or brown solids, with yields in the range of 17 % to 36 
%. The N-{ortho-(ferrocenyl)}-benzoyl-aminoalkanes, upon purification presented as oils 
with red/brown colour. These derivatives yields ranged between 17 % to 38 %.  Overall, the 
derivatives with the highest yields are the hexyl derivatives, as the percentage yield seems to 
fall with the increase of carbon atoms, however this is not consistent. A possible reason for 
the overall difference in yield can be rationalized by the respective orientations of the ortho- 
and meta-ferrocenyl benzoic acid starting material. They are more sterically hindered than 
that of the para-ferrocenyl benzoic acid starting material. Table 4.1 summarises the yields 
for all the N-(ferrocenyl)-benzoyl-aminoalkanes derivatives 
The general reaction mechanism for the synthesis of N-(ferrocenyl)-benzoyl aminoalkanes is 
outlined in figure 4.2. 
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Table 4.1 Percentage yields for N-(ferrocenyl)-benzoyl-aminoalkanes derivatives 
Compound Name Compound 
No. 
Percentage Yield 
(%) 
 
N-{ortho-(ferrocenyl)-benzoyl}- aminopropane 
 
159 34.5 
N-{ortho-(ferrocenyl)-benzoyl}- aminobutane 
 
160 29.0 
N-{ortho-(ferrocenyl)-benzoyl}- aminopentane 
 
161 21.5 
N-{ortho-(ferrocenyl)-benzoyl}- aminohexane 
 
162 35.7 
N-{ortho-(ferrocenyl)-benzoyl}- aminoheptane 
 
163 37.4 
N-{ortho-(ferrocenyl)-benzoyl}- aminooctane 
 
164 30.1 
N-{ortho-(ferrocenyl)-benzoyl}- aminononane 
 
165 25.5 
N-{ortho-(ferrocenyl)-benzoyl}- aminodecane 
 
166 37.7 
N-{ortho-(ferrocenyl)-benzoyl}- aminododecane 
 
167 33.2 
N-{meta-(ferrocenyl)-benzoyl}- aminopropane 
 
168 33.8 
N-{meta-(ferrocenyl)-benzoyl}- aminobutane 
 
169 32.8 
N-{meta-(ferrocenyl)-benzoyl}- aminopentane 
 
170 26.3 
N-{meta-(ferrocenyl)-benzoyl}- aminohexane 
 
171 30.8 
N-{meta-(ferrocenyl)-benzoyl}- aminoheptane 
 
172 30.1 
N-{meta-(ferrocenyl)-benzoyl}- aminooctane 
 
 
173 35.1 
N-{meta-(ferrocenyl)-benzoyl}- aminononane 
 
174 20.2 
N-{meta-(ferrocenyl)-benzoyl}- aminodecane 
 
175 17.3 
N-{meta-(ferrocenyl)-benzoyl}- aminododecane 
 
176 34.7 
N-{para-(ferrocenyl)-benzoyl}- aminopropane 
 
177 36.1 
N-{para-(ferrocenyl)-benzoyl}- aminobutane 
 
178 33.9 
N-{para-(ferrocenyl)-benzoyl}- aminopentane 
 
179 32.4 
N-{para-(ferrocenyl)-benzoyl}- aminohexane 
 
180 29.2 
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N-{para-(ferrocenyl)-benzoyl}- aminoheptane 
 
181 31.2 
N-{para-(ferrocenyl)-benzoyl}- aminooctane 
 
182 17.5 
N-{para-(ferrocenyl)-benzoyl}- aminononane 
 
183 24.1 
N-{para-(ferrocenyl)-benzoyl}- aminodecane 
 
184 24.4 
N-{para-(ferrocenyl)-benzoyl}- aminododecane 
 
185 30.0 
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Figure 4.2; Coupling reaction mechanism the synthesis of N-{para-(ferrocenyl)-benzoyl} 
aminoalkanes. (the same protocol is used for the ortho- and meta- derivatives). 
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4.3 
1
H NMR studies of N-(ferrocenyl)-benzoyl aminoalkane derivatives. 
All the 
1
H NMR experiments were performed in d6-DMSO as the N-(ferrocenyl)-benzoyl 
aminoalkane derivatives showed limited solubility in other deuterated solvents. In d6-DMSO  
the  amide protons of the amino acids appear between  δ 8.51 and δ 8.16. The spectra have 
three signals in the ferrocenyl region which are typical of the mono-substituted ferrocenyl 
moiety. The protons of the substituted cyclopentadienyl ring appear as either fine triplets or 
as singlets within the region of δ 4.95 to δ 4.27, while the unsubstituted cyclopentadienyl ring 
appears as a strong singlet in the region of δ 4.08 to δ 4.02. 
Table 4.2. Selected 
1H NMR spectral data (δ, d6-DMSO) for the N-(ferrocenyl) benzoyl 
aminoalkanes derivatives (ppm) 
Compound 
Number 
Amide (NH)  Unsubstituted 
Cp Ring (η5-
C5H5) 
Substituted Cp 
Ring ortho-(η5-
C5H4) 
Substituted Cp 
Ring meta-(η5-
C5H4) 
159 8.16 4.07 4.59 4.30 
162 8.13 4.07 4.56 4.29 
167 7.81 4.07 4.58 4.27 
170 8.49 4.04 4.85 4.40 
172 8.48 4.02 4.85 4.40 
175 8.48 4.02 4.85 4.39 
180 8.40 4.03 4.88 4.41 
182 8.39 4.05 4.91 4.44 
185 8.39 4.02 4.88 4.41 
 
The aromatic splitting pattern in the 
1
H NMR spectra of N-(ferrocenyl)-benzoyl 
aminoalkanes derivatives varies in appearance, depending on whether ortho-, meta-, or para- 
ferrocenyl benzoic acids were used as starting materials. The ortho- derivatives have a 
doublet, triplet, tripet, doublet splitting pattern in the majority of derivatives synthesised. 
Each peak present integrates as one, corresponding to one hydrogen on the aromatic ring. The 
meta- derivatives splitting pattern gives rise to a singlet, multiplet, triplet. Both the singlet 
and triplet give rise to one proton upon integration, whereas the multiplet integrates as two. 
The para- derivatives, give rise the archetypal para- disubstituted aromatic splitting pattern 
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with the two apparent doublets both giving integration of two protons with coupling constants 
ranging from δ 5.6 Hz  to δ 8.4 Hz. Figure 4.3 shows the aromatic splitting pattern of the 
para-, meta- and ortho- derivatives of N-(ferrocenyl)-benzoyl-aminopentane (179, 170, 161) 
 
Figure 4.3; Splitting pattern of N-(ferrocenyl)-benzoyl-aminopentane at the para-, meta- and 
ortho- positions. (179, 170, 161 respectively) 
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4.3.1 
1
H NMR spectroscopic data of N-{ortho-(ferrocenyl)-benzoyl}-aminodecane 166. 
 
 
For the 
1
H NMR spectrum of N-{ortho-(ferrocenyl)-benzoyl}-aminodecane, 166, the amide 
proton occurs at δ 8.15 as a triplet with a coupling constant of 5.6 Hz. The disubstituted 
phenyl ring is observed as a doublet, triplet, triplet and doubtet, between δ 7.81 and δ 7.11. 
Each peak integrates for one proton with coupling constants ranging from 1.8Hz to 1.2Hz. 
The protons at the positions of ortho- and meta- of the substituted cyclopentadienyl ring 
appear as fine triplets in the range of δ 4.58 to δ 4.27. Both triplets integrate as two protons 
with coupling constants of 1.8 Hz. The unsubstituted cyclopentadienyl ring, appears as a 
singlet at δ 4.07. For N-{ortho-(ferrocenyl)-benzoyl}-aminodecane, four splitting patterns of, 
quartet, quintet, multiplet, and triplet are observed. The splitting pattern of the quartet 
occuring at δ 3.13 integrates for two hydrogens, with a coupling constant of 6.8 Hz. The 
methylene group directly attached to this, occurs upfield at δ 1.43 as a quintet. The multiplet 
integrating for fourteen hydrogens, appears in the region of δ 1.39 to δ 1.25. The most upfield 
signals are due to the methyl group of the aliphatic chain. This appears as triplet at δ 0.88, 
and integrates for three hydrogens.  
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Figure 4.4; 
1
H NMR spectrum of N-{ortho-(ferrocenyl)-benzoyl}-aminodecane, 166. 
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4.5.2 
1
H NMR spectroscopic data of N-{meta-(ferrocenyl)-benzoyl}- aminooctane, 173. 
 
 
In the 
1
H NMR spectrum of N-{meta-(ferrocenyl)-benzoyl}-aminooctane, 173, the amide 
proton occurs at δ 8.49. The meta disubstituted phenyl ring appears as a singlet, multiplet, 
triplet at δ 7.93, δ  7.71-δ 7.63, and δ 7.40 respectively. The ortho and meta protons of the 
cyclopentadienyl ring (η5-C5H4) appear between δ 4.85 and δ 4.40. Both peaks integrate for 
two hydrogens. For the other meta derivatives synthesised, these peaks can also occur as 
triplets, with coupling constants of 1.6 Hz. The unsubstituted cyclopentadienyl ring, (η5-
C5H5) appears as a strong singlet at δ 4.02, integrating for five hydrogens. The methylene 
groups of the aliphatic alkane moiety, appear as a quartet, quintet, multiplet, in the region of δ 
3.30 (2H), δ 1.55 (2H), and δ 1.30-δ 1.26 (10H), respectively. The methylene splitting 
patterns integrate for two, two and ten hydrogens. The methyl group is observed at δ 0.87 as a 
triplet with a coupling constant of 6.8 Hz. 
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Figure 4.5; 
1
H NMR spectra of N-{meta-(ferrocenyl)-benzoyl}-aminooctane, 173. 
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4.5.3 
1
H NMR spectrum of N-{para-(ferrocenyl)-benzoyl}-aminododecane, 185. 
 
The amide proton of N-{para-(ferrocenyl)-benzoyl}-aminodecane, 185,  appears at δ 8.39  as 
a triplet with a coupling constant of 4 Hz. The archetypal para- substituted aromatic splitting 
pattern is observed as two apparent doublets at δ 7.77 and δ 7.61 respectively that both 
integrate for two protons and have coupling constants of 5.6 Hz. The protons at the positions 
of ortho- and meta- of the substituted cyclopentadienyl ring appear as fine triplets in the 
range of δ 4.88 to δ 4.41. Both triplets integrate as two protons with coupling constants of 1.8 
Hz. The unsubstituted cyclopentadienyl ring (η5C5H5) is observed as a strong singlet at δ 
4.04, integrating for five hydrogens. The methylene groups appear as a quartet, quintet and 
multiplet. These appear at δ 3.26 with coupling constant of 4.8 Hz for the quartet, the quintet  
occurs at δ 1.54 and the multiplet occurs in the region of δ 1.34 to δ1.25. These peaks 
integrate for two, two and eighteen hydrogens respectively, corresponding to the eleven 
methylene groups present on the aliphatic alkane chain. The methyl group with a coupling 
constant of 4.4Hz, appears as a triplet at δ 0.83. 
 
 
 
 
 
205 
 
Figure 4.6; 
1
H NMR of N-{para-(ferrocenyl)-benzoyl}-aminododecane, 185. 
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4.4 
13
C NMR and DEPT-135 studies of N-(ferrocenyl)-benzoyl-aminoalkane derivatives. 
In the 
13
C NMR spectra of N-(ferrocenyl)-benzoyl-aminoalkane derivatives the carbonyl 
carbon appears between δ 169 and δ 157. The pattern observed in the aromatic region is 
dependent on the orientation of the aromatic benzoyl moiety. For the ortho and meta 
substituted compounds, each derivative gives rise to six peaks due to the six non-equivalent 
carbons. However, for the para substituted compounds, four unique carbon signals are 
observed. The ferrocenyl carbons appear in the range of δ 86 to δ 66, with the ipso carbon of 
the substituted (η5-C5H4) cyclopentadienyl ring appearing in the narrow range of δ 83.3 to δ 
86.8. The methylene carbons and also the methyl carbons are dependent on the amount of 
methylene groups present in the aliphatic alkane chain, and appear within the region of δ 42 
to δ 14. The methylene carbons are easily identified in the DEPT 135 spectra, as they appear 
negative to the methine and methyl carbons. 
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4.4.1 
13
C NMR and DEPT-135 study of N-{para-(ferrocenyl)-benzoyl}-aminooctane, 182. 
 
The 
13
C NMR spectrum of N-{para-(ferrocenyl)-benzoyl}-aminooctane, 182, displays one 
carbonyl signal at δ 165.8. The aromatic region shows four carbon signals due to the para 
substitution. The absence of δ 142.3 and δ 131.8 in the DEPT-135 spectrum indicates their 
quaternary nature. Similarly, the signal at δ 83.3 in the ferrocenyl region, which represents 
the ipso carbon of the substituted cyclopentadienyl ring, (η5-C5H4), is not observed in the 
DEPT-135 spectrum. The unsubstituted cyclopentadienyl ring (η5-C5H5) appears at δ 69.5, 
with the meta and ortho carbon signals appearing at δ 69.4 and δ 66.5 respectively. Eight 
signals are seen below δ 40 ppm, which is due to the presence of seven methylene groups and 
one methyl group which makes up the alkane chain. These carbon peaks appear at δ 39.1, δ 
31.2, δ 29.1, δ 28.9, δ 28.7, δ 26.4, δ 22.0 and δ 13.9 for the methyl group. The methylene 
groups are easily assigned as they appear negative in the DEPT-135 carbon spectrum.  
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Figure 4.7; 
13
C NMR spectrum of N-{para-(ferrocenyl)-benzoyl}-aminooctane, 182. 
 
Figure 4.8; DEPT-135 spectrum of N-{para-(ferrocenyl)-benzoyl}-aminooctane, 182. 
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4.5 
1
H COSY studies of N-{para-(ferrocenyl)-benzoyl}-aminododecane, 185. 
In the COSY spectrum of N-{para-(ferrocenyl)-benzoyl}-aminododecane, 185, the 
1
H proton 
spectrum is plotted along each axis. It is evident that the amide proton a (δ 8.39) correlates 
with the methylene group b of the alkyl chain which is directly attached to it (δ 3.26). This 
methylene group b, also correlates with the second methylene group c of the dodecyl alkane 
chain, (δ 1.34). Correlation also occurs between the ortho and meta protons n & o, of the 
substituted cyclopentadienyl ring (η5-C5H4), (δ 4.88 & δ 4.41 respectively). The remaining 
methylene groups d to l,  of the alkyl chain, couple together to form a multiplet  (δ 1.18 – δ 
1.12), but it  is clear  that this multiplet of methylene groups d to l, does correlate with the 
secondary methylene group c,  of the alkyl chain and also the methyl group m , of the alkyl 
chain. The aromatic protons p & q, of the disubstituted phenyl ring also show coupling with 
each other. 
 
 
Figure 4.9: N-{para-(ferrocenyl)-benzoyl}-aminododecane, 185. 
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Figure 4.10: COSY spectrum of N-{para-(ferrocenyl)-benzoyl}-aminododecane, 185. 
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4.5.1 HMQC study of N-{ortho-(ferrocenyl)-benzoyl}-aminodecane, 166. 
Heteronuclear multiple quantum coherence (HMQC) is a technique for complete assignment 
of structure using the results from the correlation between the carbon atom and the proton to 
which it is attached. As a result, quaternary carbons do not appear in the HMQC.
[14]
 A full 
assignment of the chemical shifts for N-{ortho-(ferrocenyl)-benzoyl}-aminodecane, 166, is 
outlined in figure 4.11 & 4.12 and table 4.3. 
Table 4.3: C-H correlation data from HQMC spectrum of N-{ortho-(ferrocenyl)-benzoyl}-
aminodecane, 166. 
Site 
1
H NMR 
13
C NMR HQMC 
1  84.5  
2&3 4.58  68.0 
4&5 4.27  68.5 
6 to 10 4.05  69.4 
11  137.1  
12  136.8  
13to 16 7.81 – 7.11  132.8 – 125.5 
17  169.6  
18 3.12  38.8 
19 1.43 - 1.40  34.2 
20 to 26 1.29 – 1.25  33.9 – 22.0 
27 0.85  13.9 
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Figure 4.11: N-{ortho-(ferrocenyl)-benzoyl)-aminodecane, 166. 
 
 
 
Figure 4.12: HMQC spectrum of N-{ortho-(ferrocenyl)-benzoyl}-aminodecane, 166 
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4.6 Infra red spectroscopic studies of N-(ferrocenyl)-benzoyl-aminoalkanes. 
The IR spectra of N-(ferrocenyl)-benzoyl aminoalkanes were obtained as potassium bromide 
discs. The spectra of these compounds show weak sharp bands in the region of ~3400 cm 
-1
   
to 3200 cm
-1
. This corresponds to the N-H stretching of the amide in the molecule. The 
region of ~ 1700 cm 
-1
  to 1600 cm 
-1
 refers to the stretching of the carbonyl groups, (C=O) in 
the molecule, this absorption was observed at ~1630 cm
-1
 for all the derivatives synthesised. 
The fingerprint region is the region or spectral range associated with absorptions that occur 
within the range of 1500 cm
-1
 to 1000 cm
-1
. The carbon to hydrogen stretches of the aliphatic 
chain and also the aromatic moiety carbon to hydrogen stretches were observed in this area. 
The low band region of the IR spectra associates any absorptions below 1000 cm
-1
. Whether 
the molecules aromatic moiety is mono, di or multi substituted, these can be identified in this 
region. Medium peaks were seen in this area, as all the compounds synthesised are 
disubstituted via ortho-, meta- or para- disubstitution patterns. This is outlined in figure 4.13. 
Table 4.4 shows various examples of the IR vibrations with the N-(ferrocenyl)-benzoyl 
aminoalkanes derivatives synthesised. 
 
Table 4.4: IR frequencies of N-(ferrocenyl)-benzoyl aminoalkanes derivatives (cm
-1
) 
Compound N-H stretch C=O stretch C-H range 
159 3301 1631 1493 – 1105 
163 3333 1631 1533 – 1105 
167 3282 1633 1534 – 1000 
170 3314 1636 1538 – 1106 
173 3283 1629 1552 – 1103 
178 3299 1638 1534 – 1066 
183 3329 1631 1578 - 1075 
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Figure 4.13: Infra red spectrum for N-{ortho-(ferrocenyl)-benzoyl}- aminooctane, 164. 
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4.7 UV-Vis spectroscopic studies of N-(ferrocenyl)-benzoyl amino alkanes 
The UV-Vis spectra of the N-(ferrocenyl)-benzoyl aminoalkanes differ significantly. The 
para derivatives give the strongest bands. One of the possible reasons, is, compared to the 
ortho and meta disubstituted phenyl moiety of the molecules, the para benzoyl ring and the 
substituted cyclopentadienyl ring (η5C5H4) lie in the same plane as each other, resulting in a 
larger chromophore. As previously discussed in Chapter 2, the larger the chromophore, the 
stronger the absorbance. The para derivatives have a maxima approximately 353 nm and  
455 nm corresponding to the π* and π transition of the benzoyl moiety and the metal to 
ligand charge transfer (MLCT) of ferrocene respectively. As for the ortho-, and meta- 
derivatives, the absorbance’s appear lower, where as the ortho- shows maxima of 330 nm to 
446 nm, while the meta- derivatives show maxima of 340 nm to 446 nm also. The para- 
derivatives are far more efficient chromophores due to greater degree of conjugation, 
resulting in higher absorbance maxima when compared to the ortho- and meta- derivatives.  
Table 4.5 UV-Vis data (nm) for N-(ferrocenyl)-benzoyl aminoalkane derivatives 
Compound 
Number 
λ MAX 1 ε 1 λMAX2 ε2 
159 443.9 2994.8 324.0 703.7 
162 443.4 2371.9 336.1 697.7 
164 440.9 1680.2 329.0 396.3 
173 443.9 1357.8 331.1 411.2 
175 445.1 1981.2 321.1 586.8 
178 446.1 1333.9 357.1 443.3 
181 449.9 2369.2 336.0 832.3 
182 449.0 1460.0 355.0 831.9 
183 447.8 2981.7 343.1 831.9 
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Figure 4.14: UV-Vis spectra of N-{ortho-, meta-, para-(ferrocenyl)-benzoyl}-aminoalkane 
derivatives 159, 162, 164, 173, 175, 178, 181, 182 & 183. 
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4.8 Conclusions: 
The principle focus of this structure activity relationship was to explore two key areas of the 
N-(ferrocenyl)-benzoyl aminoalkane derivatives; namely the effect of the orientation around 
the benzoyl moiety and also the effect of using short or long aliphatic chains, appended to the 
benzoyl moiety. Three series of compounds were synthesised and structurally characterised 
incorporating the ortho, meta and para disubstitution pattern on the benzoyl moiety. In total, 
27 compounds were prepared by varying the aliphatic chain length from a propyl (3 carbons) 
to a dodecyl (12 carbons). Product yields were in the range of 17 % to 38% for all the 
derivatives synthesised. These yields were considered to be quite low, as product yield would 
have dropped due to the purification via column chromatography.  These novel compounds 
have been characterised by a range of spectroscopic techniques including 
1
H NMR, 
13
C 
NMR, DEPT-135, HMQC, IR, & UV spectroscopy. Each compound gave spectra in 
accordance for their proposed structures. The compounds were screened for their biological 
effect on the MCF-7 breast cancer cell line. (Chapter 5) 
This area of research holds promise for future structure activity relationships to be 
undertaken, as the list of derivatising the structure is endless. The attachment of a more 
conjugated benzoyl moiety may be a possible route for investigation. Moieties such as a 
naphthoyl or an anthracene  group could used to replace the benzoyl moiety. This type was 
previously outlined by Mooney et al, as the replacement of a benzoyl ring system for a 
naphthoyl ring system proved to be more effective for anti-proliferative activity.
[5]
 The 
incorporation of a peptide, dipeptide chain as well as an aminoalkane derivative may increase 
the cytotoxicity of the compounds. Another viable route may involve using an ethynyl spacer 
between the ferrocenyl moiety and the aromatic moiety, as this could possible aid to the 
biological efficacy of the compounds.     
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Experimental 
 
General procedures. 
 
All chemicals were purchased from Sigma-Aldrich, Lennox Chemicals, Fluorochem limited or Tokyo 
Chemical Industry UK limited; and used as received. Commercial grade reagents were used without 
further purification. When necessary, all solvents were purified and dried prior to use. Riedal-Haën 
silica gel was used for thin layer chromatography and column chromatography.  Melting points were 
determined using a Griffin melting point apparatus and are uncorrected. Optical rotation 
measurements were made on a Perkin Elmer 343 Polarimeter and are quoted in units of 10
-1
 deg cm
2
 
g
-1
.  Infrared spectra were recorded on a Nicolet 405 FT-IR spectrometer or a Perkin Elmer 
Spectrometer 100 FT-IR with ATR.  UV-Vis spectra were recorded on a Hewlett-Packard 8452A 
diode array UV-Vis spectrophotometer. NMR spectra were obtained on a Bruker AC 400 NMR 
spectrometer operating at 400 MHz for 
1
H NMR, 376 MHz for 
19
F NMR and 100 MHz for 
13
C NMR. 
The 
1
H and 
13C NMR chemical shifts (δ) are relative to tetramethylsilane. All coupling constants (J) 
are in Hertz (Hz). The abbreviations for the peak multiplicities are as follows: s (singlet), d (doublet), 
t (triplet), q (quartet), qt (quintet), st (sextet) and m (multiplet). 
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General procedures for the preparation of starting materials for the N-(ferrocenyl)-benzoyl 
aminoalkanes 
 
ortho-Ferrocenyl benzoic acid 156 
 
A mixture of 2-aminobenzoic acid (3.00 g, 21.88 mmol), distilled water (80 ml) and concentrated 
hydrochloric acid was cooled in an ice bath for 30 min at 0 
o
C. Sodium nitrite (1.50 g, 21.74 mmol) in 
15 ml of distilled water was added drop-wise under stirring. The solution was stirred for a further 30 
mins and kept at a constant temperature of 5 
o
C. Ferrocene (4.00 g, 21.50 mmol) and 
hexadecyltrimethyl-ammonium bromide (3.00 g, 8.20 mmol) were dissolved in diethyl ether (100 ml). 
The mixture was then added dropwise to the 2-aminobenzoic / sodium nitrite solution at 5 
o
C, and was 
stirred at room temperature for 3 h. The diethyl ether was removed via rotary evaporation to yield a 
red solid. The red solid is then dissolved in 100 ml of 1M NaOH solution at 90 
o
C. The reaction 
mixture was filtered. Upon cooling of the filtrate, a precipitate of ortho-ferrocenyl benzoic acid forms. 
Yield (2.50 g, 35.7 %). mp 123 – 125 0C [1,2]  ; UV-VIS λmax ACN: (368, 460)  IR: υmax (KBr):  3449, 
1678, 1607, 1284, 1105 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 12.8 (1H, s, -COOH),  7.83 (1H, d, 
J = 8 Hz, Ar-H), 7.44 ( 1H, t, J = 8 Hz, Ar- H), 7.37 (1H, d, J = 8 Hz, Ar-H), 7.27 (1H, t, J = 8 Hz, 
Ar-H), 4.55 {2H, s, ortho on (η5-C5H4)}, 4.32 {2H, s, meta on (η
5
-C5H4)}, 4.08 {5H, s, (η
5
-C5H5)}.
13
C 
NMR (100 MHz) δ (DMSO-d6): 171.2, 137.0, 133.4, 131.1, 129.9, 127.8, 126.1, 85.4, 69.9, 69.2, 
68.6.  
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meta-Ferrocenyl benzoic acid 157 
 
A mixture of 3-aminobenzoic acid (3.00 g, 21.88 mmol), distilled water (80 ml) and concentrated 
hydrochloric acid was cooled in an ice bath for 30 min at 0 
o
C. Sodium nitrite (1.45 g, 21.02 mmol) in 
15 ml of distilled water was added drop-wise under stirring. The solution was stirred for a further 30 
min and kept at a constant temperature of 5 
o
C. Ferrocene (4.00 g, 21.50 mmol) and 
hexadecyltrimethyl-ammonium bromide (3.00 g, 8.20 mmol) were dissolved in diethyl ether (100 ml). 
The mixture was then added dropwise to the 3-aminobenzoic / sodium nitrite solution at 5 
o
C, and was 
stirred at room temperature for 3 h. The diethyl ether was removed via rotary evaporation to yield a 
red solid. The red solid was then dissolved in 100 ml of 1M NaOH solution at 90 
o
C. The reaction 
mixture was filtered. Upon cooling of the filtrate, a precipitate of meta-ferrocenyl benzoic acid forms. 
Yield (2.00 g, 28.8 %). mp: 159 – 161 0C [1,2] ; UV-VIS λmax ACN: (290, 720)  IR: υmax (KBr):  3450, 
1688, 1250, 1001 cm
-1
 ; 
1
H NMR (400 MHz) δ (DMSO-d6): 13.2 (1H, s, -COOH), 8.04 (1H, s, Ar-H), 
7.81 ( 1H, d, J = 8 Hz, Ar- H), 7.76 (1H, d, J = 8 Hz, Ar-H), 7.44-7.40 (1H, m, Ar-H), 4.84 {2H, s, 
ortho on (η5-C5H4)}, 4.35 {2H, s, meta on (η
5
-C5H4)}, 4.05 {5H, s, (η
5
-C5H5)}.
13
C NMR (100 MHz) δ 
(DMSO-d6): 167.8, 140.0, 132.2, 130.7, 129.1, 127.1, 126.5, 84.0, 69.8, 69.9, 66.8  
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para-Ferrocenyl benzoic acid 158 
 
A mixture of 4-aminobenzoic acid (3.00 g, 21.88 mmol), distilled water (80 ml) and concentrated 
hydrochloric acid was cooled in an ice bath for 30 min at 0 
o
C. Sodium nitrite (1.50 g, 21.74 mmol) in 
15 ml of distilled water was added drop-wise under stirring. The solution was stirred for a further 30 
min and kept at a constant temperature of 5 
o
C. Ferrocene (4.00 g, 21.50 mmol) and 
hexadecyltrimethyl-ammonium bromide (3.00 g, 8.20 mmol) were dissolved in diethyl ether (100 ml). 
The mixture was then added dropwise to the 4-aminobenzoic / sodium nitrite solution at 5 
o
C, and was 
stirred at room temperature for 3 h. The diethyl ether was removed via rotary evaporation to yield a 
red solid. The red solid was then dissolved in 100 ml of 1M NaOH solution at 90 
o
C. The reaction 
mixture was filtered. Upon cooling of the filtrate, a precipitate of para-ferrocenyl benzoic acid forms. 
Yield (2.93 g, 41.9 %). mp: 200 - 203 
0
C 
[1,2]
; UV-VIS λmax ACN: (368, 460)  IR: υmax (KBr):  3448, 
1670, 1600, 1285, 1110 cm
-1
 ; 
1
H NMR (400 MHz) δ (DMSO-d6): 12.8 (1H, s, -COOH),  7.85 (2H, d, 
J = 5.6 Hz, Ar-H), 7.64 ( 2H, d, J = 8 Hz, Ar- H), 4.89 {2H, t, J = 5.6 Hz,  ortho on (η5-C5H4)}, 4.43 
{2H, t, J = 5.6 Hz, meta on (η5-C5H4)}, 4.03 {5H, s, (η
5
-C5H5)}.
13
C NMR (100 MHz) δ (DMSO-d6): 
167.7, 145.0, 129.9, 127.3, 126.0, 83.0, 69.9, 68.1, 67.1 
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General procedure for the synthesis of N-{ortho-(ferrocenyl)-benzoyl}-aminoalkanes 
 
N-{ortho-(ferrocenyl)-benzoyl}-aminopropane 159 
 
N-Hydroxysuccinimide (0.55 g, 4.78 mmol) was added to a solution of ortho-ferrocenylbenzoic acid 
(1.51 g, 4.93 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (1.11 g, 5.79 
mmol) and triethylamine (2 ml) in dichloromethane (40 ml) at 0 
o
C. After 30 min, propylamine (0.50 
ml, 5.92  mmol) was added and the reaction was stirred at room temperature for 72 h. The compound 
was purified by column chromatography (eluant 6:1 hexane:ethyl acetate) to give the title compound 
as a brown oil. Yield (0.77 g, 41.2 %). UV-VIS λmax ACN: (325, 444)  IR: υmax (KBr):  3301, 1631, 
1601, 1493, 1464, 1314, 1244, 1149 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.16 (1H, t,  J = 5.4 
Hz, CO-NH-CH2), 7.80 (1H, d, J = 7.8 Hz, Ar-H), 7.42 -7.37 (1H, m, Ar-H), 7.25-7.23 (1H, m, Ar-
H),  7.15 (1H, d, J = 7.8 Hz, Ar-H), 4.59 {2H, t, J = 1.8 Hz, ortho on (η5-C5H4)}, 4.30 {2H, t, J = 1.8 
Hz, meta on (η5-C5H4)}, 4.07 {5H, s, (η
5
-C5H5)}, 3.11 (2H, q, J = 4.4 Hz, -NH-CH2-CH2), 1.48 (2H, 
qt, J = 4.8 Hz, -NH-CH2CH2CH3), 0.85 (3H, t, J = 5.2 Hz, -CH2CH3). 
13
C NMR (100 MHz) δ 
(DMSO-d6): 169.0, 137.4, 136.0, 131.1, 129.9, 127.0, 125.4, 86.8, 69.4, 68.6, 68.1, 40.7, (-ve DEPT), 
21.9 (-ve DEPT), 11.5. 
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N-{ortho-(ferrocenyl)-benzoyl}-aminobutane 160 
 
For compound 160 butylamine (0.50 ml, 5.05 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane:ethyl acetate) and isolated as a red oil. 
Yield (0.65 g, 34.7 %) ; UV-VIS λmax ACN: (328, 446)  IR: υmax (KBr):  3400, 1690, 1520, 1498, 
1400, 1350, 1162, 1042 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.15 (1H, t, J = 5.6 Hz, CO-NH-
CH2-), 7.82-7.77 (1H, m, Ar-H), 7.42-7.35 (1H, m, Ar-H), 7.25 (1H, t, J = 9.6 Hz, Ar-H), 7.14-7.12 
(1H, m, Ar-H), 4.59 {2H, t, J = 2 Hz,  ortho on (η5-C5H4)}, 4.29 {2H, t, J = 2 Hz, meta on (η
5
-
C5H4)}, 4.07 {5H, s, (η
5
-C5H5)}, 3.14 (2H, q, J = 6 Hz, NH-CH2CH2CH2CH3), 1.44 (2H, qt, J = 5.2 
Hz, NH-CH2CH2CH2CH3), 1.30-1.27 (2H, m, CH2CH2CH2CH3), 0.88 (3H, t, J = 7.2 Hz, -CH2CH3). 
13
C NMR (100 MHz) δ (DMSO-d6):162.5, 135.7, 129.9, 128.3, 128.1, 126.9, 125.4, 84.5, 69.4, 68.5, 
68.1, 40.1 (-ve DEPT), 30.7 (-ve DEPT), 19.6 (-ve DEPT), 13.7 
. 
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N-{ortho-(ferrocenyl)-benzoyl}-aminopentane 161 
 
For compound 161 pentylamine (0.60 ml, 5.16 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as an orange 
oil. Yield (0.49 g, 24.9 %); UV-VIS λmax ACN: (346, 441)  IR: υmax (KBr):  3302, 1779, 1536, 1490, 
1307, 1105, 1001 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.13 (1H, t, J = 3.6 Hz, CO-NH-CH2), 
7.80 (1H, d, J = 5.2 Hz, Ar-H), 7.40  (1H, t, J = 5.2Hz,  Ar-H), 7.27 – 7.23, (1H, m,  Ar-H), 7.14 (1H, 
d, J = 4.8 Hz, Ar-H), 4.59 {2H, s, ortho on (η5-C5H4)}, 4.29 {2H, s,  meta on (η
5
-C5H4)}, 4.07 {5H, s, 
(η5-C5H5)}, 3.14 (2H, q, J = 4.4 Hz, NH-CH2-CH2), 1.44 {2H, qt, J = 5.2 Hz, NH-CH2 CH2 (CH2)2 -
CH3}, 1.30 – 1.24 {4H, m, CH2(CH2)2 -CH3}, 0.88 {3H, t, J = 4.8 Hz, (CH2)2 - CH3}. 
13
C NMR (100 
MHz) δ (DMSO-d6): 157.5, 135.9, 129.9, 126.7, 121.1, 118.9, 115.6,  84.3, 69.4, 68.6, 68.1, 38.5 (-ve 
DEPT), 33.8 (-ve DEPT),  30.8 (-ve DEPT), 19.6 (-ve DEPT), 13.6. 
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N-{ortho-(ferrocenyl)-benzoyl}-aminohexane 162 
 
For compound 162 hexylamine (0.70 ml, 5.22 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as a brown oil. 
Yield (0.81 g, 39.8 %) ; UV-VIS λmax ACN: (342, 451)  IR: υmax (KBr):  3303, 1633, 1540, 1490, 
1307, 1105, 1020 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.13 (1H, t, J = 3.2 Hz, CO-NH-CH2), 
7.80 (1H, d, J = 5.6 Hz, Ar-H), 7.40 (1H, t, J = 5.2 Hz,  Ar-H), 7.23 (1H, t, J = 4.8 Hz, Ar-H), 7.15 
(1H, d, J = 5.2 Hz, Ar-H), 4.56 {2H, s,  ortho on (η5-C5H4)}, 4.29 {2H, s,  meta on (η
5
-C5H4)}, 4.07 
{5H, s, (η5-C5H5)}, 3.14 (2H, q, J = 4.4 Hz, NH-CH2-CH2-), 1.48 {2H, qt, J = 4.8 Hz, -NH-CH2 CH2 
(CH2)3 -CH3}, 1.31 – 1.22 {6H, m, -CH2(CH2)3 -CH3}, 0.88 {3H, t, J = 4.8 Hz, (CH2)3-CH3}. 
13
C 
NMR (100 MHz) δ (DMSO-d6): 166.2, 146.6, 139.7, 132.3, 128.3, 127.2, 125.3, 83.3, 69.5, 68.9, 
68.6, 39.1 (-ve DEPT), 31.2 (-ve DEPT), 28.8 (-ve DEPT), 26.2 (-ve DEPT), 22.1 (-ve DEPT), 13.9. 
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N-{ortho-(ferrocenyl)-benzoyl}-aminoheptane 163 
 
For compound 163 heptylamine (0.75 ml, 5.01 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as a brown oil. 
Yield (0.85 g, 40.9 %) ; UV-VIS λmax ACN: (321, 445)  IR: υmax (KBr):  3333, 1631, 1533, 1463, 
1297, 1105 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.14 (1H, t, J = 3.6 Hz, CO-NH-CH2), 7.80 
(1H, d, J = 5.2 Hz, Ar-H), 7.40-7.36 (1H, m, Ar-H), 7.25 (1H, t, J = 5.2 Hz,  Ar-H), 7.14 (1H, d, J = 
5.2 Hz,  Ar-H), 4.57 {2H, t, J = 1.2 Hz,  ortho on (η5-C5H4)}, 4.27 {2H, t, J = 1.2 Hz,  meta on (η
5
-
C5H4)}, 4.07 {5H, s, (η
5
-C5H5)}, 3.12 (2H, q, J = 4.4 Hz,  NH-CH2-CH2), 1.41 {2H, qt, J = 4.4 Hz, 
NH-CH2 CH2 (CH2)4 -CH3}, 1.31-1.26 {8H, m, CH2CH2(CH2)4 -CH3}, 0.87 {3H, t, J = 6.4 Hz, 
CH2CH2(CH2)4 - CH3}. 
13
C NMR (100 MHz) δ (DMSO-d6): 169.6, 137.1, 129.9, 128.3, 127.0, 125.5, 
122.2, 84.4, 69.4, 68.6, 68.1, 39.1,(-ve DEPT), 31.3 (-ve DEPT), 28.9 (-ve DEPT),  28.6 (-ve DEPT), 
26.5 (-ve DEPT), 22.5 (-ve DEPT), 13.9. 
 
 
 
 
 
229 
N-{ortho-(ferrocenyl)-benzoyl}-aminooctane 164 
 
 
For compound 164 octylamine (0.90 ml, 5.01 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as a thick 
brown oil. Yield (0.69 g, 30.1 %) ; UV-VIS λmax ACN: (337, 443)  IR: υmax (KBr):  3239, 3050, 1629, 
1554, 1458, 1333, 1103 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.46 (1H, t, J = 5.6 Hz, CO-NH-
CH2-), 8.15 (1H, t, J = 7.2 Hz, Ar-H), 7.79 (1H, d, J = 7.2 Hz, Ar-H), 7.40 – 7.35, (1H, m,  Ar-H), 
7.22 (1H, t, J = 6.4 Hz, Ar-H), 4.59 {2H, t, J = 2 Hz,  ortho on (η5-C5H4)}, 4.28 {2H, t, J = 2 Hz,  
meta on (η5-C5H4)}, 4.06 {5H, s, (η
5
-C5H5)}, 3.13 (2H, q, J = 6.8 Hz,  -NH-CH2-CH2-), 1.43 {2H, qt, 
J = 6.4 Hz,  -NH-CH2 CH2 (CH2)5 -CH3}, 1.30-1.25 {10H, m, CH2CH2(CH2)5 -CH3}, 0.87 {3H, t, J = 
6.8 Hz, CH2CH2(CH2)5 -CH3}. 
13
C NMR (100 MHz) δ (DMSO-d6): 169.5, 137.1, 135.8, 129.8, 128.3, 
126.7, 125.5, 84.4, 69.4, 68.4, 68.1, 38.8 (-ve DEPT), 31.2 (-ve DEPT), 29.1 (-ve DEPT), 28.9 (-ve 
DEPT), 28.7 (-ve DEPT),  26.4 (-ve DEPT), 22.1 (-ve DEPT), 13.9. 
 
 
 
230 
N-{ortho-(ferrocenyl)-benzoyl}-aminononane 165 
 
For compound 165 nonylamine (0.90 ml, 4.91 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as a red oil. 
Yield (0.59 g, 26.4  %); UV-VIS λmax ACN: (325, 444)  IR: υmax (KBr):  3308, 1630, 1529, 1430, 
1267, 1104, 1003 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.14 (1H, t, J = 5.6 Hz, CO-NH-CH2), 
7.80 (1H, d, J = 7.2 Hz, Ar-H), 7.40-7.36 (1H, m, Ar-H), 7.22 (1H, t, J = 6.4 Hz, Ar-H), 7.11 (1H, d, J 
= 6.4 Hz,  Ar-H), 4.58 {2H, t, J = 2 Hz,  ortho on (η5-C5H4)}, 4.27 {2H, t, J = 2  Hz,  meta on (η
5
-
C5H4)}, 4.05 {5H, s, (η
5
-C5H5)}, 3.12 (2H, q, J = 6 Hz -NH-CH2-CH2), 1.43  {2H, qt, J = 6.4 Hz, -
NH-CH2CH2 (CH2)6 -CH3}, 1.29-1.25 {12H, m, CH2(CH2)6 -CH3}, 0.85 {3H, t, J = 6.4 Hz, (CH2)6 - 
CH3}. 
13
C NMR (100 MHz) δ (DMSO-d6): 169.6, 137.1, 135.7, 131.2, 129.3, 128.7, 125.5, 84.5, 69.4, 
68.6, 68.1, 38.8 (-ve DEPT), 31.3 (-ve DEPT), 28.9 (-ve DEPT),  28.7 (-ve DEPT), 26.8 (-ve DEPT), 
26.5 (-ve DEPT),  26.4 (-ve DEPT), 22.0 (-ve DEPT), 13.9. 
 
 
 
231 
N-{ortho-(ferrocenyl)-benzoyl}-aminodecane 166 
 
For compound 166 decylamine (1.00 ml, 5.00 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as an orange 
oil. Yield (0.88 g, 37.6 %) ; UV-VIS λmax ACN: (323, 443)  IR: υmax (KBr):  3221, 1626, 1558, 1432, 
1311, 1104, 1000 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.15 (1H, t, J = 5.6 Hz, CO-NH-CH2), 
7.81 (1H, d, J = 1.6 Hz, Ar-H), 7.39 (1H, d, J = 1.2 Hz Ar-H), 7.25, (1H, t, J = 1.2 Hz Ar-H), 7.13 
(1H, d, J = 1.2 Hz Ar-H), 4.58 {2H, t, J = 1.8 Hz,  ortho on (η5-C5H4)}, 4.27 {2H, t, J = 1.8 Hz,  meta 
on (η5-C5H4)}, 4.07 {5H, s, (η
5
-C5H5)}, 3.13 (2H, q, J = 6.8 Hz NH-CH2-CH2), 1.43  {2H, qt, J = 6.4 
Hz,  NH-CH2 CH2 (CH2)7 -CH3}, 1.39-1.25 {14H, m, CH2(CH2)7 -CH3}, 0.88 {3H, t, J = 6.8 Hz, 
(CH2)7 - CH3}. 
13
C NMR (100 MHz) δ (DMSO-d6): 169.6, 137.1, 134.9, 129.9, 128.4, 126.9, 125.3, 
84.5, 69.4, 68.6, 68.0, 38.8 (-ve DEPT), 31.2 (-ve DEPT), 28.9 (-ve DEPT),  28.7 (-ve DEPT),  28.6 (-
ve DEPT), 26.6 (-ve DEPT), 26.5 (-ve DEPT),  22.1 (-ve DEPT), 20.6 (-ve DEPT), 13.9. 
 
 
232 
N-{ortho-(ferrocenyl)-benzoyl}-aminododecane 167 
 
 
For compound 167 dodecylamine (1.10 ml, 4.78 mmol) was used as a starting material. The 
compound was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as 
a bright yellow/brown oil. Yield (0.77 g, 32.1  %) ; UV-VIS λmax ACN: (326, 446)  IR: υmax (KBr): 
3282, 1633, 1534, 1465, 1309, 1271, 1104, 1000 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.16 (1H, 
t, J = 3.6 Hz, CO-NH-CH2), 7.82-7.77 (1H, m,  Ar-H), 7.40-7.36 (1H, m, Ar-H), 7.25-7.21, (1H, m, 
Ar-H), 7.14-7.11 (1H, m, Ar-H), 4.58 {2H, t, J = 2 Hz,  ortho on (η5-C5H4)}, 4.27 {2H, t, J = 2 Hz,  
meta on (η5-C5H4)}, 4.07 {5H, s, (η
5
-C5H5)}, 3.13 (2H, q, J = 6 Hz NH-CH2-CH2), 1.40  {2H, qt, J = 
6.4 Hz, NH-CH2 CH2 (CH2)9 -CH3}, 1.39-1.25 {18 H, m, CH2(CH2)9 -CH3}, 0.87 {3H, t, J = 6.8 Hz, 
(CH2)9 - CH3}. 
13
C NMR (100 MHz) δ (DMSO-d6): 169.6, 137.0, 134.5, 130.9, 128.3, 126.7, 125.3, 
84.5, 69.4, 68.6, 68.0, 39.1 (-ve DEPT), 38.8 (-ve DEPT), 31.3 (-ve DEPT), 29.1 (-ve DEPT),  29.0 (-
ve DEPT),  28.9 (-ve DEPT), 28.8 (-ve DEPT), 28.7 (-ve DEPT), 28.6 (-ve DEPT),  26.5 (-ve DEPT), 
22.1 (-ve DEPT), 13.9 
 
 
233 
General procedure for the synthesis of N-{meta-(ferrocenyl)-benzoyl}-aminoalkanes 
 
N-{meta-(ferrocenyl)-benzoyl}-aminopropane 168 
  
N-Hydroxysuccinimide (0.50 g, 4.34 mmol) was added to a solution of meta-ferrocenylbenzoic acid 
(1.50 g, 4.89 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (1.10 g, 5.74 
mmol) and triethylamine (2 ml) in dichloromethane (40 ml) at 0 
o
C. After 30 min, propylamine (0.50 
ml, 5.92 mmol) was added and the reaction was stirred at room temperature for 72 h. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) to give yellow crystals. 
Yield (0.75 g, 37.5 %) mp 170 - 171 
0
C ; UV-VIS λmax ACN: (333, 447)  IR: υmax (KBr):  3300, 1632, 
1546, 1572, 1314, 1291, 1104, 999, 914 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.51 (1H, t, J = 5.4 
Hz, CO-NH-CH2), 7.97 (1H, s, Ar-H), 7.71 -7.67 (2H, m, Ar-H), 7.40 (1H, t, J = 5.2 Hz, Ar-H), 4.85 
{2H, s, ortho on (η5-C5H4)}, 4.39 {2H, s, meta on (η
5
-C5H4)}, 4.03 {5H, s, (η
5
-C5H5)}, 3.29 (2H, q, J 
= 4.4 Hz, -NH-CH2-CH2), 1.61 (2H, qt, J = 4.8 Hz, -NH-CH2CH2CH3), 0.95 (3H, t, J = 4.8 Hz, -
CH2CH3). 
13
C NMR (100 MHz) δ (DMSO-d6): 167.3, 139.5, 134.4, 130.9, 128.4, 127.0, 124.1, 84.1, 
69.3, 69.0, 66.4, 40.9 (-ve DEPT), 22.9 (-ve DEPT), 11.4. 
 
 
 
 
 
 
234 
N-{meta-(ferrocenyl)-benzoyl}-aminobutane 169 
 
For compound 169 butylamine (0.50 ml, 5.05 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane:ethyl acetate) and isolated as a yellow 
solid. Yield (0.62 g, 32.5 %), mp 178 - 180 
0
C ; UV-VIS λmax ACN: (331, 446)  IR: υmax (KBr):  3283, 
1632, 1544, 1517, 1310, 1104, 999, 810 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.48 (1H, t, J = 3.6 
Hz, CO-NH-CH2), 7.95 (1H, s, Ar-H), 7.77-7.64 (2H, m, Ar-H), 7.40 (1H, t, J = 5.2 Hz, Ar-H), 4.86 
{2H, s, ortho on (η5-C5H4)}, 4.39 {2H, s, meta on (η
5
-C5H4)}, 4.05 {5H, s, (η
5
-C5H5)}, 3.30 (2H, q, J 
= 4.4 Hz, NH-CH2-CH2-), 1.55  (2H, qt, J = 5.2 Hz, NH-CH2 CH2 CH2-CH3), 1.38-1.31 (2H, m, -
CH2CH2 -CH3), 0.94 (3H, t, J = 4.8 Hz, CH3).
13
C NMR (100 MHz) δ (DMSO-d6): 165.9, 139.1, 
134.7, 130.9, 128.4, 127.6, 124.1, 84.1, 69.3, 68.2, 66.4, 38.8 (-ve DEPT), 31.3(-ve DEPT), 19.6 (-ve 
DEPT), 13.7. 
 
 
 
 
 
 
 
 
235 
N-{meta-(ferrocenyl)-benzoyl}-aminopentane 170 
  
For compound 170 pentylamine (0.60 ml, 5.16 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane:ethyl acetate) and isolated as a red solid. 
Yield (0.50 g, 25.3 %), mp 179 - 182 
0
C ; UV-VIS λmax ACN: (320, 445)  IR: υmax (KBr):  3314,1636, 
1538, 1304, 1106, 803 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.49 (1H, t, J = 3.6 Hz, CO-NH-
CH2), 7.95 (1H, s, Ar-H), 7.70-7.64 (2H, m,  Ar-H), 7.40 (1H, t, J = 5.2 Hz, Ar-H), 4.85 {2H, t, J = 
1.2 Hz ortho on (η5-C5H4)}, 4.40 {2H, t, J = 1.2 Hz,  meta on (η
5
-C5H4)}, 4.04 {5H, s, (η
5
-C5H5)}, 
3.28 (2H, q, J = 4.8 Hz,, NH-CH2-CH2), 1.57  {2H, qt, J = 4.8 Hz, NH-CH2 CH2 (CH2)2 -CH3}, 1.36-
1.27 {4H, m, CH2(CH2)2 -CH3}, 0.92 {3H, t, J = 3.6 Hz, (CH2)2 - CH3}. 
13
C NMR (100 MHz) δ 
(DMSO-d6): 165.9, 139.1,  134.7, 128.4, 128.1, 127.0, 124.5, 84.1, 69.3, 69.0, 66.4, 39.2 (-ve DEPT), 
31.0 (-ve DEPT), 26.2 (-ve DEPT), 22.1 (-ve DEPT), 13.9. 
 
 
 
 
 
 
 
236 
N-{meta-(ferrocenyl)-benzoyl}-aminohexane 171 
 
For compound 171 hexylamine (0.70 ml, 5.22 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as a yellow 
solid. Yield (0.70 g, 34.4 %), mp 191 - 193 
0
C ; UV-VIS λmax ACN: (325, 440)  IR: υmax (KBr):  3314, 
1637, 1490, 1306, 1187, 1105, 1030, 1001 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.48 (1H, t, J = 
3.6 Hz, CO-NH-CH2), 7.95 (1H, s, Ar-H), 7.71–7.65 (2H,m, Ar-H), 7.40-7.37 (1H, m,  Ar-H), 4.85 
{2H, t, J = 1.2Hz, ortho on (η5-C5H4)}, 4.40 {2H, t, J = 1.2Hz, meta on (η
5
-C5H4)}, 4.02 {5H, s, (η
5
-
C5H5)}, 3.30 (2H, q, J = 4.8 Hz,, NH-CH2-CH2), 1.57 {2H, qt, J = 4.8 Hz, NH-CH2 CH2(CH2)3-CH3}, 
1.32-1.24 {6H, m, CH2(CH2)3 -CH3}, 0.91 {3H, t, J = 4 Hz, (CH2)3 - CH3}.
13
C NMR (100 MHz) δ 
(DMSO-d6): 165.9, 139.5,  134.7, 130.4, 128.4, 126.6, 124.1, 84.1, 69.4, 69.0, 66.4, 39.1 (-ve DEPT), 
31.2 (-ve DEPT), 29.1 (-ve DEPT), 26.4 (-ve DEPT), 22.0 (-ve DEPT), 13.9. 
 
 
 
 
 
 
237 
N-{meta-(ferrocenyl)-benzoyl}-aminoheptane 172 
 
For compound 172 heptylamine (0.75 ml, 5.01 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as a yellow 
solid. Yield (0.80 g, 37.6 %), mp 201 - 203 
0
C ; UV-VIS λmax ACN: (330, 440)  IR: υmax (KBr):  3267, 
1632, 1540, 1303, 1269, 1104, 999 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.48 (1H, t, J = 3.6 Hz, 
CO-NH-CH2), 7.95 (1H, s, Ar-H), 7.74–7.63 (2H, m, Ar-H), 7.38 (1H, t, J = 4.8 Hz  Ar-H), 4.85 {2H, 
t, J = 3.6 Hz ortho on (η5-C5H4)}, 4.40 {2H, t, J = 3.6 Hz meta on (η
5
-C5H4)}, 4.02 {5H, s, (η
5
-
C5H5)}, 3.28 (2H, q, J = 4.4 Hz, NH-CH2-CH2), 1.61{2H, qt, J = 4.8 Hz, NH-CH2 CH2 (CH2)4 -CH3}, 
1.32-1.27 {8H, m, CH2(CH2)4 -CH3}, 0.88 {3H, t, J = 3.2 Hz, (CH2)4-CH3}. 
13
C NMR (100 MHz) δ 
(DMSO-d6): 165.9, 139.1,  134.7, 130.9, 128.2, 127.0, 124.1, 84.1, 69.3, 69.0, 66.4, 39.4 (-ve DEPT), 
31.2 (-ve DEPT), 29.1 (-ve DEPT), 28.9 (-ve DEPT), 26.4 (-ve DEPT), 22.0 (-ve DEPT), 13.9. 
 
 
 
 
 
238 
N-{meta-(ferrocenyl)-benzoyl}-aminooctane 173 
 
For compound 173 octylamine (0.90 ml, 5.01 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as an orange 
solid. Yield (0.40 g, 18.6 %), mp 200 - 204 
0
C ; UV-VIS λmax ACN: (326, 426)  IR: υmax (KBr):  3238, 
1629, 1552, 1332, 1271, 1103, 999 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.49 (1H, t, J = 5.6 Hz, 
CO-NH-CH2), 7.93 (1H, s, Ar-H), 7.71–7.63 (2H, m, Ar-H), 7.40 (1H, t, J = 7.6 Hz  Ar-H), 4.87 {2H, 
t, J = 1.6 Hz ortho on (η5-C5H4)}, 4.40 {2H, t, J = 1.6 Hz  meta on (η
5
-C5H4)}, 4.01 {5H, s, (η
5
-
C5H5)}, 3.28 (2H, q, J = 6.4 Hz, NH-CH2-CH2), 1.55{2H, qt, J = 4.8 Hz, NH-CH2CH2(CH2)5 -CH3}, 
1.30-1.26 {10 H, m, CH2(CH2)5 -CH3}, 0.87 {3H, t, J = 6.8 Hz, (CH2)5 - CH3}. 
13
C NMR (100 MHz) 
δ (DMSO-d6): 165.9, 137.0 135.0, 130.9, 128.2, 127.0, 126.9, 84.5, 69.4, 68.5, 68.0, 38.8 (-ve DEPT), 
31.2 (-ve DEPT), 29.1 (-ve DEPT), 28.6 (-ve DEPT), 28.4 (-ve DEPT),  26.4 (-ve DEPT), 22.0 (-ve 
DEPT), 13.9. 
 
 
 
 
239 
N-{meta-(ferrocenyl)-benzoyl}-aminononane 174 
 
For compound 174 nonylamine (0.90 ml, 4.91 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as a yellow 
solid. Yield (0.40 g, 18.2 %), mp 210 - 213 
0
C ; UV-VIS λmax ACN: (327, 443)  IR: υmax (KBr):  3253, 
1651, 1545, 1452, 1270, 1103, 1033, 999, 914 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.49 (1H, t, 
J = 3.6 Hz, CO-NH-CH2), 7.95 (1H, s, Ar-H), 7.71-7.65 (2H,m, Ar-H), 7.40 (1H, t, J = 5.2 Hz , Ar-
H), 4.86 {2H, t, J = 1.2Hz ortho on (η5-C5H4)}, 4.40-4.39 {2H, t, J = 1.2Hz,  meta on (η
5
-C5H4)}, 
4.04 {5H, s, (η5-C5H5)}, 3.30 (2H, q, J = 4.4 Hz, NH-CH2-CH2), 1.57 {2H, qt, J = 4.8 Hz,NH-CH2 
CH2(CH2)6 -CH3}, 1.33-1.25 {12H, m, CH2(CH2)6 -CH3}, 0.89 {3H, t, J = 6 Hz, -CH2(CH2)6 -CH3}. 
13
C NMR (100 MHz) δ (DMSO-d6): 165.9, 139.2 134.5, 130.9, 128.6, 127.1, 126.1, 84.1, 69.3, 69.0, 
66.4, 39.2 (-ve DEPT), 31.2 (-ve DEPT), 29.1 (-ve DEPT), 28.5 (-ve DEPT), 26.5 (-ve DEPT), 22.0 (-
ve DEPT),  21.8 (-ve DEPT), 19.5 (-ve DEPT), 13.9 
 
 
 
240 
N-{meta-(ferrocenyl)-benzoyl}-aminodecane 175 
  
For compound 175 decylamine (1.00 ml, 5.00 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as a yellow 
solid. Yield (0.69 g, 29.9 %), mp 216 - 219 
0
C ; UV-VIS λmax ACN: (327, 449)  IR: υmax (KBr):  3238, 
1630, 1552, 1310, 1103, 1271, 1177, 994 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.48 (1H, t, J = 
3.6 Hz, CO-NH-CH2), 7.95 (1H, s, Ar-H), 7.71-7.65 (2H, m, Ar-H), 7.40 (1H, t, J = 5.2 Hz  Ar-H), 
4.85 {2H, t, J=1.2Hz,  ortho on (η5-C5H4)}, 4.39 {2H, t, J = 1.2Hz,  meta on (η
5
-C5H4)}, 4.02 {5H, s, 
(η5-C5H5)}, 3.28 (2H, q, J = 4 Hz,  NH-CH2-CH2). 1.56 {2H, qt, J = 4.8 Hz, NH-CH2 CH2 (CH2)7 -
CH3}, 1.32-1.27 {14H, m, CH2(CH2)7 -CH3}, 0.87 {3H, t, J = 3.2 Hz, (CH2)7 -CH3}.
13
C NMR (100 
MHz) δ (DMSO-d6): 165.9, 139.2 134.7, 130.9, 128.3, 127.1, 124.1, 84.1, 69.4, 69.2, 66.4, 39.1 (-ve 
DEPT), 31.3 (-ve DEPT), 31.2 (-ve DEPT), 29.1 (-ve DEPT), 28.9 (-ve DEPT), 28.7 (-ve DEPT), 
28.6 (-ve DEPT),  28.5 (-ve DEPT), 22.1 (-ve DEPT), 13.9. 
 
 
241 
N-{meta-(ferrocenyl)-benzoyl}-aminododecane 176 
  
For compound 176 dodecylamine (1.10 ml, 4.78 mmol) was used as a starting material. The 
compound was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as 
a yellow solid. Yield (0.80 g, 33.5 %), mp 230 - 234 
0
C ; UV-VIS λmax ACN: (342, 438)  IR: υmax 
(KBr):  3283, 1735, 1636, 1534, 1201, 1066, 996 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.45 (1H, 
s, CO-NH-CH2), 8.10-8.04 (1H, m, Ar-H), 7.88-7.80 (2H,m, Ar-H), 7.49-7.44 (1H, m,  Ar-H), 4.86 
{2H, s, ortho on (η5-C5H4)}, 4.40 {2H, s, meta on (η
5
-C5H4)}, 4.03 {5H, s, (η
5
-C5H5)}, 3.27 (2H, q, J 
= 4.4 Hz,-NH-CH2-CH2), 1.54 {2H, qt, J = 4.0 Hz, -NH-CH2 CH2 (CH2)9 -CH3}, 1.49-1.25 {18H, m, 
-CH2(CH2)9 -CH3}, 0.87 {3H, t, J = 4.8 Hz, -CH2(CH2)9 -CH3}. 
13
C NMR (100 MHz) δ (DMSO-d6): 
165.8, 139.5, 134.5, 128.4, 128.3, 124.7, 124.1, 84.1 69.3, 69.0, 66.4, 39.2 (-ve DEPT), 31.2 (-ve 
DEPT), 29.1 (-ve DEPT), 29.0 (-ve DEPT), 28.9 (-ve DEPT), 28.8 (-ve DEPT), 28.7 (-ve DEPT),  
27.9 (-ve DEPT), 26.5 (-ve DEPT), 22.1 (-ve DEPT)  20.9 (-ve DEPT), 13.9 
 
242 
General procedure for the synthesis of N-{para-(ferrocenyl)-benzoyl}-aminoalkanes 
N-{para-(ferrocenyl)-benzoyl}-aminopropane 177 
 
N-Hydroxysuccinimide (0.50 g, 4.34 mmol) was added to a solution of para-ferrocenylbenzoic acid 
(1.50 g, 4.89 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (1.10 g, 5.74 
mmol) and triethylamine (2 ml) in dichloromethane (40 ml) at 0 
o
C. After 30 min, propylamine (0.50 
ml, 5.92 mmol) was added and the reaction was stirred at room temperature for 72 h. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) to give yellow crystals. 
Yield (0.88 g, 47.5 %), mp 190-191 
0
C ; UV-VIS λmax ACN: (351, 449)  IR: υmax (KBr):  3299,1735, 
1638, 1534, 1222, 1066, 1046, 996 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.43 (1H, t, J = 4 Hz, 
CO-NH-CH2), 7.78 (2H, d, J = 5.2 Hz, Ar-H), 7.62 (2H, d, J = 5.6 Hz, Ar-H), 4.88 {2H, t, J = 1.2Hz,  
ortho on (η5-C5H4)}, 4.41 {2H, t, J = 1.2Hz meta on (η
5
-C5H4)}, 4.09 {5H, s, (η
5
-C5H5)}, 3.23 (2H, q, 
J = 4.4 Hz,, NH-CH2-CH2), 1.58 (2H, qt, J = 4.8 Hz, NH-CH2CH2CH3), 0.93 (3H, t, J = 3.6 Hz, -
CH2CH2CH3). 
13
C NMR (100 MHz) δ (DMSO-d6): 165.9, 142.3, 131.8, 127.2, 125.3, 83.3, 69.6, 69.3, 
66.5, 40.9 (-ve DEPT), 22.4 (-ve DEPT), 11.4 
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N-{para-(ferrocenyl)-benzoyl}-aminobutane 178 
  
For compound 178 butylamine (0.50 ml, 5.05 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as an orange 
solid. Yield (0.76 g, 40.6 %), mp 199-200 
0
C ; UV-VIS λmax ACN: (349, 448)  IR: υmax (KBr):  3299, 
1736, 1638, 1534, 1291, 1202, 1066, 996 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.41 (1H, t, J = 4 
Hz, CO-NH-CH2), 7.78 (2H, d, J = 8.4 Hz, Ar-H), 7.64 (2H, d, J = 8.4 Hz, Ar-H), 4.88 {2H, t, J = 2 
Hz, ortho on (η5-C5H4)}, 4.41 {2H, t, J = 2 Hz meta on (η
5
-C5H4)}, 4.01 {5H, s, (η
5
-C5H5)}, 3.27 (2H, 
q, J = 4.4 Hz,, NH-CH2-CH2), 1.56 (2H, qt, J = 4.4 Hz, NH-CH2CH2CH3), 1.36-1.32 ( 2H, m, 
CH2CH2CH2CH3), 0.91 (3H, t, J = 3.2 Hz, -CH2CH2CH3). 
13
C NMR (100 MHz) δ (DMSO-d6): 165.8, 
142.9, 134.6, 127.0, 125.3, 83.3, 69.4, 67.6, 66.5, 38.8 (-ve DEPT), 31.3 (-ve DEPT), 19.6 (-ve 
DEPT), 13.9. 
 
N-{para-(ferrocenyl)-benzoyl}-aminopentane 179 
 
For compound 179 pentylamine (0.60 ml, 5.16 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as a yellow 
solid. Yield (0.74 g, 37.4  %), mp 179 - 183 
0
C ; UV-VIS λmax ACN: (357, 455)  IR: υmax (KBr):  3299, 
1771, 1638, 1429, 1361, 1202, 996 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.41 (1H, t, J = 3.6 Hz, 
CO-NH-CH2), 7.79 (2H, d, J = 5.6 Hz Ar-H), 7.62  (2H, d, J = 5.6 Hz, Ar-H), 4.88 {2H, s, ortho on 
(η5-C5H4)}, 4.41 {2H, s,  meta on (η
5
-C5H4)}, 4.03 {5H, s, (η
5
-C5H5)}, 3.29 (2H, q, J = 4.4 Hz NH-
CH2-CH2), 1.56 {2H, qt, J = 4.4 Hz,  NH-CH2 CH2 (CH2)2 -CH3}, 1.35-1.30 {4H, m, CH2(CH2)2 -
CH3}, 0.92 {3H, t, J = 6 Hz, (CH2)2 - CH3}. 
13
C NMR (100 MHz) δ (DMSO-d6): 165.8, 142.3, 131.8, 
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127.2, 125.3, 83.3, 69.7, 67.1, 66.5, 39.0 (-ve DEPT), 28.8 (-ve DEPT), 25.5 (-ve DEPT), 21.8 (-ve 
DEPT), 13.9. 
N-{para-(ferrocenyl)-benzoyl}-aminohexane 180 
 
For compound 180 hexylamine (0.70 ml, 5.22 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as a red solid. 
Yield (0.69 g, 32.4 %), mp 199 - 203 
0
C ; UV-VIS λmax ACN: (351, 448)  IR: υmax (KBr):  3082, 1805, 
1638, 1534, 1361, 1291, 1252, 1066 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.40 (1H, t, J = 3.6 
Hz, CO-NH-CH2), 7.77 (2H, d, J = 5.6 Hz Ar-H), 7.62 (2H,d, J = 5.6 Hz, Ar-H), 4.88 {2H, t, J = 1.2 
Hz ortho on (η5-C5H4)}, 4.41 {2H, t, J = 1.2 Hz  meta on (η
5
-C5H4)}, 4.03 {5H, s, (η
5
-C5H5)}, 3.27 
(2H, q, J = 4.8 Hz, -NH-CH2-CH2), 1.55 {2H, qt, J = 4.8 Hz, -NH-CH2 CH2 (CH2)3 -CH3}, 1.35-1.24 
{6H, m, -CH2(CH2)3 -CH3}, 0.89 {3H, t, J = 6 Hz, -CH2(CH2)3 - CH3}. 
13
C NMR (100 MHz) δ 
(DMSO-d6): 165.8, 142.3, 131.8, 127.2, 125.3, 83.3, 69.4, 69.3, 66.5, 39.1 (-ve DEPT), 31.0 (-ve 
DEPT), 29.2 (-ve DEPT), 26.1 (-ve DEPT), 22.1 (-ve DEPT), 13.9. 
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N-{para-(ferrocenyl)-benzoyl}-aminoheptane 181 
 
 
For compound 181 heptylamine (0.75 ml, 5.01 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as a yellow 
solid. Yield (0.71 g, 34.2 %), mp 205 - 207 
0
C ; UV-VIS λmax ACN: (349, 450)  IR: υmax (KBr): 3320, 
1635, 1549, 1448, 1260, 1158, 1006, 990 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.40 (1H, t, J = 
3.6 Hz, CO-NH-CH2), 7.78 (2H, d, J = 5.6 Hz Ar-H), 7.60 (2H,d, J = 5.6 Hz, Ar-H), 4.87 {2H, s, 
ortho on (η5-C5H4)}, 4.41 {2H, s, meta on (η
5
-C5H4)}, 4.03 {5H, s, (η
5
-C5H5)}, 3.25 (2H, q, J = 
4.4Hz,  NH-CH2-CH2), 1.52 {2H, qt, J = 4.4 Hz, NH-CH2 CH2 (CH2)5 -CH3}, 1.29-1.25 {8H, m, 
CH2(CH2)5 -CH3}, 0.87 {3H, t, J = 4.4 Hz, (CH2)5 -CH3}. 
13
C NMR (100 MHz) δ (DMSO-d6): 165.9, 
142.3, 131.7, 127.2, 125.3, 83.3, 69.5, 69.4, 66.5, 39.1 (-ve DEPT), 31.3 (-ve DEPT), 29.1 (-ve 
DEPT), 28.7 (-ve DEPT), 28.6 (-ve DEPT), 26.5 (-ve DEPT), 13.9. 
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N-{para-(ferrocenyl)-benzoyl}-aminooctane 182 
 
 
For compound 182 octylamine (0.90 ml, 5.01 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as an orange 
solid. Yield (0.40 g, 18.6 %), mp 190 - 194 
0
C ; UV-VIS λmax ACN: (344, 450)  IR: υmax (KBr): 3300, 
1735, 1637, 1534, 1294, 1202, 1065, 997 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.39 (1H, t, J = 
3.6 Hz, CO-NH-CH2), 7.77 (2H, d, J = 5.6 Hz, Ar-H), 7.61 (2H, d, J = 5.6 Hz, Ar-H), 4.91 {2H, t, J = 
1.6 Hz, ortho on (η5-C5H4)}, 4.44 {2H, t, J = 1.6 Hz meta on (η
5
-C5H4)}, 4.05 {5H, s, (η
5
-C5H5)}, 
3.21 (2H, q, J = 4.8 Hz, -NH-CH2-CH2), 1.54  {2H, qt, J = 4.8 Hz,  NH-CH2 CH2 (CH2)5 -CH3}, 1.31-
1.24 {10H, m,-CH2CH2(CH2)5 -CH3}, 0.85 {3H, t, J = 4.8 Hz, (CH2)5 -CH3}. 
13
C NMR (100 MHz) δ 
(DMSO-d6): 165.8, 142.4, 131.8, 127.2, 125.3, 83.3, 69.4, 69.3, 66.5, 39.1 (-ve DEPT), 31.2 (-ve 
DEPT), 29.1 (-ve DEPT), 28.9 (-ve DEPT), 28.7 (-ve DEPT),  26.4 (-ve DEPT),  22.0 (-ve DEPT), 
13.9. 
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N-{para-(ferrocenyl)-benzoyl}-aminononane 183 
 
 
For compound 183 nonylamine (0.90 ml, 4.91 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as a yellow 
solid. Yield (0.55 g, 25.0 %), mp 206 - 208 
0
C ; UV-VIS λmax ACN: (350, 451)  IR: υmax (KBr): 3329, 
1631, 1578, 1489, 1376, 1075 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.41 (1H, t, J = 3.6 Hz, CO-
NH-CH2), 7.76 (2H, d, J = 5.6 Hz Ar-H), 7.61 (2H,d, J = 5.2 Hz, Ar-H), 4.87 {2H, s, ortho on (η
5
-
C5H4)}, 4.41 {2H, s, meta on (η
5
-C5H4)}, 4.02 {5H, s, (η
5
-C5H5)}, 3.26 (2H, q, J = 4.4 Hz, NH-CH2-
CH2), 1.52 {2H, qt, J = 4.8 Hz,  NH-CH2CH2 (CH2)6 -CH3}, 1.29-1.25 {12H, m, CH2(CH2)6 -CH3}, 
0.86 {3H, t, J = 4.8 Hz, (CH2)6 - CH3}. 
13
C NMR (100 MHz) δ (DMSO-d6): 165.9, 142.3,131.8, 
127.3, 125.3,  83.3, 69.5, 69.4, 66.5, 39.1 (-ve DEPT), 31.3 (-ve DEPT), 29.2 (-ve DEPT), 29.1 (-ve 
DEPT), 28.9 (-ve DEPT), 28.7 (-ve DEPT), 26.5 (-ve DEPT),  22.1 (-ve DEPT), 13.9. 
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N-{para-(ferrocenyl)-benzoyl}-aminodecane 184 
 
For compound 184 decylamine (1.10 ml, 5.50 mmol) was used as a starting material. The compound 
was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as a yellow 
solid. Yield (0.62 g, 23.7 %), mp 210 - 212 
0
C ; UV-VIS λmax ACN: (353, 448)  IR: υmax (KBr): 3331, 
1632, 1510, 1462, 1265, 1103, 999 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.41 (1H, t, J = 3.6 Hz, 
CO-NH-CH2), 7.80 (2H, d, J = 5.6 Hz Ar-H), 7.61 (2H, d, J = 5.6 Hz, Ar-H), 4.90 {2H, s, ortho on 
(η5-C5H4)}, 4.41 {2H, s,  meta on (η
5
-C5H4)}, 4.02 {5H, s, (η
5
-C5H5)}, 3.26 (2H, q, J = 4.4 Hz,  NH-
CH2-CH2), 1.51  {2H, qt, J = 4.4 Hz,  NH-CH2 CH2 (CH2)7 -CH3}, 1.39-1.29 {14H, m, CH2(CH2)7 -
CH3}, 0.89 {3H, t, J = 4.8 Hz, -CH2(CH2)7 - CH3}. 
13
C NMR (100 MHz) δ (DMSO-d6): 165.9, 142.3, 
131.8, 127.2, 125.3, 83.3, 69.4, 69.3, 66.5, 39.1 (-ve DEPT), 31.2 (-ve DEPT), 29.1 (-ve DEPT), 28.9 
(-ve DEPT), 28.9 (-ve DEPT),  28.7 (-ve DEPT), 28.6 (-ve DEPT),26.4 (-ve DEPT), 22.0 (-ve DEPT), 
13.9. 
 
 
 
 
 
 
 
 
 
249 
N-{para-(ferrocenyl)-benzoyl}-aminododecane 185 
 
For compound 185 dodecylamine (1.10 ml, 4.78 mmol) was used as a starting material. The 
compound was purified by column chromatography (eluant 6:1 hexane: ethyl acetate) and isolated as 
a red solid. Yield (0.70 g, 29.1 %), mp 215 - 218 
0
C ; UV-VIS λmax ACN: (359, 460)  IR: υmax (KBr): 
3084, 1631, 1612, 1537, 1463, 1265, 1103, 805 cm
-1
 ; 
1H NMR (400 MHz) δ (DMSO-d6): 8.39 (1H, t, 
J = 4 Hz, CO-NH-CH2), 7.77 (2H, d, J = 5.6 Hz Ar-H), 7.61 (2H, d, J = 5.6 Hz, Ar-H), 4.88 {2H,m, 
ortho on (η5-C5H4)}, 4.41 {2H, m, meta on (η
5
-C5H4)}, 4.04 {5H, s, (η
5
-C5H5)}, 3.26 (2H, q, J = 4.8 
Hz,  NH-CH2-CH2), 1.54  {2H, qt, J = 4.4 Hz,  NH-CH2 CH2 (CH2)9 -CH3}, 1.34-1.25 {18H, m, 
CH2(CH2)9 -CH3}, 0.83 {3H, t, J = 4.4 Hz, -(CH2)9 -CH3}. 
13
C NMR (100 MHz) δ (DMSO-d6): 165.8, 
142.3, 131.8, 127.2, 125.3, 83.3, 69.6, 69.4, 66.5, 39.1 (-ve DEPT), 37.7 (-ve DEPT), 31.3 (-ve 
DEPT), 29.1 (-ve DEPT),  29.0 (-ve DEPT), 28.9 (-ve DEPT),  28.8 (-ve DEPT), 28.7 (-ve DEPT), 
28.6 (-ve DEPT), 26.5 (-ve DEPT), 22.1 (-ve DEPT), 13.9. 
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Chapter 5 
Biological evaluation of N-(ferrocenyl)-benzoyl-aminoalkanes 
5.0 Introduction 
A series of N-(ferrocenyl)-benzoyl-aminoalkanes was synthesised, structurally characterised 
and biologically evaluated. In total 27 compounds were tested for their anti-proliferative 
effect on the ER (+) breast cancer cell line, MCF-7. These derivatives synthesised were 
evaluated for their anti-proliferative effect based upon two areas of the molecule.  
 The substitution pattern of the benzoyl moiety 
 The length of the aliphatic chain. 
Structure activity relationship (SAR) studies have previously been carried out on various cell 
lines, including the H1299 (lung) and SK-Mel (skin), and MDA-MB-435-SF (breast) cancer 
lines. These studies have shown that the incorporation of  various aromatic moieties and 
subsituents appended to a ferrocene molecule, increases its anti-proliferative effect on 
cancerous cells. Figure 5.1 shows a brief overview of the studies undertaken. 
[1][3][4]
  
 
 
Figure 5.1: Different SAR studies undertaken with ferrocenyl bioconjugates. 
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The orientation of a di-substituted benzoyl moiety attached to the ferrocene molecule and 
various dipeptide groups has shown to be effective on various cancer cell lines. Savage et al, 
synthesised a series of N-(ferrocenyl)-benzoyl dipeptide ethyl esters (route A) and reported an 
IC50 value of 26 µM for the N-{meta-(ferrocenyl)-benzoyl)-L-alanine-glycine ethyl ester on 
the H1299 lung cancer cell line. 
[6][7] 
Corry et al showed by changing the order of the dipeptide sequence incorporated in the 
molecule, was crucial for anti-proliferative activity (route B). The biological evaluation 
showed that when glycine was anchored to the benzoyl moiety, the anti-proliferative effect 
increased, as IC50 values of 5.3 µM (ortho- derivative), 4.0 µM (meta- derivative) and 6.6 µM 
(para- derivative) were observed on the H1299 lung cancer cell line. Other SAR studies 
involved the replacement of the benzoyl moiety with a naphthoyl moiety. 
[1][2]
  Mooney et al 
showed that, replacement by a naphthoyl subgroup, further increased the anti-proliferative 
activity (route C).  The inclusion of a more conjugated linker and using the same dipeptide 
sequence gave an IC50 of 1.3 µM on the H1299 lung cancer cell line.
[3][4]
 A series of N-
(ferrocenylmethyl)-fluorobenzene carboxamide synthesised by Kelly et al,
[3]
 (route D) 
showed the addition of fluorine atoms on a benzoyl moiety had an anti-proliferative effect on 
the MDA-MB-435-SF breast cancer cell line. Initial results from the first SAR study of this 
research (chapter 3) showed that the inclusion of an amino acid into this structure increased 
their biological activity. The inclusion of a di-substituted benzoyl moiety with a series of 
aliphatic alkyl chains was appended to a ferrocene molecule and evaluated on the MCF-7 
breast cancer cell line. The primary aim of this biological evaluation was to investigate 
whether the orientation of benzoyl moiety and/or the alkyl chain gives a greater anti-
proliferative effect. 
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5.1 In vitro evaluation of N-(ferrocenyl)-benzoyl amino alkanes 
Two ferrocenyl-benzoyl aminoalkane derivatives were preliminary screened for their anti-
proliferative activity on the MCF-7 breast cancer cell line. The two compounds were part of 
the para- series of N-(ferrocenyl)-benzoyl aminoalkane derivatives. The para- derivatives 
were the first to be synthesised and a preliminary screen was carried out to observe if the 
compounds had an anti-proliferative effect on cancerous cells. Compound 177, N-{para-
(ferrocenyl)-benzoyl}-aminopropane and compound 184, N-{para-(ferrocenyl)-benzoyl}-
aminodecane were the compounds tested as each compound incorporated a short and long 
aliphatic chain respectively. The compounds were screened at concentrations of 10 to 90 µM 
on the MCF-7 breast cancer cell line of which both derivatives displayed an anti-proliferative 
effect. This concentration range was chosen as it was the range used for all the derivatives 
tested on the MCF-7 breast cancer cell line.  
 
Figure 5.2 Preliminary screening of N-{para-(ferrocenyl)-benzoyl}-aminopropane (177) and 
N-{para-(ferrocenyl)-benzoyl}-aminodecane (184) on the MCF-7 breast cancer cells. 
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The results showed that from the preliminary screen that the compounds had an anti-
proliferative effect, and also that the length of the aliphatic chain would be a contributing 
factor in increasing the anti-cancer potential of these compounds.  Following the preliminary 
screen, a more in depth study was undertaken on all the derivatives (159-185) synthesised.  
The cells were treated with the N-(ferrocenyl)-benzoyl-aminoalkanes at a concentration range 
of 10 µM to 90 µM and incubated for 4-5 days until the cell confluency of 70 % was reached. 
Cell survival was determined by measuring the acid phosphatase activity.
[8]
 In total, 27 
compounds were tested on the MCF-7 breast cancer cell line, comprising of 9 derivatives of 
each ortho-, meta-, para- series. (Figure 5.3) All compounds were put forward for IC50 data 
studies. The values of these compounds are presented in Table 5.1. 
 
 
 
 
Figure 5.3: Substitution patterns of N-{ortho, meta, para-(ferrocenyl)-benzoyl}-aminoalkane 
derivatives, 159-185. 
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Table 5.1: IC50 data values for N-{ortho, meta, para-(ferrocenyl)-benzoyl}-aminoalkanes 
158-184. 
Name of Compound Compound Number IC50 Value µM (RSD % ) 
N-{ortho-(ferrocenyl)-
benzoyl}-aminopropane 
159 47.6 ± 20 % 
N-{ortho-(ferrocenyl)-
benzoyl}-aminobutane 
160 1.75 ± 4.0 % 
N-{ortho-(ferrocenyl)-
benzoyl}-aminopentane 
161 1.98 ± 1.4 % 
N-{ortho-(ferrocenyl)-
benzoyl}-aminohexane 
162 4.80 ± 5.0 % 
N-{ortho-(ferrocenyl)-
benzoyl}-aminoheptane 
163 4.24 ± 0.5 % 
N-{ortho-(ferrocenyl)-
benzoyl}-aminooctane 
164 Value ›100* 
N-{ortho-(ferrocenyl)-
benzoyl}-aminononane 
165 1.28 ± 1.5 % 
N-{ortho-(ferrocenyl)-
benzoyl}-aminodecane 
166 5.82 ± 3.0 % 
N-{ortho-(ferrocenyl)-
benzoyl}-aminododecane 
167 69.7 ± 4.0 % 
N-{meta-(ferrocenyl)-
benzoyl}-aminopropane 
168 Value ›100* 
N-{meta-(ferrocenyl)-
benzoyl}-aminobutane 
169 Value ›100* 
N-{meta-(ferrocenyl)-
benzoyl}-aminopentane 
170 Value ›100* 
N-{meta-(ferrocenyl)-
benzoyl}-aminohexane 
171 51.5 ± 5.0 % 
N-{meta-(ferrocenyl)-
benzoyl}-aminoheptane 
172 51.2 ± 10.0 % 
N-{meta-(ferrocenyl)-
benzoyl}-aminooctane 
173 Value ›100* 
N-{meta-(ferrocenyl)-
benzoyl}-aminononane 
174 Value ›100* 
N-{meta-(ferrocenyl)-
benzoyl}-aminodecane 
175 Value ›100* 
N-{meta-(ferrocenyl)-
benzoyl}-aminododecane 
176 Value ›100* 
N-{para-(ferrocenyl)-
benzoyl}-aminopropane 
177 89.0 ± 15.0 % 
N-{para-(ferrocenyl)-
benzoyl}-aminobutane 
178 62.3 ± 16.0 % 
N-{para-(ferrocenyl)-
benzoyl}-aminopentane 
179 Value ›100* 
N-{para-(ferrocenyl)-
benzoyl}-aminohexane 
180 4.01 ± 7.0 % 
N-{para-(ferrocenyl)- 181 84.5 ± 6.0 % 
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benzoyl}-aminoheptane 
N-{para-(ferrocenyl)-
benzoyl}-aminooctane 
182 1.1 ± 2.0 % 
N-{para-(ferrocenyl)-
benzoyl}-aminononane 
183 2.4 ± 0.5 % 
N-{para-(ferrocenyl)-
benzoyl}-aminodecane 
184 21.3 ± 6.0 % 
N-{para-(ferrocenyl)-
benzoyl}-aminododecane 
185 11.85 ± 12.0 % 
 
Note: * on calculation of the IC50 value, these values were too high to calculate as no 
inhibition was observed.  
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5.1.1 Effect of orientation around the central benzoyl moiety on cell proliferation. 
From the activity seen from the derivatives tested, it is clear that the substitution pattern of 
the N-(ferrocenyl)-benzoyl aminoalkanes has a significant effect on the anti-proliferative 
activity. Figure 5.4, figure 5.5 and figure 5.6, shows the plot of concentration vs. percentage 
cell growth for the N-{ortho, meta, para-(ferrocenyl)-benzoyl}-aminoalkanes respectively. 
Only two meta- derivatives (171 & 172) synthesized showed cell survival, as the other 
derivatives (168, 169, 170, 173, 174, 175 & 176) showed no survival below 100 % This trend 
was also seen for compound 164 of the ortho- series and compound 179 of the para- series.  
 
Figure 5.4: Plot of cell survival (%) vs. concentration of N-{ortho-(ferrocenyl)-benzoyl}-
aminoalkanes.  
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Figure 5.5: Plot of cell survival (%) vs. concentration of N-{meta-(ferrocenyl)-benzoyl}-
aminoalkanes.  
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Figure 5.6: Plot of cell survival (%) vs. concentration of N-{para-(ferrocenyl)-benzoyl}-
aminoalkanes. 
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The N-{meta-(ferrocenyl)-benzoyl}-aminoalkanes showed no inhibitory activity with the 
exception of N-{meta-(ferrocenyl)-benzoyl}-aminohexane (171) and N-{meta-(ferrocenyl)-
benzoyl}-aminoheptane (172) displaying IC50 values of 51.5 µM (RSD ± 5 %) and 51.2 µM 
(RSD ± 10 %) respectively.  (Figure 5.7) 
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Figure 5.7: IC50 values of N-{meta-(ferrocenyl)-benzoyl}-aminoalkanes  relative to DMSO 
control. 
 
It is evident, from the IC50 data studies that the substitution pattern of the compounds has an 
influence on the efficacy of biological activity. The number of derivatives that have a greater 
effect are those that are ortho- substituted. The ortho- and para- substituted compounds have 
eight derivatives that have shown inhibitory activity on the MCF-7 cell line. Even though the 
para- derivative, 182, recorded the lowest IC50 value of 1.1 µM (RSD ± 2 %), the number of 
derivatives with an IC50 value of under 5 µM is greater when they are substituted in the 
ortho- position. 
In comparison, N-{ortho-(ferrocenyl)-benzoyl)-aminobutane, 160, and N-{para-(ferrocenyl)-
benzoyl}-aminobutane, 178, structurally differ only by the substitution pattern around the 
benzoyl moiety. (Figure 5.8) However, the IC50 values for each compound observed were 
1.75 µM (RSD ± 4.0 %) and 62.32 µM (RSD ± 16 %) respectively. This was also observed 
for the aminopentane derivatives. N-{ortho-(ferrocenyl)-benzoyl)-aminopentane, 161, 
displayed an IC50 of 1.98 µM (RSD ± 1.4 %). Both the meta- (171) and para- (179) 
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derivatives were completely inactive.  It is evident that the orientation of the benzoyl moiety 
does indeed play a vital role on the cytotoxicity against cancerous cells.   
  
 
 
Figure 5.8 Effect of orientation around the benzoyl moiety on cell proliferation. 
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5.1.2 Effect of increasing or decreasing the aliphatic chain on the N-(ferrocenyl)-benzoyl 
aminoalkane derivatives. 
Another factor that may increase the anti-proliferative activity, is increasing or decreasing the 
amount of methylene spacers of the aliphatic chain of N-{ortho-, meta-, para-(ferrocenyl)-
benzoyl}-aminoalkane derivatives. From the preliminary screening of the derivatives 177 & 
184, both compounds were shown to exhibit a cytotoxic effect (figure 5.2). Therefore the 
other derivatives were evaluated for their anti-cancer activity against the MCF-7 breast 
cancer cell line, to further investigate if the anti-cancer effect increased or decreased with the 
differing of the aliphatic chain.   
The derivatives with the shortest chain length, 159, 168 and 177, were less active  compared 
to longer aliphatic chains as IC50 values were all above 40 µM. The compounds with six 
carbons on the aliphatic chain (hexane derivatives) seemed to have an effect on all three 
series as IC50 values of 4.8 µM, 51.5 µM and 4.0 µM for the ortho-, meta- and para- 
derivatives respectively, were observed. The increase of carbons on the aliphatic chain had a 
greater effect on the ortho- and para- series.  The effect of 9 carbons on the aliphatic chain 
(nonane) for the ortho- series, showed an IC50 value of 1.28 µM (RSD ± 1.5 %). (Figure 5.9)  
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Figure 5.9: IC50 values of N-{ortho-(ferrocenyl)-benzoyl}-aminoalkanes relative to DMSO 
control. 
This was also the case for the para- derivatives, as the increase to 8 carbons on the chain, 
gave an IC50 of 1.10 µM (RSD ± 2 %). The activity dropped to 2.4 µM (RSD ± 0.5%) when 
the chain was increased to 9 carbons. (Figure 5.10)  
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Figure 5.10: IC50 values of N-{para-(ferrocenyl)-benzoyl}-aminoalkanes relative to DMSO 
control. 
For the biological activity, the increase of methylene groups on a chain or ring increases the 
size and thus makes the molecule more lipophilic. An improvement in activity following an 
increase in the number of methylene groups is possibly due to an increase lipid solubility 
leading to the eventual greater membrane permeability, as this is evident for both the N-
{para-(ferrocenyl)-benzoyl}-aminoalkanes & N-{ortho-(ferrocenyl)-benzoyl}-aminoalkanes. 
The opposite effect, as seen for the N-{meta-(ferrocenyl)-benzoyl}-aminoalkanes, where the 
increase of the methylene groups above 7 methylene groups along a chain leads to the 
decrease in activity . In the case of the meta- series, it caused the compounds to be 
completely inactive. This can often to lead to poor distribution and trapping of the drug in the 
biological membrane.
 [9] 
  
 
 
 
265 
5.2 Conclusions. 
As part of a second SAR study, N-(ferrocenyl)-benzoyl-aminoalkane derivatives were 
evaluated in vitro for an anti-proliferative effect on the MCF-7 breast cancer cell line. The 
investigation involved two key areas, the orientation of aromatic substitution around the 
benzoyl moiety and also with the attachment of aliphatic alkanes to the benzoyl moiety. 
Previous work in this laboratory had shown that using the ferrocenyl-benzoyl backbone, and 
the attachment of various subgroups to it, exerts an anti-proliferative effect on cancerous cell 
lines, including the H1299 and Sk-Mel-28, but the testing on breast cancer cell lines had not 
yet been investigated using this type structure.
 
In total, 27 compounds were biologically evaluated. These novel-ferrocenyl-benzoyl alkane 
derivatives exhibited a strong anti-proliferative effect in the MCF-7 cell line. The derivatives 
tested illustrated that the orientation of the benzoyl moiety and the length of the alkyl chain  
were crucial for achieving the best possible anti-proliferative effect. N-{ortho-(ferrocenyl)-
benzoyl}-aminononane, 165, displayed the greatest effect with an IC50 value of 1.28 µM (± 
1.5%) for all the ortho derivatives synthesised.  N-{meta-(ferrocenyl)-benzoyl}-
aminoheptane, 172, IC50 of 51.2 µM (± 10%) for the meta- derivatives, and N-para-
(ferrocenyl)-benzoyl}-aminooctane, 182, 1.10 µM  (± 2%) for the para- derivatives showed 
the greatest effect. It clearly demonstrated that with the specific substitution around the 
benzoyl moiety combined with a long aliphatic chain produces the strongest anti-proliferative 
effect.   
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Materials and Methods 
Cell culture media, supplements and related solutions were purchased from Sigma-Aldrich 
(Dublin, Ireland) unless otherwise stated. The H1299 cell line was obtained from the 
American Type Culture Collection (ATCC). The MCF-7 breast cancer cell line was obtained 
from the Health Protection Agency. The cells were grown in modified eagles’ medium with 
5% foetal bovine serum (FBS).  The cell medium used was RPMI-1640 medium 
supplemented with 10 % foetal calf serum (FCS) for the H1299 cells. Both lines were grown 
as a monolayer culture at 37 
0
C, under a humidified atmosphere of 95 % O2, and 5 % CO2 in 
75 cm
2
 flasks). All cell culture work was carried out in a class II laminar airflow cabinet 
(Holten LaminAir). All experiments involving cytotoxic compounds were conducted in a 
cytoguard laminar airflow cabinet (Holten LaminAir Maxisafe). Before and after use the 
laminar airflow cabinet was cleaned with 70 % industrial methylated spirits (IMS). Any items 
brought to the airflow cabinet were swabbed using IMS. At any one time, only one cell line 
was used in the laminar airflow cabinet and after completion of work with the cell line, the 
laminar airflow cabinet was allowed stand for 15 minutes before use. This was to eliminate 
any possibility of cross contamination between cell lines. The Laminar Airflow was cleaned 
daily with industrial disinfectants (Virkon or Tego) and also with IMS. These disinfectants 
were alternated fortnightly. Cells were fed with fresh media or subcultured when confluency 
reached 70 % in order to maintain active cell growth. 
Subculture techniques of cell lines. 
Media and trypsin/EDTA solution (0.25 % trypsin (Gibco), 0.01 % EDTA (Sigma Aldrich) 
solution in PBS) were incubated at 37 
0
C for 20 min in a water bath. The cell culture medium 
was removed from the tissue culture flask and discarded into a sterile bottle. The flask was 
then rinsed with PBS (7 ml) to ensure the removal of any residual media. Once removed to a 
sterile waste bottle, fresh trypsin/EDTA solution (4 ml) was added and incubated at 37 
0
C for 
the required time  (dependant on cell line) until all the cells were detached from the inside 
surface of the tissue culture flask. The trypsin was deactivated by adding PBS (6 ml). The cell 
suspension was removed from the flask and placed in a sterile universal container and 
centrifuged at 2000 rpm for 5 minutes. The supernatant was then removed and discarded 
from the universal container and the pellet was suspended in complete medium. A cell count 
was performed. Depending on number of tests, an aliquot of cells was used to reseed a flask 
at the required density, topping up the flask with fresh medium. 
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Assessment of cell number 
Cells were trypsinised, pelleted and resuspended in media. An aliquot (10 µL) of the cell 
suspension was then applied to a universal vial and dye was added. This was then applied to 
the chamber of a glass cover slip enclosed haemocytometer. Cells in the 16 squares of the 
four grids of the chamber were counted. The average cell number, per 16 squares, was 
multiplied by a factor of 104 and the relevant dilution factor to determine the number of cells 
per ml in the original cell suspension. 
Cryopreservation of cells. 
Cells for cryopreservation were harvested when the cells had reached the log phase of growth 
and counted as described above. Cell pellets were resuspended and the medium was removed 
and discarded. The cells were resuspended in cryogenic freezing medium (3 ml) and then 
placed in a cryovial (Greiner). These were then placed in the -20 
0
C  freezer for a period of 1-
2 hrs and then in the -80 
0
C freezer overnight.  Following this period, the vials were removed 
from the -80 
0
C freezer and transferred to the liquid nitrogen tanks for storage (-196 
0
C).  
Removing cells from cryopreservation 
A volume of prepared culture media (8 ml) was placed in a hot water bath for 20 minutes. 
The cryovial was removed from the liquid nitrogen storage tanks (-196 
0
C) and placed in a 
hot water bath for 10 minutes at 37 
0
C. The cryopreserved cells were then resuspended in the 
prepared culture media in a 75 cm
2
 flask. The cells were observed at 12 hr, 24 hr and 48 hr 
intervals for adhesion and confluency and growth. Following substantial growth the cells 
were fed with fresh culture media. 
In vitro proliferation assays 
Confluent cells in the exponential growth phase were harvested by trypsinising and a cell 
suspension of 5 x 10
4
 cells/ml was prepared in fresh culture medium. The cell suspension (40 
µL ) was added to a flat bottom 96 well plate (Costar 3599), followed by culture medium (60 
µL).  The plate was slightly agitated in order to ensure complete dispersion of the cells. The 
cells were the incubated for an initial 24 hours in a 37 
0
C , 5 % CO2 incubator to allow the 
adhesion  of cells to flat bottom wells. The compounds for testing were prepared in 1 mM 
stocks. The different concentrations used in the preliminary scans and for the further IC50 
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data studies were made up accordingly by adding the desired amount of compound stock 
solution to fresh culture media.  Once the compounds and media were added to the 96 well 
flat bottom plates, the plate was gently agitated and then incubated at 37 
0
C, 5 % CO2, for 4-5 
days until cell confluency reached over 85 %. Assessment of cell survival in the presence of 
test sample was determined by the acid phosphatase assay. For the full comprehensive screen, 
cell growth percentage in the presence of each sample was calculated relative to the DMSO 
control cells. For the preliminary studies and IC50 data studies, the concentration of drug that 
causes 50 % growth inhibition was determined by plotting the percentage (%) survival of 
cells (relative to control cells) against the concentration of the test sample. In relation to IC50 
data studies, IC50 values were calculated using  Calcusyn software (Biosoft, UK). 
Acid Phosphatase assay 
Following an incubation period of 5-6 days, drug media was removed from the 96-well plate 
and each well was washed with 100 µL of PBS. This was then removed and 100 µL of 
freshly prepared phosphatase substrate (10 mM p-nitrophenol phosphate in 0.1M sodium 
acetate, 0.1 % triton X-100, pH 5.5) was added to each well. The plate was then incubated at 
37 
0
C for 2 hours. The enzymatic reaction was stopped upon addition of 1M NaOH (50 µL) 
to each well. The absorbance of each well was read in a dual beam reader (Synergy HT, Bio-
Tek, USA) at 405 nm with a reference wavelength of 620 nm. 
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Abbreviations: 
 
A 
A  absorbance 
ACE  angiotensin-converting enzyme 
ACN  acetonitrile 
Ag/AgC silver/silver chloride (reference electrode) 
ATCC  American Tissue Culture Centre 
Anal.  analysis 
ATR  attenuated total reflection 
AR  androgen receptor 
B 
BF4
-  
tetrafluoroborate ion 
Boc  tert-butoxycarbonyl 
Bpoc  2-(4-biphenyl)-isopropoxylcarbonyl 
Br  bromine 
C 
C  carbon; concentration 
Calc.  calculated 
CD  cyclodextrin 
CDCL3 deuterated chloroform 
CF3  trifluoromethyl group 
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Cl  chlorine 
CN  nitrile 
Co  cobalt 
Cu  copper 
CO2  carbon dioxide 
Cp  cyclopentadienyl ring 
Cα  alpha carbon 
COSY  correlated spectroscopy 
C=O   carbonyl 
D 
d  doublet (spectroscopy) 
DCC  1,3-dicyclohexylcarbdiimide 
DCM  dichloromethane 
DCU  Dublin City University 
dd  doublet of doubles 
DEPT-135 distortionless enhancement by polarisation transfer 
DHT  dihydrotestosterone 
DTIC  dacarbazine 
DMSO  dimethylsulfoxide 
DMSO-d6 deuterated dimethylsulfoxide 
DNA  deoxyriboneucleic acid 
DCIS  ductal carcinoma in situ 
DHFR  dihydrofolate reductase 
 
272 
E 
e
-
  electron 
EDC  N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
ESR  electron spin resonance 
ESI  electron spin ionisation 
ER  estrogen receptor 
ER(+)  estrogen receptor positive cells 
ER(-)  estrogen receptor negative cells 
EDTA  ethylenediaminetetraacetic acid 
F 
FCS  foetal calf serum 
FBS  foetal bovine serum 
Fmoc  9-fluorenylmethoxycarbonyl 
FACS  fluorescence activated cell sorting 
Fc/Fc
+
  ferrocene/ferrocenium ion 
Fe  iron 
Fe(II)  ferrous ion 
Fe(III)  ferric ion 
FT  Fourier transform 
G 
G0/G1/G2 gap phase 
Ga  gallium 
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Gly  glycine 
GI  gastro-intestinal tract 
H 
H  hydrogen 
H2O  water 
HBr  hydrogen bromide 
HCl  hydrochloric acid 
HPLC-EC high performance liquid chromatography- electrochemical 
HQMC Heteronuclear multiple quantum coherence 
HOBt  1-hydroxybenzotriazole 
HMG  high mobility group 
I 
IC50  half maximal inhibitory concentration 
IR  infra red spectroscopy 
IMS  industrial methylated spirits 
J 
J  coupling constant 
K 
KBr  potassium bromide 
L 
l  path length (cm) 
L-Ala  L-alanine 
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LCIS  lobular carcinoma in situ 
LDH  lactate dehydrogenase 
M 
m  meta; mass 
m  multiplet (spectral) 
M  metal; mitosis phase 
MeOH  methanol 
MgSO4 magnesium sulphate 
MLCT  metal-ligand charge transfer 
mp  melting point 
MS  mass spectrometry 
MDR  multiple drug resistance 
MTX  methotrexate 
M-Cp  metal-cyclopentadienyl ring (bond) 
M-L  metal-ligand 
MCF-7 breast cancer cell line (Michigan Cancer Foundation) 
MBC  metastatic breast cancer 
MDA-MB-435-S-F  breast cancer cell line (MD Anderson-Metastatic Breast) 
MDA-MB-231 breast cancer cell line (MD Anderson-Metastatic Breast) 
MTT  3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide 
N 
NICB  National Institute for Cellular Biotechnology 
NCI  National Cancer Institute 
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NMR  nuclear magnetic resonance 
NaOH  sodium hydroxide 
NHS  N-hydroxysuccinimide 
NSCLC non-small cell lung carcinoma 
O 
o  ortho 
O  oxygen 
OD  optical density 
OH  hydroxy 
OMe  methoxy 
P 
p  para 
P  phosphorous 
PBS  phosphate buffered saline 
PLA  polylactic acid 
PEG  polyethyleneglycol 
Pt  platnium 
ppm  parts per million 
Q 
q  quartet 
qt  quintet 
R 
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Rh  rhodium 
Ru  ruthenium 
RNA  ribonucleic acid 
rpm  rotations per minute 
RSD  relative standard deviation 
ROS  reactive oxygenated species 
S 
s  singlet 
S  sulphur; synthesis phase 
SAR  structure activity relationship 
SERM  selective estrogen receptor modulator 
SCLC  small cell lung carcinoma 
SOD  superoxidase dismutase 
T 
TEA  triethylamine 
TMS  tetramethylsilane 
TCD  Trinity College Dublin 
TFA  trifluoroacetic acid 
Ti  titanium 
U 
UV  ultraviolet 
V 
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V  vanadium 
Vis  visible 
W 
WHO  World Health Organisation 
WW1  World War One 
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Units 
Å  angstrom 
cm  centimetre 
cm
-1  
wavenumber / per centimetre 
dm  decimetre 
g  gram 
Hr  hour 
Hz  hertz 
L  litre 
K  Kelvin 
kg
-1  
per kilogram 
M  molar 
MHz  megahertz 
mg  milligram 
ml  millilitre 
mm  millimetre 
mM  millimolar 
mmol  millimetre 
µl  microlitre 
µm  micrometre 
µM  micromolar 
nm  nanometre 
nM  nanomolar 
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o
C  degree celcius 
ppm  parts per million 
s  second 
δ  chemical shift 
%  percentage 
 
 
 
